drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB04552
|
DB00685
| 774 | 862 |
Niflumic acid
|
Trovafloxacin
|
Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
|
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
|
Niflumic acid may increase the neuroexcitatory activities of Trovafloxacin.
| 26 |
[
[
[
774,
49,
862
]
],
[
[
774,
49,
863
],
[
863,
155,
862
]
],
[
[
774,
182,
169
],
[
169,
28,
862
]
],
[
[
774,
225,
4
],
[
4,
49,
862
]
],
[
[
774,
71,
766
],
[
766,
49,
862
]
],
[
[
774,
270,
582
],
[
582,
49,
862
]
],
[
[
774,
233,
798
],
[
798,
49,
862
]
],
[
[
774,
182,
687
],
[
687,
49,
862
]
],
[
[
774,
71,
124
],
[
124,
71,
862
]
],
[
[
774,
249,
457
],
[
457,
234,
862
]
]
] |
[
[
[
"Niflumic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiaprofenic acid"
],
[
"Tiaprofenic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
],
[
"Epirizole",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trovafloxacin"
]
],
[
[
"Niflumic acid",
"{u} may increase the serum concentration of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Trovafloxacin"
]
]
] |
Niflumic acid may increase the neuroexcitatory activities of Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Niflumic acid may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Trovafloxacin
Niflumic acid may increase the severity of adverse effects when combined with Tiaprofenic acid and Tiaprofenic acid may increase the neuroexcitatory activities of Trovafloxacin
Niflumic acid may increase the severity of adverse effects when combined with Epirizole and Epirizole may increase the neuroexcitatory activities of Trovafloxacin
Niflumic acid (Compound) resembles Leflunomide (Compound) and Niflumic acid may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may increase the neuroexcitatory activities of Trovafloxacin
Niflumic acid may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the neuroexcitatory activities of Trovafloxacin
Niflumic acid may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the neuroexcitatory activities of Trovafloxacin
Niflumic acid may increase the severity of adverse effects when combined with Estrone and Estrone may increase the severity of adverse effects when combined with Trovafloxacin
Niflumic acid may increase the serum concentration of Digoxin and Digoxin may decrease the cardiotoxic activities of Trovafloxacin
|
DB00489
|
DB01628
| 1,027 | 364 |
Sotalol
|
Etoricoxib
|
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]
|
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
|
Sotalol may decrease the antihypertensive activities of Etoricoxib.
| 36 |
[
[
[
1027,
59,
364
]
],
[
[
1027,
21,
28506
],
[
28506,
175,
364
]
],
[
[
1027,
236,
164
],
[
164,
26,
364
]
],
[
[
1027,
251,
147
],
[
147,
26,
364
]
],
[
[
1027,
59,
687
],
[
687,
28,
364
]
],
[
[
1027,
42,
863
],
[
863,
203,
364
]
],
[
[
1027,
225,
557
],
[
557,
205,
364
]
],
[
[
1027,
71,
893
],
[
893,
205,
364
]
],
[
[
1027,
71,
731
],
[
731,
59,
364
]
],
[
[
1027,
225,
1034
],
[
1034,
59,
364
]
]
] |
[
[
[
"Sotalol",
"{u} may decrease the antihypertensive activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may decrease the antihypertensive activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may decrease the antihypertensive activities of {v}",
"Etoricoxib"
]
],
[
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may decrease the antihypertensive activities of {v}",
"Etoricoxib"
]
]
] |
Sotalol (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Etoricoxib (Compound)
Sotalol may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Etoricoxib
Sotalol may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Etoricoxib
Sotalol may decrease the antihypertensive activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Etoricoxib
Sotalol may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the neuroexcitatory activities of Etoricoxib
Sotalol may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Etoricoxib
Sotalol may increase the severity of adverse effects when combined with Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Etoricoxib
Sotalol may increase the severity of adverse effects when combined with Nebivolol and Nebivolol may decrease the antihypertensive activities of Etoricoxib
Sotalol may increase the severity of adverse effects when combined with Esmolol and Esmolol may decrease the antihypertensive activities of Etoricoxib
|
DB00321
|
DB00835
| 262 | 165 |
Amitriptyline
|
Brompheniramine
|
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
|
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
|
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine.
| 48 |
[
[
[
262,
71,
165
]
],
[
[
262,
192,
72
],
[
72,
155,
165
]
],
[
[
262,
1,
38
],
[
38,
155,
165
]
],
[
[
262,
155,
1637
],
[
1637,
1,
165
]
],
[
[
262,
71,
979
],
[
979,
71,
165
]
],
[
[
262,
6,
8167
],
[
8167,
160,
165
]
],
[
[
262,
180,
171
],
[
171,
26,
165
]
],
[
[
262,
38,
1262
],
[
1262,
192,
165
]
],
[
[
262,
192,
1266
],
[
1266,
38,
165
]
],
[
[
262,
71,
556
],
[
556,
223,
165
]
]
] |
[
[
[
"Amitriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Brompheniramine"
]
],
[
[
"Amitriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Brompheniramine"
]
]
] |
Amitriptyline may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine (Compound) resembles Brompheniramine (Compound)
Amitriptyline (Compound) resembles Doxylamine (Compound) and Doxylamine (Compound) resembles Brompheniramine (Compound)
Amitriptyline (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Brompheniramine (Compound)
Amitriptyline may increase the severity of adverse effects when combined with Dexbrompheniramine and Dexbrompheniramine may increase the severity of adverse effects when combined with Brompheniramine
Amitriptyline (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Brompheniramine (Compound)
Amitriptyline can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Brompheniramine
Amitriptyline may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Brompheniramine
Amitriptyline may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Brompheniramine
Amitriptyline may increase the severity of adverse effects when combined with Citalopram and Citalopram may decrease the metabolism of Brompheniramine
|
DB00401
|
DB06636
| 512 | 1,077 |
Nisoldipine
|
Isavuconazonium
|
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
|
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent
|
The metabolism of Isavuconazonium can be decreased when combined with Nisoldipine.
| 46 |
[
[
[
512,
69,
1077
]
],
[
[
512,
249,
150
],
[
150,
33,
1077
]
],
[
[
512,
251,
173
],
[
173,
33,
1077
]
],
[
[
512,
288,
177
],
[
177,
33,
1077
]
],
[
[
512,
180,
164
],
[
164,
33,
1077
]
],
[
[
512,
69,
755
],
[
755,
223,
1077
]
],
[
[
512,
225,
438
],
[
438,
69,
1077
]
],
[
[
512,
249,
439
],
[
439,
69,
1077
]
],
[
[
512,
82,
454
],
[
454,
69,
1077
]
],
[
[
512,
59,
230
],
[
230,
69,
1077
]
]
] |
[
[
[
"Nisoldipine",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} can increase the metabolism of {v} and {u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may increase the serum concentration of {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may increase the hypotensive activities of {v}",
"Selexipag"
],
[
"Selexipag",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
],
[
[
"Nisoldipine",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
]
]
] |
Nisoldipine may increase the serum concentration of Fosphenytoin and Fosphenytoin may reduce the serum concentration of the active metabolites of Isavuconazonium
Nisoldipine may decrease the serum concentration of Nevirapine and Nevirapine may reduce the serum concentration of the active metabolites of Isavuconazonium
Nisoldipine can increase the metabolism of Rifapentine and Nisoldipine may decrease the serum concentration of Rifapentine and Rifapentine may reduce the serum concentration of the active metabolites of Isavuconazonium
Nisoldipine can increase the metabolism of Phenobarbital and Phenobarbital may reduce the serum concentration of the active metabolites of Isavuconazonium
Nisoldipine may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Isavuconazonium
Nisoldipine may increase the severity of adverse effects when combined with Imipramine and Imipramine may decrease the metabolism of Isavuconazonium
Nisoldipine may increase the serum concentration of Simvastatin and Simvastatin may decrease the metabolism of Isavuconazonium
Nisoldipine may increase the hypotensive activities of Selexipag and Selexipag may decrease the metabolism of Isavuconazonium
Nisoldipine may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the metabolism of Isavuconazonium
|
DB01267
|
DB01433
| 1,007 | 984 |
Paliperidone
|
Methadyl acetate
|
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
|
A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
|
The risk or severity of adverse effects can be increased when Paliperidone is combined with Methadyl acetate.
| 48 |
[
[
[
1007,
71,
984
]
],
[
[
1007,
71,
973
],
[
973,
225,
984
]
],
[
[
1007,
192,
72
],
[
72,
38,
984
]
],
[
[
1007,
225,
942
],
[
942,
155,
984
]
],
[
[
1007,
71,
289
],
[
289,
71,
984
]
],
[
[
1007,
209,
589
],
[
589,
1,
984
]
],
[
[
1007,
38,
702
],
[
702,
192,
984
]
],
[
[
1007,
59,
543
],
[
543,
38,
984
]
],
[
[
1007,
54,
471
],
[
471,
208,
984
]
],
[
[
1007,
251,
156
],
[
156,
71,
984
]
]
] |
[
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Methadyl acetate"
]
],
[
[
"Paliperidone",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
]
] |
Paliperidone may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine may increase the severity of adverse effects when combined with Methadyl acetate
Paliperidone may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Methadyl acetate
Paliperidone may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate (Compound) resembles Methadyl acetate (Compound)
Paliperidone may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Methadyl acetate
Paliperidone may increase the severity of QTc prolonging effects when combined with Disopyramide and Disopyramide (Compound) resembles Methadyl acetate (Compound)
Paliperidone may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Methadyl acetate
Paliperidone may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Methadyl acetate
Paliperidone may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Methadyl acetate
Paliperidone may decrease the serum concentration of Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Methadyl acetate
|
DB00976
|
DB00983
| 528 | 253 |
Telithromycin
|
Formoterol
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
|
Telithromycin may increase the QTc-prolonging activities of Formoterol.
| 19 |
[
[
[
528,
42,
253
]
],
[
[
528,
42,
420
],
[
420,
1,
253
]
],
[
[
528,
6,
18777
],
[
18777,
160,
253
]
],
[
[
528,
21,
28608
],
[
28608,
175,
253
]
],
[
[
528,
180,
171
],
[
171,
26,
253
]
],
[
[
528,
249,
509
],
[
509,
27,
253
]
],
[
[
528,
223,
248
],
[
248,
27,
253
]
],
[
[
528,
196,
1322
],
[
1322,
42,
253
]
],
[
[
528,
249,
955
],
[
955,
42,
253
]
],
[
[
528,
223,
494
],
[
494,
42,
253
]
]
] |
[
[
[
"Telithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Arformoterol"
],
[
"Arformoterol",
"{u} (Compound) resembles {v} (Compound)",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may increase the serum concentration of {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may decrease the metabolism of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the vasoconstricting activities of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may increase the serum concentration of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
],
[
[
"Telithromycin",
"{u} may decrease the metabolism of {v}",
"Asenapine"
],
[
"Asenapine",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
]
] |
Telithromycin may increase the QTc prolonging activities of Arformoterol and Arformoterol (Compound) resembles Formoterol (Compound)
Telithromycin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Telithromycin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Formoterol (Compound)
Telithromycin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Formoterol
Telithromycin may increase the serum concentration of Tamsulosin and Tamsulosin may decrease the vasoconstricting activities of Formoterol
Telithromycin may decrease the metabolism of Carvedilol and Carvedilol may decrease the vasoconstricting activities of Formoterol
Telithromycin may increase the QTc prolonging activities of Procainamide and Procainamide may increase the QTc prolonging activities of Formoterol
Telithromycin may increase the serum concentration of Quetiapine and Quetiapine may increase the QTc prolonging activities of Formoterol
Telithromycin may decrease the metabolism of Asenapine and Asenapine may increase the QTc prolonging activities of Formoterol
|
DB11609
|
DB01235
| 1,009 | 968 |
Normethadone
|
Levodopa
|
Normethadone is used as an opioid antitussive in combination with. It is marketed in Canada by Valeant under the tradename Cophylac.
|
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
|
The risk or severity of adverse effects can be increased when Normethadone is combined with Levodopa.
| 48 |
[
[
[
1009,
71,
968
]
],
[
[
1009,
184,
674
],
[
674,
30,
968
]
],
[
[
1009,
38,
1265
],
[
1265,
192,
968
]
],
[
[
1009,
192,
491
],
[
491,
38,
968
]
],
[
[
1009,
225,
510
],
[
510,
52,
968
]
],
[
[
1009,
71,
1072
],
[
1072,
52,
968
]
],
[
[
1009,
38,
702
],
[
702,
52,
968
]
],
[
[
1009,
240,
828
],
[
828,
206,
968
]
],
[
[
1009,
192,
679
],
[
679,
52,
968
]
],
[
[
1009,
54,
1046
],
[
1046,
208,
968
]
]
] |
[
[
[
"Normethadone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the serotonergic activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
]
],
[
[
"Normethadone",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Levodopa"
]
]
] |
Normethadone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Levodopa
Normethadone may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Levodopa
Normethadone may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Levodopa
Normethadone may increase the severity of adverse effects when combined with Sufentanil and Sufentanil may increase the orthostatic hypotensive activities of Levodopa
Normethadone may increase the severity of adverse effects when combined with Hydroflumethiazide and Hydroflumethiazide may increase the orthostatic hypotensive activities of Levodopa
Normethadone may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the orthostatic hypotensive activities of Levodopa
Normethadone may increase the serotonergic activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Levodopa
Normethadone may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the orthostatic hypotensive activities of Levodopa
Normethadone may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Levodopa
|
DB13323
|
DB00660
| 927 | 958 |
Trichloroethylene
|
Metaxalone
|
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits.
|
Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.
|
The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Metaxalone.
| 48 |
[
[
[
927,
71,
958
]
],
[
[
927,
184,
674
],
[
674,
30,
958
]
],
[
[
927,
192,
287
],
[
287,
38,
958
]
],
[
[
927,
38,
1262
],
[
1262,
192,
958
]
],
[
[
927,
54,
1046
],
[
1046,
208,
958
]
],
[
[
927,
225,
197
],
[
197,
71,
958
]
],
[
[
927,
71,
977
],
[
977,
71,
958
]
],
[
[
927,
71,
434
],
[
434,
225,
958
]
],
[
[
927,
184,
674
],
[
674,
21,
28384
],
[
28384,
175,
958
]
],
[
[
927,
192,
287
],
[
287,
21,
28384
],
[
28384,
175,
958
]
]
] |
[
[
[
"Trichloroethylene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metaxalone"
]
],
[
[
"Trichloroethylene",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metaxalone"
]
]
] |
Trichloroethylene can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Metaxalone
Trichloroethylene may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Metaxalone
Trichloroethylene may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Metaxalone
Trichloroethylene may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Metaxalone
Trichloroethylene may increase the severity of adverse effects when combined with Amobarbital and Amobarbital may increase the severity of adverse effects when combined with Metaxalone
Trichloroethylene may increase the severity of adverse effects when combined with Butalbital and Butalbital may increase the severity of adverse effects when combined with Metaxalone
Trichloroethylene may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Metaxalone
Trichloroethylene can increase the therapeutic efficacy of Pregabalin and Pregabalin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metaxalone (Compound)
Trichloroethylene may increase the central nervous system depressant activities of Zolpidem and Zolpidem (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metaxalone (Compound)
|
DB01400
|
DB03128
| 1,292 | 1,423 |
Neostigmine
|
Acetylcholine
|
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
|
A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
|
The risk or severity of adverse effects can be increased when Neostigmine is combined with Acetylcholine.
| 48 |
[
[
[
1292,
71,
1423
]
],
[
[
1292,
249,
379
],
[
379,
223,
1423
]
],
[
[
1292,
92,
59
],
[
59,
223,
1423
]
],
[
[
1292,
76,
576
],
[
576,
223,
1423
]
],
[
[
1292,
76,
731
],
[
731,
71,
1423
]
],
[
[
1292,
92,
60
],
[
60,
71,
1423
]
],
[
[
1292,
1,
1290
],
[
1290,
71,
1423
]
],
[
[
1292,
249,
379
],
[
379,
196,
539
],
[
539,
223,
1423
]
],
[
[
1292,
92,
59
],
[
59,
249,
288
],
[
288,
223,
1423
]
],
[
[
1292,
76,
576
],
[
576,
95,
288
],
[
288,
223,
1423
]
]
] |
[
[
[
"Neostigmine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may increase the bradycardic activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may increase the bradycardic activities of {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Gallamine triethiodide"
],
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Edrophonium"
],
[
"Edrophonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
],
[
"Artemether",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the serum concentration of {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
],
[
[
"Neostigmine",
"{u} may increase the bradycardic activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Acetylcholine"
]
]
] |
Neostigmine may increase the serum concentration of Ranolazine and Ranolazine may decrease the metabolism of Acetylcholine
Neostigmine may decrease the therapeutic efficacy of Quinidine and Quinidine may decrease the metabolism of Acetylcholine
Neostigmine may increase the bradycardic activities of Metoprolol and Metoprolol may decrease the metabolism of Acetylcholine
Neostigmine may increase the bradycardic activities of Nebivolol and Nebivolol may increase the severity of adverse effects when combined with Acetylcholine
Neostigmine may decrease the therapeutic efficacy of Gallamine triethiodide and Gallamine triethiodide may increase the severity of adverse effects when combined with Acetylcholine
Neostigmine (Compound) resembles Edrophonium (Compound) and Edrophonium may increase the severity of adverse effects when combined with Acetylcholine
Neostigmine may increase the serum concentration of Ranolazine and Ranolazine may increase the QTc prolonging activities of Artemether and Artemether may decrease the metabolism of Acetylcholine
Neostigmine may decrease the therapeutic efficacy of Quinidine and Quinidine may increase the serum concentration of Promazine and Promazine may decrease the metabolism of Acetylcholine
Neostigmine may increase the bradycardic activities of Metoprolol and Metoprolol may increase the serum concentration of Promazine and Promazine may decrease the metabolism of Acetylcholine
|
DB01045
|
DB00845
| 147 | 448 |
Rifampicin
|
Clofazimine
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].
|
The metabolism of Clofazimine can be increased when combined with Rifampicin.
| 3 |
[
[
[
147,
26,
448
]
],
[
[
147,
6,
10007
],
[
10007,
160,
448
]
],
[
[
147,
180,
171
],
[
171,
26,
448
]
],
[
[
147,
97,
150
],
[
150,
26,
448
]
],
[
[
147,
26,
156
],
[
156,
26,
448
]
],
[
[
147,
97,
1099
],
[
1099,
223,
448
]
],
[
[
147,
26,
198
],
[
198,
223,
448
]
],
[
[
147,
95,
657
],
[
657,
223,
448
]
],
[
[
147,
69,
41
],
[
41,
223,
448
]
],
[
[
147,
71,
501
],
[
501,
223,
448
]
]
] |
[
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB11"
],
[
"ABCB11",
"{u} (Gene) is bound by {v} (Compound)",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may decrease the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} may increase the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Clofazimine"
]
],
[
[
"Rifampicin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may decrease the metabolism of {v}",
"Clofazimine"
]
]
] |
Rifampicin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Clofazimine (Compound)
Rifampicin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Clofazimine
Rifampicin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Clofazimine
Rifampicin can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Clofazimine
Rifampicin may decrease the serum concentration of Idelalisib and Idelalisib may decrease the metabolism of Clofazimine
Rifampicin can increase the metabolism of Cyclosporine and Cyclosporine may decrease the metabolism of Clofazimine
Rifampicin may increase the serum concentration of Voriconazole and Voriconazole may decrease the metabolism of Clofazimine
Rifampicin may decrease the metabolism of Clemastine and Clemastine may decrease the metabolism of Clofazimine
Rifampicin may increase the severity of adverse effects when combined with Saquinavir and Saquinavir may decrease the metabolism of Clofazimine
|
DB01023
|
DB00653
| 516 | 405 |
Felodipine
|
Magnesium sulfate
|
Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium sulfate.
| 48 |
[
[
[
516,
71,
405
]
],
[
[
516,
6,
10574
],
[
10574,
160,
405
]
],
[
[
516,
21,
29305
],
[
29305,
175,
405
]
],
[
[
516,
180,
157
],
[
157,
26,
405
]
],
[
[
516,
69,
41
],
[
41,
38,
405
]
],
[
[
516,
223,
312
],
[
312,
38,
405
]
],
[
[
516,
236,
298
],
[
298,
38,
405
]
],
[
[
516,
225,
347
],
[
347,
38,
405
]
],
[
[
516,
82,
453
],
[
453,
38,
405
]
],
[
[
516,
180,
171
],
[
171,
38,
405
]
]
] |
[
[
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"CACNA1S"
],
[
"CACNA1S",
"{u} (Gene) is bound by {v} (Compound)",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} can increase the metabolism of {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Temazepam"
],
[
"Temazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} may increase the hypotensive activities of {v}",
"Hexobarbital"
],
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Felodipine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
]
] |
Felodipine (Compound) binds CACNA1S (Gene) and CACNA1S (Gene) is bound by Magnesium sulfate (Compound)
Felodipine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Magnesium sulfate (Compound)
Felodipine can increase the metabolism of Nafcillin and Nafcillin can increase the metabolism of Magnesium sulfate
Felodipine may decrease the metabolism of Clemastine and Clemastine may increase the central nervous system depressant activities of Magnesium sulfate
Felodipine may decrease the metabolism of Temazepam and Temazepam may increase the central nervous system depressant activities of Magnesium sulfate
Felodipine may increase the hypotensive activities of Hexobarbital and Hexobarbital may increase the central nervous system depressant activities of Magnesium sulfate
Felodipine may increase the severity of adverse effects when combined with Isoflurane and Isoflurane may increase the central nervous system depressant activities of Magnesium sulfate
Felodipine may increase the hypotensive activities of Risperidone and Risperidone may increase the central nervous system depressant activities of Magnesium sulfate
Felodipine can increase the metabolism of Pentobarbital and Pentobarbital may increase the central nervous system depressant activities of Magnesium sulfate
|
DB09555
|
DB00908
| 627 | 59 |
Dexchlorpheniramine maleate
|
Quinidine
|
Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
|
Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
|
The metabolism of Quinidine can be decreased when combined with Dexchlorpheniramine maleate.
| 46 |
[
[
[
627,
69,
59
]
],
[
[
627,
69,
640
],
[
640,
1,
59
]
],
[
[
627,
180,
171
],
[
171,
26,
59
]
],
[
[
627,
69,
438
],
[
438,
196,
59
]
],
[
[
627,
180,
150
],
[
150,
196,
59
]
],
[
[
627,
69,
530
],
[
530,
223,
59
]
],
[
[
627,
69,
681
],
[
681,
69,
59
]
],
[
[
627,
252,
718
],
[
718,
69,
59
]
],
[
[
627,
69,
1092
],
[
1092,
71,
59
]
],
[
[
627,
69,
482
],
[
482,
236,
59
]
]
] |
[
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} (Compound) resembles {v} (Compound)",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the sedative activities of {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
]
],
[
[
"Dexchlorpheniramine maleate",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may increase the hypotensive activities of {v}",
"Quinidine"
]
]
] |
Dexchlorpheniramine maleate may decrease the metabolism of Quinine and Quinine (Compound) resembles Quinidine (Compound)
Dexchlorpheniramine maleate can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Quinidine
Dexchlorpheniramine maleate may decrease the metabolism of Imipramine and Imipramine may increase the QTc prolonging activities of Quinidine
Dexchlorpheniramine maleate can increase the metabolism of Fosphenytoin and Fosphenytoin may increase the QTc prolonging activities of Quinidine
Dexchlorpheniramine maleate may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Quinidine
Dexchlorpheniramine maleate may decrease the metabolism of Clozapine and Clozapine may decrease the metabolism of Quinidine
Dexchlorpheniramine maleate may decrease the sedative activities of Pseudoephedrine and Pseudoephedrine may decrease the metabolism of Quinidine
Dexchlorpheniramine maleate may decrease the metabolism of Telaprevir and Telaprevir may increase the severity of adverse effects when combined with Quinidine
Dexchlorpheniramine maleate may decrease the metabolism of Verapamil and Verapamil may increase the hypotensive activities of Quinidine
|
DB05294
|
DB01149
| 1,185 | 648 |
Vandetanib
|
Nefazodone
|
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
|
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
|
The metabolism of Nefazodone can be decreased when combined with Vandetanib.
| 46 |
[
[
[
1185,
69,
648
]
],
[
[
1185,
209,
370
],
[
370,
95,
648
]
],
[
[
1185,
42,
1262
],
[
1262,
71,
648
]
],
[
[
1185,
42,
175
],
[
175,
69,
648
]
],
[
[
1185,
42,
932
],
[
932,
95,
648
]
],
[
[
1185,
6,
4590
],
[
4590,
160,
648
]
],
[
[
1185,
21,
28515
],
[
28515,
175,
648
]
],
[
[
1185,
251,
161
],
[
161,
26,
648
]
],
[
[
1185,
69,
381
],
[
381,
69,
648
]
],
[
[
1185,
69,
755
],
[
755,
223,
648
]
]
] |
[
[
[
"Vandetanib",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Domperidone"
],
[
"Domperidone",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Vandetanib",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
]
] |
Vandetanib may increase the severity of QTc prolonging effects when combined with Domperidone and Domperidone may increase the serum concentration of Nefazodone
Vandetanib may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the severity of adverse effects when combined with Nefazodone
Vandetanib may increase the QTc prolonging activities of Trazodone and Trazodone may decrease the metabolism of Nefazodone
Vandetanib may increase the QTc prolonging activities of Aripiprazole and Aripiprazole may increase the serum concentration of Nefazodone
Vandetanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Vandetanib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Nefazodone (Compound)
Vandetanib may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Nefazodone
Vandetanib may decrease the metabolism of Rucaparib and Rucaparib may decrease the metabolism of Nefazodone
Vandetanib may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Nefazodone
|
DB01247
|
DB00217
| 42 | 1,061 |
Isocarboxazid
|
Bethanidine
|
Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
|
A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
|
Isocarboxazid may increase the hypotensive activities of Bethanidine.
| 59 |
[
[
[
42,
82,
1061
]
],
[
[
42,
247,
1335
],
[
1335,
155,
1061
]
],
[
[
42,
1,
1395
],
[
1395,
155,
1061
]
],
[
[
42,
225,
39
],
[
39,
155,
1061
]
],
[
[
42,
155,
1345
],
[
1345,
155,
1061
]
],
[
[
42,
225,
53
],
[
53,
82,
1061
]
],
[
[
42,
71,
702
],
[
702,
32,
1061
]
],
[
[
42,
82,
519
],
[
519,
201,
1061
]
],
[
[
42,
225,
1025
],
[
1025,
201,
1061
]
],
[
[
42,
71,
1027
],
[
1027,
201,
1061
]
]
] |
[
[
[
"Isocarboxazid",
"{u} may increase the hypotensive activities of {v}",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the hypertensive activities of {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} (Compound) resembles {v} (Compound)",
"Phenylalanine"
],
[
"Phenylalanine",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} (Compound) resembles {v} (Compound)",
"Lacosamide"
],
[
"Lacosamide",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the hypotensive activities of {v}",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the hypotensive activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Bethanidine"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Bethanidine"
]
]
] |
Isocarboxazid may increase the hypertensive activities of Phentermine and Phentermine (Compound) resembles Bethanidine (Compound)
Isocarboxazid (Compound) resembles Phenylalanine (Compound) and Phenylalanine (Compound) resembles Bethanidine (Compound)
Isocarboxazid may increase the severity of adverse effects when combined with Selegiline and Selegiline (Compound) resembles Bethanidine (Compound)
Isocarboxazid (Compound) resembles Lacosamide (Compound) and Lacosamide (Compound) resembles Bethanidine (Compound)
Isocarboxazid may increase the severity of adverse effects when combined with Phenelzine and Phenelzine may increase the hypotensive activities of Bethanidine
Isocarboxazid may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Bethanidine
Isocarboxazid may increase the hypotensive activities of Celiprolol and Celiprolol may increase the atrioventricular blocking activities of Bethanidine
Isocarboxazid may increase the severity of adverse effects when combined with Arotinolol and Arotinolol may increase the atrioventricular blocking activities of Bethanidine
Isocarboxazid may increase the severity of adverse effects when combined with Sotalol and Sotalol may increase the atrioventricular blocking activities of Bethanidine
|
DB00607
|
DB00528
| 157 | 444 |
Nafcillin
|
Lercanidipine
|
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections.
|
Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
|
The metabolism of Lercanidipine can be increased when combined with Nafcillin.
| 3 |
[
[
[
157,
26,
444
]
],
[
[
157,
26,
516
],
[
516,
236,
444
]
],
[
[
157,
6,
4590
],
[
4590,
160,
444
]
],
[
[
157,
21,
28937
],
[
28937,
175,
444
]
],
[
[
157,
26,
482
],
[
482,
223,
444
]
],
[
[
157,
246,
755
],
[
755,
223,
444
]
],
[
[
157,
26,
605
],
[
605,
71,
444
]
],
[
[
157,
26,
662
],
[
662,
225,
444
]
],
[
[
157,
26,
385
],
[
385,
82,
444
]
],
[
[
157,
94,
1351
],
[
1351,
92,
444
]
]
] |
[
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the hypotensive activities of {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} may decrease the therapeutic efficacy of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Clevidipine"
],
[
"Clevidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} can increase the metabolism of {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may increase the hypotensive activities of {v}",
"Lercanidipine"
]
],
[
[
"Nafcillin",
"{u} may decrease the excretion rate {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may decrease the therapeutic efficacy of {v}",
"Lercanidipine"
]
]
] |
Nafcillin can increase the metabolism of Felodipine and Felodipine may increase the hypotensive activities of Lercanidipine
Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lercanidipine (Compound)
Nafcillin (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Lercanidipine (Compound)
Nafcillin can increase the metabolism of Verapamil and Verapamil may decrease the metabolism of Lercanidipine
Nafcillin may decrease the therapeutic efficacy of Doxycycline and Doxycycline may decrease the metabolism of Lercanidipine
Nafcillin can increase the metabolism of Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Lercanidipine
Nafcillin can increase the metabolism of Clevidipine and Clevidipine may increase the severity of adverse effects when combined with Lercanidipine
Nafcillin can increase the metabolism of Amlodipine and Amlodipine may increase the hypotensive activities of Lercanidipine
Nafcillin may decrease the excretion rate Acemetacin and Acemetacin may decrease the therapeutic efficacy of Lercanidipine
|
DB01590
|
DB08901
| 1,392 | 675 |
Everolimus
|
Ponatinib
|
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
|
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
|
The serum concentration of Ponatinib can be increased when it is combined with Everolimus.
| 72 |
[
[
[
1392,
95,
675
]
],
[
[
1392,
6,
4590
],
[
4590,
160,
675
]
],
[
[
1392,
7,
4220
],
[
4220,
160,
675
]
],
[
[
1392,
7,
10694
],
[
10694,
161,
675
]
],
[
[
1392,
18,
10629
],
[
10629,
161,
675
]
],
[
[
1392,
18,
3955
],
[
3955,
172,
675
]
],
[
[
1392,
7,
9905
],
[
9905,
172,
675
]
],
[
[
1392,
21,
28411
],
[
28411,
175,
675
]
],
[
[
1392,
95,
556
],
[
556,
223,
675
]
],
[
[
1392,
95,
152
],
[
152,
71,
675
]
]
] |
[
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"LYN"
],
[
"LYN",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"GFOD1"
],
[
"GFOD1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"ZNF586"
],
[
"ZNF586",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"PPARG"
],
[
"PPARG",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"NOSIP"
],
[
"NOSIP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Ponatinib"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ponatinib"
]
]
] |
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Everolimus (Compound) upregulates LYN (Gene) and LYN (Gene) is bound by Ponatinib (Compound)
Everolimus (Compound) upregulates GFOD1 (Gene) and GFOD1 (Gene) is upregulated by Ponatinib (Compound)
Everolimus (Compound) downregulates ZNF586 (Gene) and ZNF586 (Gene) is upregulated by Ponatinib (Compound)
Everolimus (Compound) downregulates PPARG (Gene) and PPARG (Gene) is downregulated by Ponatinib (Compound)
Everolimus (Compound) upregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Ponatinib (Compound)
Everolimus (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Everolimus may increase the serum concentration of Citalopram and Citalopram may decrease the metabolism of Ponatinib
Everolimus may increase the serum concentration of Cabazitaxel and Cabazitaxel may increase the severity of adverse effects when combined with Ponatinib
|
DB01192
|
DB01440
| 327 | 974 |
Oxymorphone
|
gamma-Hydroxybutyric acid
|
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
|
Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
|
The risk or severity of adverse effects can be increased when Oxymorphone is combined with gamma-Hydroxybutyric acid.
| 48 |
[
[
[
327,
71,
974
]
],
[
[
327,
21,
28549
],
[
28549,
175,
974
]
],
[
[
327,
184,
674
],
[
674,
30,
974
]
],
[
[
327,
38,
1264
],
[
1264,
192,
974
]
],
[
[
327,
276,
491
],
[
491,
38,
974
]
],
[
[
327,
192,
1266
],
[
1266,
38,
974
]
],
[
[
327,
54,
1046
],
[
1046,
208,
974
]
],
[
[
327,
240,
193
],
[
193,
225,
974
]
],
[
[
327,
71,
948
],
[
948,
225,
974
]
],
[
[
327,
71,
202
],
[
202,
71,
974
]
]
] |
[
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the serotonergic activities of {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethyl loflazepate"
],
[
"Ethyl loflazepate",
"{u} may increase the severity of adverse effects when combined with {v}",
"gamma-Hydroxybutyric acid"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"gamma-Hydroxybutyric acid"
]
]
] |
Oxymorphone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by gamma-Hydroxybutyric acid (Compound)
Oxymorphone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of gamma-Hydroxybutyric acid
Oxymorphone may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of gamma-Hydroxybutyric acid
Oxymorphone (Compound) resembles Buprenorphine (Compound) and Oxymorphone may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of gamma-Hydroxybutyric acid
Oxymorphone may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of gamma-Hydroxybutyric acid
Oxymorphone may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of gamma-Hydroxybutyric acid
Oxymorphone may increase the serotonergic activities of Levomilnacipran and Levomilnacipran may increase the severity of adverse effects when combined with gamma-Hydroxybutyric acid
Oxymorphone may increase the severity of adverse effects when combined with Ethyl loflazepate and Ethyl loflazepate may increase the severity of adverse effects when combined with gamma-Hydroxybutyric acid
Oxymorphone may increase the severity of adverse effects when combined with Ketamine and Ketamine may increase the severity of adverse effects when combined with gamma-Hydroxybutyric acid
|
DB00996
|
DB01209
| 652 | 966 |
Gabapentin
|
Dezocine
|
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin].
|
Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.
|
The risk or severity of adverse effects can be increased when Gabapentin is combined with Dezocine.
| 48 |
[
[
[
652,
71,
966
]
],
[
[
652,
246,
674
],
[
674,
30,
966
]
],
[
[
652,
192,
1266
],
[
1266,
38,
966
]
],
[
[
652,
38,
405
],
[
405,
192,
966
]
],
[
[
652,
54,
471
],
[
471,
208,
966
]
],
[
[
652,
71,
1009
],
[
1009,
225,
966
]
],
[
[
652,
225,
515
],
[
515,
71,
966
]
],
[
[
652,
71,
275
],
[
275,
71,
966
]
],
[
[
652,
249,
150
],
[
150,
225,
966
]
],
[
[
652,
71,
828
],
[
828,
86,
966
]
]
] |
[
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Normethadone"
],
[
"Normethadone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dezocine"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the serotonergic activities of {v}",
"Dezocine"
]
]
] |
Gabapentin may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Dezocine
Gabapentin may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Dezocine
Gabapentin may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Dezocine
Gabapentin may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Dezocine
Gabapentin may increase the severity of adverse effects when combined with Normethadone and Normethadone may increase the severity of adverse effects when combined with Dezocine
Gabapentin may increase the severity of adverse effects when combined with Alprazolam and Alprazolam may increase the severity of adverse effects when combined with Dezocine
Gabapentin may increase the severity of adverse effects when combined with Estazolam and Estazolam may increase the severity of adverse effects when combined with Dezocine
Gabapentin may increase the serum concentration of Fosphenytoin and Fosphenytoin may increase the severity of adverse effects when combined with Dezocine
Gabapentin may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the serotonergic activities of Dezocine
|
DB00653
|
DB06817
| 405 | 1,435 |
Magnesium sulfate
|
Raltegravir
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
|
The serum concentration of Raltegravir can be decreased when it is combined with Magnesium sulfate.
| 74 |
[
[
[
405,
97,
1435
]
],
[
[
405,
21,
28988
],
[
28988,
175,
1435
]
],
[
[
405,
71,
307
],
[
307,
70,
1435
]
],
[
[
405,
251,
177
],
[
177,
249,
1435
]
],
[
[
405,
71,
94
],
[
94,
97,
1435
]
],
[
[
405,
251,
147
],
[
147,
97,
1435
]
],
[
[
405,
21,
28988
],
[
28988,
175,
808
],
[
808,
97,
1435
]
],
[
[
405,
21,
28396
],
[
28396,
175,
350
],
[
350,
70,
1435
]
],
[
[
405,
71,
307
],
[
307,
6,
11345
],
[
11345,
160,
1435
]
],
[
[
405,
71,
598
],
[
598,
18,
4263
],
[
4263,
161,
1435
]
]
] |
[
[
[
"Magnesium sulfate",
"{u} may decrease the serum concentration of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Depressed level of consciousness"
],
[
"Depressed level of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may increase the myopathic rhabdomyolysis activities of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} may increase the serum concentration of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may decrease the serum concentration of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Depressed level of consciousness"
],
[
"Depressed level of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may decrease the serum concentration of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pravastatin"
],
[
"Pravastatin",
"{u} may increase the myopathic rhabdomyolysis activities of {v}",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Raltegravir"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) downregulates {v} (Gene)",
"ICAM3"
],
[
"ICAM3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Raltegravir"
]
]
] |
Magnesium sulfate (Compound) causes Depressed level of consciousness (Side Effect) and Depressed level of consciousness (Side Effect) is caused by Raltegravir (Compound)
Magnesium sulfate may increase the severity of adverse effects when combined with Fluvastatin and Fluvastatin may increase the myopathic rhabdomyolysis activities of Raltegravir
Magnesium sulfate may decrease the serum concentration of Rifapentine and Rifapentine may increase the serum concentration of Raltegravir
Magnesium sulfate may increase the severity of adverse effects when combined with Magnesium oxide and Magnesium oxide may decrease the serum concentration of Raltegravir
Magnesium sulfate may decrease the serum concentration of Rifampicin and Rifampicin may decrease the serum concentration of Raltegravir
Magnesium sulfate (Compound) causes Depressed level of consciousness (Side Effect) and Depressed level of consciousness (Side Effect) is caused by Magnesium salicylate (Compound) and Magnesium salicylate may decrease the serum concentration of Raltegravir
Magnesium sulfate (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Pravastatin (Compound) and Pravastatin may increase the myopathic rhabdomyolysis activities of Raltegravir
Magnesium sulfate may increase the severity of adverse effects when combined with Fluvastatin and Fluvastatin (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Raltegravir (Compound)
Magnesium sulfate may increase the severity of adverse effects when combined with Pitavastatin and Pitavastatin (Compound) downregulates ICAM3 (Gene) and ICAM3 (Gene) is upregulated by Raltegravir (Compound)
|
DB00337
|
DB00768
| 331 | 478 |
Pimecrolimus
|
Olopatadine
|
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
|
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of [doxepin], which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions. An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes. Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations. It is currently marketed
|
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.
| 48 |
[
[
[
331,
71,
478
]
],
[
[
331,
6,
4590
],
[
4590,
160,
478
]
],
[
[
331,
21,
28725
],
[
28725,
175,
478
]
],
[
[
331,
180,
171
],
[
171,
26,
478
]
],
[
[
331,
69,
173
],
[
173,
26,
478
]
],
[
[
331,
182,
560
],
[
560,
28,
478
]
],
[
[
331,
49,
884
],
[
884,
203,
478
]
],
[
[
331,
51,
557
],
[
557,
205,
478
]
],
[
[
331,
213,
1033
],
[
1033,
59,
478
]
],
[
[
331,
69,
1085
],
[
1085,
223,
478
]
]
] |
[
[
[
"Pimecrolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may increase the anticoagulant activities of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may increase the neuroexcitatory activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may decrease the diuretic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may decrease the antihypertensive activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Olopatadine"
]
],
[
[
"Pimecrolimus",
"{u} may decrease the metabolism of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may decrease the metabolism of {v}",
"Olopatadine"
]
]
] |
Pimecrolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Olopatadine (Compound)
Pimecrolimus (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Olopatadine (Compound)
Pimecrolimus can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Olopatadine
Pimecrolimus may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Olopatadine
Pimecrolimus may increase the anticoagulant activities of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Olopatadine
Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin and Levofloxacin may increase the neuroexcitatory activities of Olopatadine
Pimecrolimus may decrease the diuretic activities of Torasemide and Torasemide may decrease the diuretic activities of Olopatadine
Pimecrolimus may decrease the antihypertensive activities of Bupranolol and Bupranolol may decrease the antihypertensive activities of Olopatadine
Pimecrolimus may decrease the metabolism of Olaparib and Olaparib may decrease the metabolism of Olopatadine
|
DB01624
|
DB00281
| 971 | 611 |
Zuclopenthixol
|
Lidocaine
|
Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A)
|
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
|
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lidocaine.
| 48 |
[
[
[
971,
71,
611
]
],
[
[
971,
71,
541
],
[
541,
69,
611
]
],
[
[
971,
71,
937
],
[
937,
225,
611
]
],
[
[
971,
6,
18777
],
[
18777,
160,
611
]
],
[
[
971,
21,
28522
],
[
28522,
175,
611
]
],
[
[
971,
251,
142
],
[
142,
26,
611
]
],
[
[
971,
38,
1261
],
[
1261,
192,
611
]
],
[
[
971,
192,
491
],
[
491,
38,
611
]
],
[
[
971,
1,
1262
],
[
1262,
192,
611
]
],
[
[
971,
95,
143
],
[
143,
223,
611
]
]
] |
[
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chloroprocaine"
],
[
"Chloroprocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Lidocaine"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the serum concentration of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
]
] |
Zuclopenthixol may increase the severity of adverse effects when combined with Ropivacaine and Ropivacaine may decrease the metabolism of Lidocaine
Zuclopenthixol may increase the severity of adverse effects when combined with Chloroprocaine and Chloroprocaine may increase the severity of adverse effects when combined with Lidocaine
Zuclopenthixol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Lidocaine (Compound)
Zuclopenthixol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Lidocaine (Compound)
Zuclopenthixol may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Lidocaine
Zuclopenthixol may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Lidocaine
Zuclopenthixol may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Lidocaine
Zuclopenthixol (Compound) resembles Hydroxyzine (Compound) and Hydroxyzine may increase the central nervous system depressant activities of Lidocaine
Zuclopenthixol may increase the serum concentration of Erythromycin and Erythromycin may decrease the metabolism of Lidocaine
|
DB01182
|
DB06603
| 1,318 | 1,098 |
Propafenone
|
Panobinostat
|
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
The serum concentration of Panobinostat can be increased when it is combined with Propafenone.
| 72 |
[
[
[
1318,
95,
1098
]
],
[
[
1318,
42,
568
],
[
568,
187,
1098
]
],
[
[
1318,
42,
818
],
[
818,
196,
1098
]
],
[
[
1318,
196,
784
],
[
784,
42,
1098
]
],
[
[
1318,
95,
472
],
[
472,
196,
1098
]
],
[
[
1318,
121,
361
],
[
361,
196,
1098
]
],
[
[
1318,
249,
1027
],
[
1027,
42,
1098
]
],
[
[
1318,
258,
589
],
[
589,
42,
1098
]
],
[
[
1318,
95,
1079
],
[
1079,
42,
1098
]
],
[
[
1318,
249,
730
],
[
730,
196,
1098
]
]
] |
[
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the QTc prolonging activities of {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the arrhythmogenic activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
]
] |
Propafenone may increase the QTc prolonging activities of Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Panobinostat
Propafenone may increase the QTc prolonging activities of Norfloxacin and Norfloxacin may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the QTc prolonging activities of Anagrelide and Anagrelide may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the serum concentration of Isradipine and Isradipine may increase the QTc prolonging activities of Panobinostat
Propafenone (Compound) resembles Salmeterol (Compound) and Propafenone may increase the QTc prolonging activities of Salmeterol and Salmeterol may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the serum concentration of Sotalol and Sotalol may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the arrhythmogenic activities of Disopyramide and Disopyramide may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the serum concentration of Crizotinib and Crizotinib may increase the QTc prolonging activities of Panobinostat
Propafenone may increase the serum concentration of Tizanidine and Tizanidine may increase the QTc prolonging activities of Panobinostat
|
DB09281
|
DB06589
| 90 | 437 |
Magnesium trisilicate
|
Pazopanib
|
Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
|
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
|
The serum concentration of Pazopanib can be decreased when it is combined with Magnesium trisilicate.
| 74 |
[
[
[
90,
97,
437
]
],
[
[
90,
243,
863
],
[
863,
196,
437
]
],
[
[
90,
97,
1320
],
[
1320,
196,
437
]
],
[
[
90,
243,
755
],
[
755,
223,
437
]
],
[
[
90,
97,
959
],
[
959,
249,
437
]
],
[
[
90,
25,
119
],
[
119,
249,
437
]
],
[
[
90,
249,
640
],
[
640,
249,
437
]
],
[
[
90,
243,
653
],
[
653,
95,
437
]
],
[
[
90,
243,
764
],
[
764,
249,
437
]
],
[
[
90,
97,
684
],
[
684,
97,
437
]
]
] |
[
[
[
"Magnesium trisilicate",
"{u} may decrease the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the absorption and serum concentration of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the serum concentration of {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} may increase the QTc prolonging activities of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the absorption and serum concentration of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the serum concentration of {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} can decrease the bioavailability of {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may increase the serum concentration of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the absorption and serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the absorption and serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
]
],
[
[
"Magnesium trisilicate",
"{u} may decrease the serum concentration of {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Pazopanib"
]
]
] |
Magnesium trisilicate may decrease the absorption and serum concentration of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Pazopanib
Magnesium trisilicate may decrease the serum concentration of Ibandronate and Ibandronate may increase the QTc prolonging activities of Pazopanib
Magnesium trisilicate may decrease the absorption and serum concentration of Doxycycline and Doxycycline may decrease the metabolism of Pazopanib
Magnesium trisilicate may decrease the serum concentration of Fexofenadine and Fexofenadine may increase the serum concentration of Pazopanib
Magnesium trisilicate can decrease the bioavailability of Dexamethasone and Dexamethasone may increase the serum concentration of Pazopanib
Magnesium trisilicate may increase the serum concentration of Quinine and Quinine may increase the serum concentration of Pazopanib
Magnesium trisilicate may decrease the absorption and serum concentration of Thioridazine and Thioridazine may increase the serum concentration of Pazopanib
Magnesium trisilicate may decrease the absorption and serum concentration of Dasatinib and Dasatinib may increase the serum concentration of Pazopanib
Magnesium trisilicate may decrease the serum concentration of Dabrafenib and Dabrafenib may decrease the serum concentration of Pazopanib
|
DB01400
|
DB00340
| 1,292 | 64 |
Neostigmine
|
Metixene
|
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
|
Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
|
The therapeutic efficacy of Metixene can be decreased when used in combination with Neostigmine.
| 69 |
[
[
[
1292,
92,
64
]
],
[
[
1292,
92,
26
],
[
26,
24,
64
]
],
[
[
1292,
92,
40
],
[
40,
71,
64
]
],
[
[
1292,
92,
13
],
[
13,
225,
64
]
],
[
[
1292,
1,
1290
],
[
1290,
92,
64
]
],
[
[
1292,
92,
69
],
[
69,
116,
64
]
],
[
[
1292,
92,
26
],
[
26,
69,
653
],
[
653,
1,
64
]
],
[
[
1292,
92,
20
],
[
20,
24,
16
],
[
16,
178,
64
]
],
[
[
1292,
92,
28
],
[
28,
6,
5535
],
[
5535,
160,
64
]
],
[
[
1292,
92,
17
],
[
17,
155,
989
],
[
989,
1,
64
]
]
] |
[
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Methscopolamine"
],
[
"Methscopolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Edrophonium"
],
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Profenamine"
],
[
"Profenamine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} may increase the anticholinergic activities of {v}",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Metixene"
]
],
[
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Trimethaphan"
],
[
"Trimethaphan",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Metixene"
]
]
] |
Neostigmine may decrease the therapeutic efficacy of Tiotropium and Tiotropium may increase the anticholinergic activities of Metixene
Neostigmine may decrease the therapeutic efficacy of Vecuronium and Vecuronium may increase the severity of adverse effects when combined with Metixene
Neostigmine may decrease the therapeutic efficacy of Methscopolamine and Methscopolamine may increase the severity of adverse effects when combined with Metixene
Neostigmine (Compound) resembles Edrophonium (Compound) and Edrophonium may decrease the therapeutic efficacy of Metixene
Neostigmine may decrease the therapeutic efficacy of Profenamine and Profenamine (Compound) resembles Metixene (Compound) and Profenamine may increase the severity of adverse effects when combined with Metixene
Neostigmine may decrease the therapeutic efficacy of Tiotropium and Tiotropium may decrease the metabolism of Thioridazine and Thioridazine (Compound) resembles Metixene (Compound)
Neostigmine may decrease the therapeutic efficacy of Umeclidinium and Umeclidinium may increase the anticholinergic activities of Mianserin and Mianserin may increase the anticholinergic activities of Metixene
Neostigmine may decrease the therapeutic efficacy of Glycopyrronium and Glycopyrronium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Metixene (Compound)
Neostigmine may decrease the therapeutic efficacy of Trimethaphan and Trimethaphan (Compound) resembles Cyclizine (Compound) and Cyclizine (Compound) resembles Metixene (Compound)
|
DB00802
|
DB01601
| 419 | 429 |
Alfentanil
|
Lopinavir
|
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
|
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
|
The metabolism of Lopinavir can be decreased when combined with Alfentanil.
| 46 |
[
[
[
419,
69,
429
]
],
[
[
419,
95,
244
],
[
244,
69,
429
]
],
[
[
419,
6,
8339
],
[
8339,
160,
429
]
],
[
[
419,
180,
161
],
[
161,
26,
429
]
],
[
[
419,
71,
552
],
[
552,
180,
429
]
],
[
[
419,
251,
177
],
[
177,
26,
429
]
],
[
[
419,
225,
464
],
[
464,
180,
429
]
],
[
[
419,
71,
175
],
[
175,
42,
429
]
],
[
[
419,
71,
970
],
[
970,
196,
429
]
],
[
[
419,
225,
347
],
[
347,
196,
429
]
]
] |
[
[
[
"Alfentanil",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the serum concentration of {v}",
"Ritonavir"
],
[
"Ritonavir",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meprobamate"
],
[
"Meprobamate",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
]
] |
Alfentanil may increase the serum concentration of Ritonavir and Ritonavir may decrease the metabolism of Lopinavir
Alfentanil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lopinavir (Compound)
Alfentanil can increase the metabolism of Primidone and Primidone can increase the metabolism of Lopinavir
Alfentanil may increase the severity of adverse effects when combined with Methsuximide and Methsuximide can increase the metabolism of Lopinavir
Alfentanil may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Lopinavir
Alfentanil may increase the severity of adverse effects when combined with Meprobamate and Meprobamate can increase the metabolism of Lopinavir
Alfentanil may increase the severity of adverse effects when combined with Trazodone and Trazodone may increase the QTc prolonging activities of Lopinavir
Alfentanil may increase the severity of adverse effects when combined with Thiothixene and Thiothixene may increase the QTc prolonging activities of Lopinavir
Alfentanil may increase the severity of adverse effects when combined with Isoflurane and Isoflurane may increase the QTc prolonging activities of Lopinavir
|
DB00680
|
DB00295
| 1,450 | 540 |
Moricizine
|
Morphine
|
An antiarrhythmia agent used primarily for ventricular rhythm disturbances.
|
Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.
|
Moricizine may increase the hypotensive activities of Morphine.
| 59 |
[
[
[
1450,
82,
540
]
],
[
[
1450,
82,
1083
],
[
1083,
38,
540
]
],
[
[
1450,
82,
579
],
[
579,
225,
540
]
],
[
[
1450,
1,
55
],
[
55,
30,
540
]
],
[
[
1450,
71,
648
],
[
648,
223,
540
]
],
[
[
1450,
95,
755
],
[
755,
223,
540
]
],
[
[
1450,
1,
653
],
[
653,
223,
540
]
],
[
[
1450,
82,
1037
],
[
1037,
223,
540
]
],
[
[
1450,
71,
499
],
[
499,
71,
540
]
],
[
[
1450,
1,
1014
],
[
1014,
225,
540
]
]
] |
[
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Moclobemide"
],
[
"Moclobemide",
"{u} can increase the therapeutic efficacy of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the metabolism of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the metabolism of {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
]
] |
Moricizine may increase the hypotensive activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Morphine
Moricizine may increase the hypotensive activities of Codeine and Codeine may increase the severity of adverse effects when combined with Morphine
Moricizine (Compound) resembles Moclobemide (Compound) and Moclobemide can increase the therapeutic efficacy of Morphine
Moricizine may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may decrease the metabolism of Morphine
Moricizine may increase the serum concentration of Doxycycline and Doxycycline may decrease the metabolism of Morphine
Moricizine (Compound) resembles Thioridazine (Compound) and Thioridazine may decrease the metabolism of Morphine
Moricizine may increase the hypotensive activities of Betaxolol and Betaxolol may decrease the metabolism of Morphine
Moricizine may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Morphine
Moricizine (Compound) resembles Fluphenazine (Compound) and Fluphenazine may increase the severity of adverse effects when combined with Morphine
|
DB00641
|
DB06697
| 439 | 539 |
Simvastatin
|
Artemether
|
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
|
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
|
The metabolism of Artemether can be decreased when combined with Simvastatin.
| 46 |
[
[
[
439,
69,
539
]
],
[
[
439,
6,
18777
],
[
18777,
160,
539
]
],
[
[
439,
180,
171
],
[
171,
33,
539
]
],
[
[
439,
251,
142
],
[
142,
33,
539
]
],
[
[
439,
95,
458
],
[
458,
189,
539
]
],
[
[
439,
69,
158
],
[
158,
196,
539
]
],
[
[
439,
95,
705
],
[
705,
196,
539
]
],
[
[
439,
95,
285
],
[
285,
55,
539
]
],
[
[
439,
69,
588
],
[
588,
55,
539
]
],
[
[
439,
249,
365
],
[
365,
55,
539
]
]
] |
[
[
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Progesterone"
],
[
"Progesterone",
"{u} may decrease the absorption of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Amodiaquine"
],
[
"Amodiaquine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
]
] |
Simvastatin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Simvastatin can increase the metabolism of Pentobarbital and Pentobarbital may reduce the serum concentration of the active metabolites of Artemether
Simvastatin may decrease the serum concentration of Phenytoin and Phenytoin may reduce the serum concentration of the active metabolites of Artemether
Simvastatin may increase the serum concentration of Progesterone and Progesterone may decrease the absorption of Artemether
Simvastatin may decrease the metabolism of Nicardipine and Nicardipine may increase the QTc prolonging activities of Artemether
Simvastatin may increase the serum concentration of Salbutamol and Salbutamol may increase the QTc prolonging activities of Artemether
Simvastatin may increase the serum concentration of Mefloquine and Mefloquine may increase the severity of QTc prolonging effects when combined with Artemether
Simvastatin may decrease the metabolism of Chloroquine and Chloroquine may increase the severity of QTc prolonging effects when combined with Artemether
Simvastatin may increase the serum concentration of Amodiaquine and Amodiaquine may increase the severity of QTc prolonging effects when combined with Artemether
|
DB00454
|
DB01267
| 465 | 1,007 |
Meperidine
|
Paliperidone
|
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
|
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
|
The risk or severity of adverse effects can be increased when Meperidine is combined with Paliperidone.
| 48 |
[
[
[
465,
71,
1007
]
],
[
[
465,
71,
196
],
[
196,
1,
1007
]
],
[
[
465,
6,
18777
],
[
18777,
160,
1007
]
],
[
[
465,
21,
29547
],
[
29547,
175,
1007
]
],
[
[
465,
38,
1261
],
[
1261,
192,
1007
]
],
[
[
465,
192,
72
],
[
72,
38,
1007
]
],
[
[
465,
95,
1019
],
[
1019,
42,
1007
]
],
[
[
465,
225,
501
],
[
501,
196,
1007
]
],
[
[
465,
69,
878
],
[
878,
196,
1007
]
],
[
[
465,
95,
1098
],
[
1098,
196,
1007
]
]
] |
[
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Myoclonus"
],
[
"Myoclonus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
]
],
[
[
"Meperidine",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
]
]
] |
Meperidine may increase the severity of adverse effects when combined with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Meperidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paliperidone (Compound)
Meperidine (Compound) causes Myoclonus (Side Effect) and Myoclonus (Side Effect) is caused by Paliperidone (Compound)
Meperidine may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Paliperidone
Meperidine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Paliperidone
Meperidine may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Paliperidone
Meperidine may increase the severity of adverse effects when combined with Saquinavir and Saquinavir may increase the QTc prolonging activities of Paliperidone
Meperidine may decrease the metabolism of Paroxetine and Paroxetine may increase the QTc prolonging activities of Paliperidone
Meperidine may increase the serum concentration of Panobinostat and Panobinostat may increase the QTc prolonging activities of Paliperidone
|
DB01320
|
DB00273
| 150 | 1,108 |
Fosphenytoin
|
Topiramate
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
|
The serum concentration of Topiramate can be decreased when it is combined with Fosphenytoin.
| 74 |
[
[
[
150,
97,
1108
]
],
[
[
150,
5,
17899
],
[
17899,
159,
1108
]
],
[
[
150,
6,
4590
],
[
4590,
160,
1108
]
],
[
[
150,
169,
24704
],
[
24704,
15,
1108
]
],
[
[
150,
21,
28994
],
[
28994,
175,
1108
]
],
[
[
150,
26,
597
],
[
597,
187,
1108
]
],
[
[
150,
95,
405
],
[
405,
192,
1108
]
],
[
[
150,
38,
1262
],
[
1262,
192,
1108
]
],
[
[
150,
192,
679
],
[
679,
38,
1108
]
],
[
[
150,
54,
1365
],
[
1365,
208,
1108
]
]
] |
[
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) treats {v} (Disease)",
"epilepsy syndrome"
],
[
"epilepsy syndrome",
"{u} (Disease) is treated by {v} (Compound)",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Decreased Central Nervous System Disorganized Electrical Activity"
],
[
"Decreased Central Nervous System Disorganized Electrical Activity",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Vaginal inflammation"
],
[
"Vaginal inflammation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Topiramate"
]
],
[
[
"Fosphenytoin",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Topiramate"
]
]
] |
Fosphenytoin (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Topiramate (Compound)
Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topiramate (Compound)
Fosphenytoin (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class) and Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class) includes Topiramate (Compound)
Fosphenytoin (Compound) causes Vaginal inflammation (Side Effect) and Vaginal inflammation (Side Effect) is caused by Topiramate (Compound)
Fosphenytoin can increase the metabolism of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Topiramate
Fosphenytoin may increase the serum concentration of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Topiramate
Fosphenytoin may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Topiramate
Fosphenytoin may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Topiramate
Fosphenytoin may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Topiramate
|
DB00648
|
DB00976
| 1,080 | 528 |
Mitotane
|
Telithromycin
|
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
The serum concentration of Telithromycin can be decreased when it is combined with Mitotane.
| 74 |
[
[
[
1080,
97,
528
]
],
[
[
1080,
97,
1088
],
[
1088,
42,
528
]
],
[
[
1080,
21,
28611
],
[
28611,
175,
528
]
],
[
[
1080,
97,
147
],
[
147,
26,
528
]
],
[
[
1080,
97,
680
],
[
680,
187,
528
]
],
[
[
1080,
97,
588
],
[
588,
196,
528
]
],
[
[
1080,
97,
438
],
[
438,
69,
528
]
],
[
[
1080,
97,
163
],
[
163,
225,
528
]
],
[
[
1080,
97,
482
],
[
482,
230,
528
]
],
[
[
1080,
97,
437
],
[
437,
95,
528
]
]
] |
[
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may increase the bradycardic activities of {v}",
"Telithromycin"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may increase the serum concentration of {v}",
"Telithromycin"
]
]
] |
Mitotane may decrease the serum concentration of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Mitotane (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Telithromycin (Compound)
Mitotane may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Telithromycin
Mitotane may decrease the serum concentration of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Telithromycin
Mitotane may decrease the serum concentration of Chloroquine and Chloroquine may increase the QTc prolonging activities of Telithromycin
Mitotane may decrease the serum concentration of Imipramine and Imipramine may decrease the metabolism of Telithromycin
Mitotane may decrease the serum concentration of Oxycodone and Oxycodone may increase the severity of adverse effects when combined with Telithromycin
Mitotane may decrease the serum concentration of Verapamil and Verapamil may increase the bradycardic activities of Telithromycin
Mitotane may decrease the serum concentration of Pazopanib and Pazopanib may increase the serum concentration of Telithromycin
|
DB06228
|
DB00495
| 560 | 162 |
Rivaroxaban
|
Zidovudine
|
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
|
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
|
The serum concentration of Zidovudine can be decreased when it is combined with Rivaroxaban.
| 74 |
[
[
[
560,
97,
162
]
],
[
[
560,
6,
4590
],
[
4590,
160,
162
]
],
[
[
560,
21,
28410
],
[
28410,
175,
162
]
],
[
[
560,
251,
150
],
[
150,
26,
162
]
],
[
[
560,
180,
156
],
[
156,
26,
162
]
],
[
[
560,
69,
1077
],
[
1077,
223,
162
]
],
[
[
560,
249,
615
],
[
615,
223,
162
]
],
[
[
560,
223,
482
],
[
482,
223,
162
]
],
[
[
560,
28,
582
],
[
582,
223,
162
]
],
[
[
560,
97,
508
],
[
508,
223,
162
]
]
] |
[
[
[
"Rivaroxaban",
"{u} may decrease the serum concentration of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) causes {v} (Side Effect)",
"Malaise"
],
[
"Malaise",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Rivaroxaban",
"{u} may decrease the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
]
] |
Rivaroxaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zidovudine (Compound)
Rivaroxaban (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Zidovudine (Compound)
Rivaroxaban may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Zidovudine
Rivaroxaban can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Zidovudine
Rivaroxaban may decrease the metabolism of Isavuconazonium and Isavuconazonium may decrease the metabolism of Zidovudine
Rivaroxaban may increase the serum concentration of Sildenafil and Sildenafil may decrease the metabolism of Zidovudine
Rivaroxaban may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Zidovudine
Rivaroxaban may increase the anticoagulant activities of Leflunomide and Leflunomide may decrease the metabolism of Zidovudine
Rivaroxaban may decrease the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Zidovudine
|
DB00338
|
DB01601
| 451 | 429 |
Omeprazole
|
Lopinavir
|
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
|
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
|
The metabolism of Lopinavir can be decreased when combined with Omeprazole.
| 46 |
[
[
[
451,
69,
429
]
],
[
[
451,
243,
564
],
[
564,
155,
429
]
],
[
[
451,
6,
8339
],
[
8339,
160,
429
]
],
[
[
451,
180,
161
],
[
161,
26,
429
]
],
[
[
451,
223,
430
],
[
430,
180,
429
]
],
[
[
451,
69,
297
],
[
297,
180,
429
]
],
[
[
451,
69,
795
],
[
795,
187,
429
]
],
[
[
451,
223,
680
],
[
680,
187,
429
]
],
[
[
451,
249,
730
],
[
730,
196,
429
]
],
[
[
451,
223,
492
],
[
492,
196,
429
]
]
] |
[
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the absorption and serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Oxiconazole"
],
[
"Oxiconazole",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may increase the serum concentration of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
],
[
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
]
] |
Omeprazole may decrease the absorption and serum concentration of Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound)
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lopinavir (Compound)
Omeprazole can increase the metabolism of Primidone and Primidone can increase the metabolism of Lopinavir
Omeprazole may decrease the metabolism of Oxiconazole and Oxiconazole can increase the metabolism of Lopinavir
Omeprazole may decrease the metabolism of Tolbutamide and Tolbutamide can increase the metabolism of Lopinavir
Omeprazole may decrease the metabolism of Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Lopinavir
Omeprazole may decrease the metabolism of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Lopinavir
Omeprazole may increase the serum concentration of Tizanidine and Tizanidine may increase the QTc prolonging activities of Lopinavir
Omeprazole may decrease the metabolism of Famotidine and Famotidine may increase the QTc prolonging activities of Lopinavir
|
DB00454
|
DB09225
| 465 | 935 |
Meperidine
|
Zotepine
|
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
|
Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's. Zotepine was never approved by the FDA. In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive. When the analysis of antipsychotics was retaken in 2016 by the FDA, zotepine did not reach the threshold effect to be further studied.. In the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.
|
The risk or severity of adverse effects can be increased when Meperidine is combined with Zotepine.
| 48 |
[
[
[
465,
71,
935
]
],
[
[
465,
184,
674
],
[
674,
30,
935
]
],
[
[
465,
38,
1264
],
[
1264,
192,
935
]
],
[
[
465,
192,
491
],
[
491,
38,
935
]
],
[
[
465,
251,
495
],
[
495,
55,
935
]
],
[
[
465,
71,
18
],
[
18,
58,
935
]
],
[
[
465,
71,
354
],
[
354,
71,
935
]
],
[
[
465,
71,
1268
],
[
1268,
225,
935
]
],
[
[
465,
225,
540
],
[
540,
71,
935
]
],
[
[
465,
69,
861
],
[
861,
71,
935
]
]
] |
[
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vigabatrin"
],
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zotepine"
]
],
[
[
"Meperidine",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zotepine"
]
]
] |
Meperidine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Zotepine
Meperidine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Zotepine
Meperidine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Zotepine
Meperidine may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Zotepine
Meperidine may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Zotepine
Meperidine may increase the severity of adverse effects when combined with Sevoflurane and Sevoflurane may increase the severity of adverse effects when combined with Zotepine
Meperidine may increase the severity of adverse effects when combined with Vigabatrin and Vigabatrin may increase the severity of adverse effects when combined with Zotepine
Meperidine may increase the severity of adverse effects when combined with Morphine and Morphine may increase the severity of adverse effects when combined with Zotepine
Meperidine may decrease the metabolism of Fluvoxamine and Fluvoxamine may increase the severity of adverse effects when combined with Zotepine
|
DB00631
|
DB01189
| 1,172 | 914 |
Clofarabine
|
Desflurane
|
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
The risk or severity of adverse effects can be increased when Clofarabine is combined with Desflurane.
| 48 |
[
[
[
1172,
71,
914
]
],
[
[
1172,
71,
347
],
[
347,
71,
914
]
],
[
[
1172,
21,
28614
],
[
28614,
175,
914
]
],
[
[
1172,
71,
702
],
[
702,
192,
914
]
],
[
[
1172,
225,
137
],
[
137,
42,
914
]
],
[
[
1172,
71,
955
],
[
955,
42,
914
]
],
[
[
1172,
52,
968
],
[
968,
206,
914
]
],
[
[
1172,
71,
471
],
[
471,
208,
914
]
],
[
[
1172,
71,
535
],
[
535,
225,
914
]
],
[
[
1172,
236,
197
],
[
197,
225,
914
]
]
] |
[
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Irbesartan"
],
[
"Irbesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
],
[
[
"Clofarabine",
"{u} may increase the hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
]
] |
Clofarabine may increase the severity of adverse effects when combined with Isoflurane and Isoflurane may increase the severity of adverse effects when combined with Desflurane
Clofarabine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Desflurane (Compound)
Clofarabine may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the central nervous system depressant activities of Desflurane
Clofarabine may increase the severity of adverse effects when combined with Amiodarone and Amiodarone may increase the QTc prolonging activities of Desflurane
Clofarabine may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the QTc prolonging activities of Desflurane
Clofarabine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Desflurane
Clofarabine may increase the severity of adverse effects when combined with Rotigotine and Rotigotine may increase the sedative activities of Desflurane
Clofarabine may increase the severity of adverse effects when combined with Irbesartan and Irbesartan may increase the severity of adverse effects when combined with Desflurane
Clofarabine may increase the hypotensive activities of Amobarbital and Amobarbital may increase the severity of adverse effects when combined with Desflurane
|
DB00706
|
DB01001
| 509 | 705 |
Tamsulosin
|
Salbutamol
|
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension. Tamsulosin was first approved by the FDA on April 15, 1997.
|
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma,
|
Tamsulosin may decrease the vasoconstricting activities of Salbutamol.
| 4 |
[
[
[
509,
27,
705
]
],
[
[
509,
27,
716
],
[
716,
1,
705
]
],
[
[
509,
27,
711
],
[
711,
155,
705
]
],
[
[
509,
206,
1033
],
[
1033,
36,
705
]
],
[
[
509,
206,
1038
],
[
1038,
155,
705
]
],
[
[
509,
6,
4590
],
[
4590,
160,
705
]
],
[
[
509,
21,
28392
],
[
28392,
175,
705
]
],
[
[
509,
186,
278
],
[
278,
27,
705
]
],
[
[
509,
1,
248
],
[
248,
27,
705
]
],
[
[
509,
69,
245
],
[
245,
42,
705
]
]
] |
[
[
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Terbutaline"
],
[
"Terbutaline",
"{u} (Compound) resembles {v} (Compound)",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nadolol"
],
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may increase the antihypertensive activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} (Compound) resembles {v} (Compound)",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the vasoconstricting activities of {v}",
"Salbutamol"
]
],
[
[
"Tamsulosin",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the QTc prolonging activities of {v}",
"Salbutamol"
]
]
] |
Tamsulosin may decrease the vasoconstricting activities of Terbutaline and Terbutaline (Compound) resembles Salbutamol (Compound)
Tamsulosin may decrease the vasoconstricting activities of Phenylephrine and Phenylephrine (Compound) resembles Salbutamol (Compound)
Tamsulosin may increase the orthostatic hypotensive activities of Bupranolol and Bupranolol may decrease the bronchodilatory activities of Salbutamol
Tamsulosin may increase the orthostatic hypotensive activities of Nadolol and Nadolol (Compound) resembles Salbutamol (Compound)
Tamsulosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Tamsulosin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Salbutamol (Compound)
Tamsulosin may increase the antihypertensive activities of Alfuzosin and Alfuzosin may decrease the vasoconstricting activities of Salbutamol
Tamsulosin (Compound) resembles Carvedilol (Compound) and Carvedilol may decrease the vasoconstricting activities of Salbutamol
Tamsulosin may decrease the metabolism of Haloperidol and Haloperidol may increase the QTc prolonging activities of Salbutamol
|
DB08860
|
DB08827
| 598 | 517 |
Pitavastatin
|
Lomitapide
|
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those
|
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
|
The serum concentration of Lomitapide can be increased when it is combined with Pitavastatin.
| 72 |
[
[
[
598,
95,
517
]
],
[
[
598,
95,
531
],
[
531,
249,
517
]
],
[
[
598,
6,
8339
],
[
8339,
160,
517
]
],
[
[
598,
21,
28484
],
[
28484,
175,
517
]
],
[
[
598,
180,
164
],
[
164,
26,
517
]
],
[
[
598,
251,
150
],
[
150,
26,
517
]
],
[
[
598,
95,
177
],
[
177,
26,
517
]
],
[
[
598,
95,
563
],
[
563,
71,
517
]
],
[
[
598,
69,
613
],
[
613,
249,
517
]
],
[
[
598,
95,
1168
],
[
1168,
95,
517
]
]
] |
[
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Nasopharyngitis"
],
[
"Nasopharyngitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may increase the serum concentration of {v}",
"Lomitapide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may increase the serum concentration of {v}",
"Lomitapide"
]
]
] |
Pitavastatin may increase the serum concentration of Conivaptan and Conivaptan may increase the serum concentration of Lomitapide
Pitavastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lomitapide (Compound)
Pitavastatin (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Lomitapide (Compound)
Pitavastatin can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Lomitapide
Pitavastatin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Lomitapide
Pitavastatin may increase the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Lomitapide
Pitavastatin may increase the serum concentration of Ergotamine and Ergotamine may increase the severity of adverse effects when combined with Lomitapide
Pitavastatin may decrease the metabolism of Ticlopidine and Ticlopidine may increase the serum concentration of Lomitapide
Pitavastatin may increase the serum concentration of Topotecan and Topotecan may increase the serum concentration of Lomitapide
|
DB00774
|
DB01054
| 1,072 | 329 |
Hydroflumethiazide
|
Nitrendipine
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
|
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
|
Hydroflumethiazide may increase the hypotensive activities of Nitrendipine.
| 59 |
[
[
[
1072,
82,
329
]
],
[
[
1072,
236,
472
],
[
472,
223,
329
]
],
[
[
1072,
82,
435
],
[
435,
1,
329
]
],
[
[
1072,
236,
158
],
[
158,
1,
329
]
],
[
[
1072,
18,
2826
],
[
2826,
172,
329
]
],
[
[
1072,
206,
197
],
[
197,
26,
329
]
],
[
[
1072,
186,
344
],
[
344,
32,
329
]
],
[
[
1072,
52,
968
],
[
968,
206,
329
]
],
[
[
1072,
59,
230
],
[
230,
213,
329
]
],
[
[
1072,
77,
648
],
[
648,
223,
329
]
]
] |
[
[
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may decrease the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"PSMD2"
],
[
"PSMD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Hydroflumethiazide",
"{u} may increase the hyponatremic activities of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Nitrendipine"
]
]
] |
Hydroflumethiazide may increase the hypotensive activities of Isradipine and Isradipine may decrease the metabolism of Nitrendipine
Hydroflumethiazide may increase the hypotensive activities of Nilvadipine and Nilvadipine (Compound) resembles Nitrendipine (Compound)
Hydroflumethiazide may increase the hypotensive activities of Nicardipine and Nicardipine (Compound) resembles Nitrendipine (Compound)
Hydroflumethiazide (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Nitrendipine (Compound)
Hydroflumethiazide may increase the orthostatic hypotensive activities of Amobarbital and Amobarbital can increase the metabolism of Nitrendipine
Hydroflumethiazide may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Nitrendipine
Hydroflumethiazide may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Nitrendipine
Hydroflumethiazide may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Nitrendipine
Hydroflumethiazide may increase the hyponatremic activities of Nefazodone and Nefazodone may decrease the metabolism of Nitrendipine
|
DB06695
|
DB00469
| 677 | 584 |
Dabigatran etexilate
|
Tenoxicam
|
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. Dabigatran etexilate was approved by the FDA in 2010.
|
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
|
Dabigatran etexilate may increase the anticoagulant activities of Tenoxicam.
| 5 |
[
[
[
677,
28,
584
]
],
[
[
677,
21,
28747
],
[
28747,
175,
584
]
],
[
[
677,
251,
164
],
[
164,
26,
584
]
],
[
[
677,
180,
156
],
[
156,
26,
584
]
],
[
[
677,
182,
744
],
[
744,
28,
584
]
],
[
[
677,
28,
560
],
[
560,
28,
584
]
],
[
[
677,
253,
884
],
[
884,
203,
584
]
],
[
[
677,
253,
504
],
[
504,
59,
584
]
],
[
[
677,
253,
267
],
[
267,
223,
584
]
],
[
[
677,
249,
615
],
[
615,
223,
584
]
]
] |
[
[
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Dabigatran etexilate",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Tenoxicam"
]
]
] |
Dabigatran etexilate (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Tenoxicam (Compound)
Dabigatran etexilate may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Tenoxicam
Dabigatran etexilate can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Tenoxicam
Dabigatran etexilate may increase the anticoagulant activities of Edoxaban and Edoxaban may increase the anticoagulant activities of Tenoxicam
Dabigatran etexilate may increase the anticoagulant activities of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Tenoxicam
Dabigatran etexilate may increase the serum concentration of the active metabolites of Levofloxacin and Levofloxacin may increase the neuroexcitatory activities of Tenoxicam
Dabigatran etexilate may increase the serum concentration of the active metabolites of Propranolol and Propranolol may decrease the antihypertensive activities of Tenoxicam
Dabigatran etexilate may increase the serum concentration of the active metabolites of Lovastatin and Lovastatin may decrease the metabolism of Tenoxicam
Dabigatran etexilate may increase the serum concentration of Sildenafil and Sildenafil may decrease the metabolism of Tenoxicam
|
DB00531
|
DB01030
| 243 | 1,168 |
Cyclophosphamide
|
Topotecan
|
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
|
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
|
Cyclophosphamide may increase the cardiotoxic activities of Topotecan.
| 14 |
[
[
[
243,
37,
1168
]
],
[
[
243,
37,
1212
],
[
1212,
155,
1168
]
],
[
[
243,
6,
4590
],
[
4590,
160,
1168
]
],
[
[
243,
18,
5334
],
[
5334,
172,
1168
]
],
[
[
243,
21,
28398
],
[
28398,
175,
1168
]
],
[
[
243,
210,
1388
],
[
1388,
56,
1168
]
],
[
[
243,
225,
1303
],
[
1303,
71,
1168
]
],
[
[
243,
71,
582
],
[
582,
225,
1168
]
],
[
[
243,
37,
889
],
[
889,
71,
1168
]
],
[
[
243,
80,
1350
],
[
1350,
234,
1168
]
]
] |
[
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} (Compound) resembles {v} (Compound)",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the immunosuppressive activities of {v}",
"Roflumilast"
],
[
"Roflumilast",
"{u} may increase the immunosuppressive activities of {v}",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Carboplatin"
],
[
"Carboplatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topotecan"
]
],
[
[
"Cyclophosphamide",
"{u} may decrease the cardiotoxic activities of {v}",
"Deslanoside"
],
[
"Deslanoside",
"{u} may decrease the cardiotoxic activities of {v}",
"Topotecan"
]
]
] |
Cyclophosphamide may increase the cardiotoxic activities of Irinotecan and Irinotecan (Compound) resembles Topotecan (Compound)
Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topotecan (Compound)
Cyclophosphamide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Topotecan (Compound)
Cyclophosphamide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Topotecan (Compound)
Cyclophosphamide may increase the immunosuppressive activities of Roflumilast and Roflumilast may increase the immunosuppressive activities of Topotecan
Cyclophosphamide may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Topotecan
Cyclophosphamide may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may increase the severity of adverse effects when combined with Topotecan
Cyclophosphamide may increase the cardiotoxic activities of Carboplatin and Carboplatin may increase the severity of adverse effects when combined with Topotecan
Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside and Deslanoside may decrease the cardiotoxic activities of Topotecan
|
DB00712
|
DB00429
| 388 | 1,489 |
Flurbiprofen
|
Carboprost tromethamine
|
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
|
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
|
The therapeutic efficacy of Carboprost tromethamine can be decreased when used in combination with Flurbiprofen.
| 69 |
[
[
[
388,
92,
1489
]
],
[
[
388,
92,
1428
],
[
1428,
155,
1489
]
],
[
[
388,
21,
28506
],
[
28506,
175,
1489
]
],
[
[
388,
155,
211
],
[
211,
92,
1489
]
],
[
[
388,
71,
774
],
[
774,
92,
1489
]
],
[
[
388,
233,
768
],
[
768,
92,
1489
]
],
[
[
388,
69,
582
],
[
582,
92,
1489
]
],
[
[
388,
1,
11
],
[
11,
92,
1489
]
],
[
[
388,
225,
770
],
[
770,
92,
1489
]
],
[
[
388,
116,
334
],
[
334,
92,
1489
]
]
] |
[
[
[
"Flurbiprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Dinoprostone"
],
[
"Dinoprostone",
"{u} (Compound) resembles {v} (Compound)",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Niflumic acid"
],
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Carprofen"
],
[
"Carprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
]
]
] |
Flurbiprofen may decrease the therapeutic efficacy of Dinoprostone and Dinoprostone (Compound) resembles Carboprost tromethamine (Compound)
Flurbiprofen (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Carboprost tromethamine (Compound)
Flurbiprofen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen may increase the severity of adverse effects when combined with Niflumic acid and Niflumic acid may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen may increase the nephrotoxic activities of Olsalazine and Olsalazine may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen may decrease the metabolism of Leflunomide and Leflunomide may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen (Compound) resembles Carprofen (Compound) and Carprofen may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen may increase the severity of adverse effects when combined with Floctafenine and Floctafenine may decrease the therapeutic efficacy of Carboprost tromethamine
Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may increase the severity of adverse effects when combined with Ibuprofen and Ibuprofen may decrease the therapeutic efficacy of Carboprost tromethamine
|
DB01355
|
DB13323
| 298 | 927 |
Hexobarbital
|
Trichloroethylene
|
A barbiturate that is effective as a hypnotic and sedative.
|
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits.
|
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Trichloroethylene.
| 48 |
[
[
[
298,
71,
927
]
],
[
[
298,
184,
674
],
[
674,
30,
927
]
],
[
[
298,
38,
1257
],
[
1257,
192,
927
]
],
[
[
298,
192,
587
],
[
587,
38,
927
]
],
[
[
298,
54,
1046
],
[
1046,
208,
927
]
],
[
[
298,
71,
552
],
[
552,
225,
927
]
],
[
[
298,
95,
639
],
[
639,
71,
927
]
],
[
[
298,
180,
156
],
[
156,
71,
927
]
],
[
[
298,
225,
371
],
[
371,
71,
927
]
],
[
[
298,
71,
911
],
[
911,
71,
927
]
]
] |
[
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the serum concentration of {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
]
] |
Hexobarbital can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Trichloroethylene
Hexobarbital may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Trichloroethylene
Hexobarbital may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Trichloroethylene
Hexobarbital may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Trichloroethylene
Hexobarbital may increase the severity of adverse effects when combined with Methsuximide and Methsuximide may increase the severity of adverse effects when combined with Trichloroethylene
Hexobarbital may increase the serum concentration of Valproic acid and Valproic acid may increase the severity of adverse effects when combined with Trichloroethylene
Hexobarbital can increase the metabolism of Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Trichloroethylene
Hexobarbital may increase the severity of adverse effects when combined with Quazepam and Quazepam may increase the severity of adverse effects when combined with Trichloroethylene
Hexobarbital may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the severity of adverse effects when combined with Trichloroethylene
|
DB01030
|
DB00831
| 1,168 | 940 |
Topotecan
|
Trifluoperazine
|
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
The serum concentration of Trifluoperazine can be increased when it is combined with Topotecan.
| 72 |
[
[
[
1168,
95,
940
]
],
[
[
1168,
71,
681
],
[
681,
155,
940
]
],
[
[
1168,
95,
1014
],
[
1014,
71,
940
]
],
[
[
1168,
6,
8339
],
[
8339,
160,
940
]
],
[
[
1168,
7,
7264
],
[
7264,
161,
940
]
],
[
[
1168,
18,
5969
],
[
5969,
161,
940
]
],
[
[
1168,
7,
12709
],
[
12709,
172,
940
]
],
[
[
1168,
18,
5353
],
[
5353,
172,
940
]
],
[
[
1168,
21,
28387
],
[
28387,
175,
940
]
],
[
[
1168,
95,
491
],
[
491,
38,
940
]
]
] |
[
[
[
"Topotecan",
"{u} may increase the serum concentration of {v}",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} may increase the serum concentration of {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"FOXO4"
],
[
"FOXO4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDK7"
],
[
"CDK7",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"BPHL"
],
[
"BPHL",
"{u} (Gene) is downregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Topotecan",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Trifluoperazine"
]
]
] |
Topotecan may increase the severity of adverse effects when combined with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Topotecan may increase the serum concentration of Fluphenazine and Fluphenazine may increase the severity of adverse effects when combined with Trifluoperazine
Topotecan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Trifluoperazine (Compound)
Topotecan (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Trifluoperazine (Compound)
Topotecan (Compound) downregulates CDK7 (Gene) and CDK7 (Gene) is upregulated by Trifluoperazine (Compound)
Topotecan (Compound) upregulates BPHL (Gene) and BPHL (Gene) is downregulated by Trifluoperazine (Compound)
Topotecan (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Trifluoperazine (Compound)
Topotecan (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Trifluoperazine (Compound)
Topotecan may increase the serum concentration of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Trifluoperazine
|
DB01708
|
DB08865
| 126 | 1,079 |
Prasterone
|
Crizotinib
|
Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion. In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
The metabolism of Crizotinib can be decreased when combined with Prasterone.
| 46 |
[
[
[
126,
69,
1079
]
],
[
[
126,
69,
610
],
[
610,
196,
1079
]
],
[
[
126,
71,
863
],
[
863,
196,
1079
]
],
[
[
126,
225,
588
],
[
588,
196,
1079
]
],
[
[
126,
105,
183
],
[
183,
196,
1079
]
],
[
[
126,
69,
755
],
[
755,
223,
1079
]
],
[
[
126,
71,
651
],
[
651,
69,
1079
]
],
[
[
126,
69,
1077
],
[
1077,
69,
1079
]
],
[
[
126,
225,
487
],
[
487,
69,
1079
]
],
[
[
126,
69,
137
],
[
137,
249,
1079
]
]
] |
[
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may increase the hypokalemic activities of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Malathion"
],
[
"Malathion",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zileuton"
],
[
"Zileuton",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may increase the serum concentration of {v}",
"Crizotinib"
]
]
] |
Prasterone may decrease the metabolism of Atomoxetine and Atomoxetine may increase the QTc prolonging activities of Crizotinib
Prasterone may increase the severity of adverse effects when combined with Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Crizotinib
Prasterone may increase the severity of adverse effects when combined with Chloroquine and Chloroquine may increase the QTc prolonging activities of Crizotinib
Prasterone may increase the hypokalemic activities of Indapamide and Indapamide may increase the QTc prolonging activities of Crizotinib
Prasterone may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Crizotinib
Prasterone may increase the severity of adverse effects when combined with Malathion and Malathion may decrease the metabolism of Crizotinib
Prasterone may decrease the metabolism of Isavuconazonium and Isavuconazonium may decrease the metabolism of Crizotinib
Prasterone may increase the severity of adverse effects when combined with Zileuton and Zileuton may decrease the metabolism of Crizotinib
Prasterone may decrease the metabolism of Amiodarone and Amiodarone may increase the serum concentration of Crizotinib
|
DB00849
|
DB01154
| 194 | 145 |
Methylphenobarbital
|
Thiamylal
|
A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
|
A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
|
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.
| 48 |
[
[
[
194,
71,
145
]
],
[
[
194,
71,
977
],
[
977,
155,
145
]
],
[
[
194,
225,
197
],
[
197,
71,
145
]
],
[
[
194,
155,
240
],
[
240,
1,
145
]
],
[
[
194,
6,
18796
],
[
18796,
160,
145
]
],
[
[
194,
26,
486
],
[
486,
180,
145
]
],
[
[
194,
180,
156
],
[
156,
26,
145
]
],
[
[
194,
1,
164
],
[
164,
26,
145
]
],
[
[
194,
155,
150
],
[
150,
26,
145
]
],
[
[
194,
246,
674
],
[
674,
30,
145
]
]
] |
[
[
[
"Methylphenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Methohexital"
],
[
"Methohexital",
"{u} (Compound) resembles {v} (Compound)",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} (Compound) binds {v} (Gene)",
"GABRA5"
],
[
"GABRA5",
"{u} (Gene) is bound by {v} (Compound)",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Doxepin"
],
[
"Doxepin",
"{u} can increase the metabolism of {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Thiamylal"
]
],
[
[
"Methylphenobarbital",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Thiamylal"
]
]
] |
Methylphenobarbital may increase the severity of adverse effects when combined with Butalbital and Butalbital (Compound) resembles Thiamylal (Compound)
Methylphenobarbital may increase the severity of adverse effects when combined with Amobarbital and Amobarbital may increase the severity of adverse effects when combined with Thiamylal
Methylphenobarbital (Compound) resembles Methohexital (Compound) and Methohexital (Compound) resembles Thiamylal (Compound)
Methylphenobarbital (Compound) binds GABRA5 (Gene) and GABRA5 (Gene) is bound by Thiamylal (Compound)
Methylphenobarbital can increase the metabolism of Doxepin and Doxepin can increase the metabolism of Thiamylal
Methylphenobarbital can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Thiamylal
Methylphenobarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital can increase the metabolism of Thiamylal
Methylphenobarbital (Compound) resembles Fosphenytoin (Compound) and Fosphenytoin can increase the metabolism of Thiamylal
Methylphenobarbital may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Thiamylal
|
DB00780
|
DB00850
| 53 | 525 |
Phenelzine
|
Perphenazine
|
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
The risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.
| 48 |
[
[
[
53,
71,
525
]
],
[
[
53,
71,
971
],
[
971,
225,
525
]
],
[
[
53,
71,
1378
],
[
1378,
155,
525
]
],
[
[
53,
71,
270
],
[
270,
71,
525
]
],
[
[
53,
71,
1379
],
[
1379,
1,
525
]
],
[
[
53,
71,
653
],
[
653,
95,
525
]
],
[
[
53,
6,
10999
],
[
10999,
160,
525
]
],
[
[
53,
18,
5785
],
[
5785,
161,
525
]
],
[
[
53,
21,
28562
],
[
28562,
175,
525
]
],
[
[
53,
225,
156
],
[
156,
26,
525
]
]
] |
[
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Periciazine"
],
[
"Periciazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} (Compound) downregulates {v} (Gene)",
"NPC1"
],
[
"NPC1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Perphenazine"
]
]
] |
Phenelzine may increase the severity of adverse effects when combined with Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Perphenazine
Phenelzine may increase the severity of adverse effects when combined with Acetophenazine and Acetophenazine (Compound) resembles Perphenazine (Compound)
Phenelzine may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Perphenazine
Phenelzine may increase the severity of adverse effects when combined with Periciazine and Periciazine (Compound) resembles Perphenazine (Compound)
Phenelzine may increase the severity of adverse effects when combined with Thioridazine and Thioridazine may increase the serum concentration of Perphenazine
Phenelzine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Perphenazine (Compound)
Phenelzine (Compound) downregulates NPC1 (Gene) and NPC1 (Gene) is upregulated by Perphenazine (Compound)
Phenelzine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Perphenazine (Compound)
Phenelzine may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Perphenazine
|
DB00492
|
DB09038
| 656 | 953 |
Fosinopril
|
Empagliflozin
|
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
|
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues
|
The risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.
| 48 |
[
[
[
656,
71,
953
]
],
[
[
656,
236,
63
],
[
63,
185,
953
]
],
[
[
656,
249,
648
],
[
648,
185,
953
]
],
[
[
656,
59,
844
],
[
844,
185,
953
]
],
[
[
656,
71,
798
],
[
798,
185,
953
]
],
[
[
656,
52,
968
],
[
968,
206,
953
]
],
[
[
656,
71,
315
],
[
315,
71,
953
]
],
[
[
656,
82,
190
],
[
190,
71,
953
]
],
[
[
656,
223,
461
],
[
461,
71,
953
]
],
[
[
656,
225,
512
],
[
512,
71,
953
]
]
] |
[
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the hypotensive activities of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the hypoglycemic activities of {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the hypoglycemic activities of {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may decrease the antihypertensive activities of {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may increase the hypoglycemic activities of {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the hypoglycemic activities of {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
]
] |
Fosinopril may increase the hypotensive activities of Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Empagliflozin
Fosinopril may increase the serum concentration of Nefazodone and Nefazodone may increase the hypoglycemic activities of Empagliflozin
Fosinopril may decrease the antihypertensive activities of Diflunisal and Diflunisal may increase the hypoglycemic activities of Empagliflozin
Fosinopril may increase the severity of adverse effects when combined with Balsalazide and Balsalazide may increase the hypoglycemic activities of Empagliflozin
Fosinopril may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Empagliflozin
Fosinopril may increase the severity of adverse effects when combined with Enalapril and Enalapril may increase the severity of adverse effects when combined with Empagliflozin
Fosinopril may increase the hypotensive activities of Bepridil and Bepridil may increase the severity of adverse effects when combined with Empagliflozin
Fosinopril may decrease the metabolism of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Empagliflozin
Fosinopril may increase the severity of adverse effects when combined with Nisoldipine and Nisoldipine may increase the severity of adverse effects when combined with Empagliflozin
|
DB09211
|
DB00569
| 1,444 | 758 |
Limaprost
|
Fondaparinux
|
Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect. It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. Limaprost alfadex was discovered from collaborative research between Ono Pharmaceutical (Ono) and Dainippon Sumitomo Pharma (DSP). It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness
|
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture
|
The risk or severity of adverse effects can be increased when Limaprost is combined with Fondaparinux.
| 48 |
[
[
[
1444,
71,
758
]
],
[
[
1444,
246,
789
],
[
789,
182,
758
]
],
[
[
1444,
71,
784
],
[
784,
182,
758
]
],
[
[
1444,
71,
342
],
[
342,
28,
758
]
],
[
[
1444,
229,
238
],
[
238,
182,
758
]
],
[
[
1444,
246,
1351
],
[
1351,
242,
758
]
],
[
[
1444,
246,
789
],
[
789,
225,
180
],
[
180,
182,
758
]
],
[
[
1444,
246,
180
],
[
180,
21,
28747
],
[
28747,
175,
758
]
],
[
[
1444,
71,
784
],
[
784,
21,
28747
],
[
28747,
175,
758
]
],
[
[
1444,
246,
768
],
[
768,
79,
789
],
[
789,
182,
758
]
]
] |
[
[
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may increase the antiplatelet activities of {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase bleeding risks when combined with {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fondaparinux"
]
],
[
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
]
] |
Limaprost may decrease the therapeutic efficacy of Benzydamine and Benzydamine may increase the anticoagulant activities of Fondaparinux
Limaprost may increase the severity of adverse effects when combined with Anagrelide and Anagrelide may increase the anticoagulant activities of Fondaparinux
Limaprost may increase the severity of adverse effects when combined with Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Fondaparinux
Limaprost may increase the antiplatelet activities of Nimesulide and Nimesulide may increase the anticoagulant activities of Fondaparinux
Limaprost may decrease the therapeutic efficacy of Acemetacin and Acemetacin may increase bleeding risks when combined with Fondaparinux
Limaprost may decrease the therapeutic efficacy of Benzydamine and Benzydamine may increase the severity of adverse effects when combined with Oxaprozin and Oxaprozin may increase the anticoagulant activities of Fondaparinux
Limaprost may decrease the therapeutic efficacy of Oxaprozin and Oxaprozin (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Fondaparinux (Compound)
Limaprost may increase the severity of adverse effects when combined with Anagrelide and Anagrelide (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Fondaparinux (Compound)
Limaprost may decrease the therapeutic efficacy of Olsalazine and Olsalazine may increase the nephrotoxic activities of Benzydamine and Benzydamine may increase the anticoagulant activities of Fondaparinux
|
DB00753
|
DB09072
| 347 | 1,264 |
Isoflurane
|
Sodium oxybate
|
A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
|
Sodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter and a metabolite of the inhibitory neurotransmitter GABA. Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. Sodium oxybate has been misused to stimulate body growth and to induce euphoria, disinhibition, and sexual arousal as a "party drug" or "club drug." For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 and was fully approved in May 2023. In some countries, sodium
|
Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
| 15 |
[
[
[
347,
38,
1264
]
],
[
[
347,
71,
41
],
[
41,
38,
1264
]
],
[
[
347,
38,
702
],
[
702,
38,
1264
]
],
[
[
347,
196,
1007
],
[
1007,
38,
1264
]
],
[
[
347,
192,
543
],
[
543,
38,
1264
]
],
[
[
347,
225,
540
],
[
540,
38,
1264
]
],
[
[
347,
95,
371
],
[
371,
38,
1264
]
],
[
[
347,
116,
522
],
[
522,
38,
1264
]
],
[
[
347,
180,
142
],
[
142,
38,
1264
]
],
[
[
347,
236,
932
],
[
932,
38,
1264
]
]
] |
[
[
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the serum concentration of {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
],
[
"Halothane",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Isoflurane",
"{u} may increase the hypotensive activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
]
] |
Isoflurane may increase the severity of adverse effects when combined with Clemastine and Clemastine may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the QTc prolonging activities of Paliperidone and Paliperidone may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the severity of adverse effects when combined with Morphine and Morphine may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the serum concentration of Quazepam and Quazepam may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane (Compound) resembles Halothane (Compound) and Isoflurane may increase the severity of adverse effects when combined with Halothane and Halothane may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane can increase the metabolism of Phenytoin and Phenytoin may increase the central nervous system depressant activities of Sodium oxybate
Isoflurane may increase the hypotensive activities of Aripiprazole and Aripiprazole may increase the central nervous system depressant activities of Sodium oxybate
|
DB01282
|
DB00350
| 1,353 | 1,065 |
Carbetocin
|
Minoxidil
|
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
|
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
|
The risk or severity of adverse effects can be increased when Carbetocin is combined with Minoxidil.
| 48 |
[
[
[
1353,
71,
1065
]
],
[
[
1353,
71,
702
],
[
702,
32,
1065
]
],
[
[
1353,
52,
968
],
[
968,
206,
1065
]
],
[
[
1353,
71,
642
],
[
642,
225,
1065
]
],
[
[
1353,
71,
1361
],
[
1361,
71,
1065
]
],
[
[
1353,
225,
1025
],
[
1025,
71,
1065
]
],
[
[
1353,
155,
1067
],
[
1067,
236,
1065
]
],
[
[
1353,
236,
171
],
[
171,
82,
1065
]
],
[
[
1353,
71,
56
],
[
56,
82,
1065
]
],
[
[
1353,
71,
185
],
[
185,
236,
1065
]
]
] |
[
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
],
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levosimendan"
],
[
"Levosimendan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} (Compound) resembles {v} (Compound)",
"Terlipressin"
],
[
"Terlipressin",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the hypotensive activities of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lacidipine"
],
[
"Lacidipine",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
]
] |
Carbetocin may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Minoxidil
Carbetocin may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Minoxidil
Carbetocin may increase the severity of adverse effects when combined with Benazepril and Benazepril may increase the severity of adverse effects when combined with Minoxidil
Carbetocin may increase the severity of adverse effects when combined with Levosimendan and Levosimendan may increase the severity of adverse effects when combined with Minoxidil
Carbetocin may increase the severity of adverse effects when combined with Arotinolol and Arotinolol may increase the severity of adverse effects when combined with Minoxidil
Carbetocin (Compound) resembles Terlipressin (Compound) and Terlipressin may increase the hypotensive activities of Minoxidil
Carbetocin may increase the hypotensive activities of Pentobarbital and Pentobarbital may increase the hypotensive activities of Minoxidil
Carbetocin may increase the severity of adverse effects when combined with Rasagiline and Rasagiline may increase the hypotensive activities of Minoxidil
Carbetocin may increase the severity of adverse effects when combined with Lacidipine and Lacidipine may increase the hypotensive activities of Minoxidil
|
DB09076
|
DB01173
| 20 | 72 |
Umeclidinium
|
Orphenadrine
|
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. Parasympathetic ganglia are associated with the larger airways while postganglionic fibers innervate the smaller diameter bronchioles contributing to airway resistance. By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. However,
|
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
|
Umeclidinium may increase the anticholinergic activities of Orphenadrine.
| 1 |
[
[
[
20,
24,
72
]
],
[
[
20,
24,
44
],
[
44,
1,
72
]
],
[
[
20,
69,
394
],
[
394,
155,
72
]
],
[
[
20,
24,
12
],
[
12,
24,
72
]
],
[
[
20,
24,
16
],
[
16,
178,
72
]
],
[
[
20,
69,
173
],
[
173,
26,
72
]
],
[
[
20,
71,
465
],
[
465,
192,
72
]
],
[
[
20,
69,
63
],
[
63,
192,
72
]
],
[
[
20,
107,
1261
],
[
1261,
192,
72
]
],
[
[
20,
71,
491
],
[
491,
38,
72
]
]
] |
[
[
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may decrease the metabolism of {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} may increase the anticholinergic activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
]
],
[
[
"Umeclidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
]
]
] |
Umeclidinium may increase the anticholinergic activities of Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Umeclidinium may decrease the metabolism of Fluoxetine and Fluoxetine (Compound) resembles Orphenadrine (Compound)
Umeclidinium may increase the anticholinergic activities of Aclidinium and Aclidinium may increase the anticholinergic activities of Orphenadrine
Umeclidinium may increase the anticholinergic activities of Mianserin and Mianserin may increase the anticholinergic activities of Orphenadrine
Umeclidinium may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Orphenadrine
Umeclidinium may increase the severity of adverse effects when combined with Meperidine and Meperidine may increase the central nervous system depressant activities of Orphenadrine
Umeclidinium may decrease the metabolism of Tranylcypromine and Tranylcypromine may increase the central nervous system depressant activities of Orphenadrine
Umeclidinium may increase the tachycardic activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Orphenadrine
Umeclidinium may increase the severity of adverse effects when combined with Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Orphenadrine
|
DB01253
|
DB06016
| 376 | 387 |
Ergometrine
|
Cariprazine
|
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
|
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
|
The risk or severity of adverse effects can be increased when Ergometrine is combined with Cariprazine.
| 48 |
[
[
[
376,
71,
387
]
],
[
[
376,
180,
161
],
[
161,
26,
387
]
],
[
[
376,
71,
997
],
[
997,
57,
387
]
],
[
[
376,
69,
137
],
[
137,
223,
387
]
],
[
[
376,
225,
556
],
[
556,
223,
387
]
],
[
[
376,
95,
496
],
[
496,
223,
387
]
],
[
[
376,
71,
640
],
[
640,
223,
387
]
],
[
[
376,
41,
1037
],
[
1037,
223,
387
]
],
[
[
376,
71,
193
],
[
193,
71,
387
]
],
[
[
376,
225,
39
],
[
39,
71,
387
]
]
] |
[
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may decrease the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the serum concentration of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may decrease the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the metabolism of {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cariprazine"
]
],
[
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cariprazine"
]
]
] |
Ergometrine can increase the metabolism of Primidone and Primidone can increase the metabolism of Cariprazine
Ergometrine may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the neurotoxic activities of Cariprazine
Ergometrine may decrease the metabolism of Amiodarone and Amiodarone may decrease the metabolism of Cariprazine
Ergometrine may increase the severity of adverse effects when combined with Citalopram and Citalopram may decrease the metabolism of Cariprazine
Ergometrine may increase the serum concentration of Ketoconazole and Ketoconazole may decrease the metabolism of Cariprazine
Ergometrine may increase the severity of adverse effects when combined with Quinine and Quinine may decrease the metabolism of Cariprazine
Ergometrine may increase the vasoconstricting activities of Betaxolol and Betaxolol may decrease the metabolism of Cariprazine
Ergometrine may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may increase the severity of adverse effects when combined with Cariprazine
Ergometrine may increase the severity of adverse effects when combined with Selegiline and Selegiline may increase the severity of adverse effects when combined with Cariprazine
|
DB00924
|
DB00722
| 195 | 676 |
Cyclobenzaprine
|
Lisinopril
|
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
|
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.
|
The serum concentration of Lisinopril can be increased when it is combined with Cyclobenzaprine.
| 72 |
[
[
[
195,
95,
676
]
],
[
[
195,
95,
315
],
[
315,
71,
676
]
],
[
[
195,
95,
607
],
[
607,
155,
676
]
],
[
[
195,
21,
28577
],
[
28577,
175,
676
]
],
[
[
195,
38,
702
],
[
702,
32,
676
]
],
[
[
195,
71,
968
],
[
968,
206,
676
]
],
[
[
195,
249,
230
],
[
230,
213,
676
]
],
[
[
195,
69,
461
],
[
461,
69,
676
]
],
[
[
195,
71,
955
],
[
955,
225,
676
]
],
[
[
195,
71,
522
],
[
522,
71,
676
]
]
] |
[
[
[
"Cyclobenzaprine",
"{u} may increase the serum concentration of {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the serum concentration of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the serum concentration of {v}",
"Ramipril"
],
[
"Ramipril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) causes {v} (Side Effect)",
"Pharyngitis"
],
[
"Pharyngitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the serum concentration of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
],
[
"Halothane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
]
]
] |
Cyclobenzaprine may increase the serum concentration of Enalapril and Enalapril may increase the severity of adverse effects when combined with Lisinopril
Cyclobenzaprine may increase the serum concentration of Ramipril and Ramipril (Compound) resembles Lisinopril (Compound)
Cyclobenzaprine (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Lisinopril (Compound)
Cyclobenzaprine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Lisinopril
Cyclobenzaprine may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Lisinopril
Cyclobenzaprine may increase the serum concentration of Yohimbine and Yohimbine may decrease the antihypertensive activities of Lisinopril
Cyclobenzaprine may decrease the metabolism of Diltiazem and Diltiazem may decrease the metabolism of Lisinopril
Cyclobenzaprine may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Lisinopril
Cyclobenzaprine may increase the severity of adverse effects when combined with Halothane and Halothane may increase the severity of adverse effects when combined with Lisinopril
|
DB00312
|
DB01433
| 171 | 984 |
Pentobarbital
|
Methadyl acetate
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
|
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadyl acetate.
| 48 |
[
[
[
171,
71,
984
]
],
[
[
171,
26,
355
],
[
355,
155,
984
]
],
[
[
171,
71,
973
],
[
973,
225,
984
]
],
[
[
171,
26,
488
],
[
488,
1,
984
]
],
[
[
171,
192,
72
],
[
72,
38,
984
]
],
[
[
171,
71,
942
],
[
942,
155,
984
]
],
[
[
171,
26,
289
],
[
289,
71,
984
]
],
[
[
171,
184,
674
],
[
674,
30,
984
]
],
[
[
171,
38,
702
],
[
702,
192,
984
]
],
[
[
171,
54,
471
],
[
471,
208,
984
]
]
] |
[
[
[
"Pentobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Pentobarbital",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Methadyl acetate"
]
]
] |
Pentobarbital can increase the metabolism of Phenoxybenzamine and Phenoxybenzamine (Compound) resembles Methadyl acetate (Compound)
Pentobarbital may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine may increase the severity of adverse effects when combined with Methadyl acetate
Pentobarbital can increase the metabolism of Modafinil and Modafinil (Compound) resembles Methadyl acetate (Compound)
Pentobarbital may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Methadyl acetate
Pentobarbital may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate (Compound) resembles Methadyl acetate (Compound)
Pentobarbital can increase the metabolism of Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Methadyl acetate
Pentobarbital can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Methadyl acetate
Pentobarbital may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Methadyl acetate
Pentobarbital may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Methadyl acetate
|
DB01090
|
DB00761
| 21 | 1,531 |
Pentolinium
|
Potassium chloride
|
Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
|
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.
|
Pentolinium may increase the ulcerogenic activities of Potassium chloride.
| 58 |
[
[
[
21,
81,
1531
]
],
[
[
21,
71,
72
],
[
72,
81,
1531
]
],
[
[
21,
178,
26
],
[
26,
81,
1531
]
],
[
[
21,
225,
37
],
[
37,
81,
1531
]
],
[
[
21,
71,
72
],
[
72,
21,
28398
],
[
28398,
175,
1531
]
],
[
[
21,
71,
49
],
[
49,
178,
28
],
[
28,
71,
1531
]
],
[
[
21,
178,
26
],
[
26,
21,
28770
],
[
28770,
175,
1531
]
],
[
[
21,
71,
13
],
[
13,
225,
59
],
[
59,
81,
1531
]
],
[
[
21,
225,
37
],
[
37,
178,
28
],
[
28,
71,
1531
]
],
[
[
21,
225,
70
],
[
70,
21,
28398
],
[
28398,
175,
1531
]
]
] |
[
[
[
"Pentolinium",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the anticholinergic activities of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butylscopolamine"
],
[
"Butylscopolamine",
"{u} may increase the anticholinergic activities of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the anticholinergic activities of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methscopolamine"
],
[
"Methscopolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the anticholinergic activities of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Potassium chloride"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tropicamide"
],
[
"Tropicamide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
]
]
] |
Pentolinium may increase the severity of adverse effects when combined with Orphenadrine and Orphenadrine may increase the ulcerogenic activities of Potassium chloride
Pentolinium may increase the anticholinergic activities of Tiotropium and Tiotropium may increase the ulcerogenic activities of Potassium chloride
Pentolinium may increase the severity of adverse effects when combined with Oxyphenonium and Oxyphenonium may increase the ulcerogenic activities of Potassium chloride
Pentolinium may increase the severity of adverse effects when combined with Orphenadrine and Orphenadrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Potassium chloride (Compound)
Pentolinium may increase the severity of adverse effects when combined with Butylscopolamine and Butylscopolamine may increase the anticholinergic activities of Glycopyrronium and Glycopyrronium may increase the severity of adverse effects when combined with Potassium chloride
Pentolinium may increase the anticholinergic activities of Tiotropium and Tiotropium (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium chloride (Compound)
Pentolinium may increase the severity of adverse effects when combined with Methscopolamine and Methscopolamine may increase the severity of adverse effects when combined with Quinidine and Quinidine may increase the ulcerogenic activities of Potassium chloride
Pentolinium may increase the severity of adverse effects when combined with Oxyphenonium and Oxyphenonium may increase the anticholinergic activities of Glycopyrronium and Glycopyrronium may increase the severity of adverse effects when combined with Potassium chloride
Pentolinium may increase the severity of adverse effects when combined with Tropicamide and Tropicamide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Potassium chloride (Compound)
|
DB00784
|
DB08991
| 375 | 766 |
Mefenamic acid
|
Epirizole
|
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
|
Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.
|
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Epirizole.
| 48 |
[
[
[
375,
71,
766
]
],
[
[
375,
182,
760
],
[
760,
28,
766
]
],
[
[
375,
49,
862
],
[
862,
203,
766
]
],
[
[
375,
51,
893
],
[
893,
205,
766
]
],
[
[
375,
213,
1032
],
[
1032,
59,
766
]
],
[
[
375,
225,
1442
],
[
1442,
71,
766
]
],
[
[
375,
71,
808
],
[
808,
71,
766
]
],
[
[
375,
71,
110
],
[
110,
225,
766
]
],
[
[
375,
69,
582
],
[
582,
71,
766
]
],
[
[
375,
1,
780
],
[
780,
71,
766
]
]
] |
[
[
[
"Mefenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may increase the anticoagulant activities of {v}",
"Pentaerythritol tetranitrate"
],
[
"Pentaerythritol tetranitrate",
"{u} may increase the anticoagulant activities of {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may decrease the diuretic activities of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Bopindolol"
],
[
"Bopindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Talniflumate"
],
[
"Talniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
],
[
"Desoximetasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
],
[
[
"Mefenamic acid",
"{u} (Compound) resembles {v} (Compound)",
"Nepafenac"
],
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Epirizole"
]
]
] |
Mefenamic acid may increase the anticoagulant activities of Pentaerythritol tetranitrate and Pentaerythritol tetranitrate may increase the anticoagulant activities of Epirizole
Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin and Trovafloxacin may increase the neuroexcitatory activities of Epirizole
Mefenamic acid may decrease the diuretic activities of Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Epirizole
Mefenamic acid may decrease the antihypertensive activities of Bopindolol and Bopindolol may decrease the antihypertensive activities of Epirizole
Mefenamic acid may increase the severity of adverse effects when combined with Talniflumate and Talniflumate may increase the severity of adverse effects when combined with Epirizole
Mefenamic acid may increase the severity of adverse effects when combined with Magnesium salicylate and Magnesium salicylate may increase the severity of adverse effects when combined with Epirizole
Mefenamic acid may increase the severity of adverse effects when combined with Desoximetasone and Desoximetasone may increase the severity of adverse effects when combined with Epirizole
Mefenamic acid may decrease the metabolism of Leflunomide and Leflunomide may increase the severity of adverse effects when combined with Epirizole
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac may increase the severity of adverse effects when combined with Epirizole
|
DB11093
|
DB00999
| 1,453 | 1,069 |
Calcium citrate
|
Hydrochlorothiazide
|
Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.
|
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.
|
Calcium citrate may decrease the excretion rate of Hydrochlorothiazide which could result in a higher serum level.
| 71 |
[
[
[
1453,
94,
1069
]
],
[
[
1453,
94,
1049
],
[
1049,
71,
1069
]
],
[
[
1453,
94,
1066
],
[
1066,
236,
1069
]
],
[
[
1453,
94,
1072
],
[
1072,
82,
1069
]
],
[
[
1453,
94,
1325
],
[
1325,
1,
1069
]
],
[
[
1453,
92,
461
],
[
461,
71,
1069
]
],
[
[
1453,
258,
1350
],
[
1350,
225,
1069
]
],
[
[
1453,
92,
662
],
[
662,
225,
1069
]
],
[
[
1453,
71,
1482
],
[
1482,
73,
1069
]
],
[
[
1453,
243,
1492
],
[
1492,
79,
1069
]
]
] |
[
[
[
"Calcium citrate",
"{u} may decrease the excretion rate {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the excretion rate {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the excretion rate {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the excretion rate {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the excretion rate {v}",
"Quinethazone"
],
[
"Quinethazone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the therapeutic efficacy of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may increase the arrhythmogenic activities of {v}",
"Deslanoside"
],
[
"Deslanoside",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the therapeutic efficacy of {v}",
"Clevidipine"
],
[
"Clevidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may increase the hypercalcemic activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Calcium citrate",
"{u} may decrease the absorption and serum concentration of {v}",
"Sodium phosphate, monobasic"
],
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Hydrochlorothiazide"
]
]
] |
Calcium citrate may decrease the excretion rate Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Hydrochlorothiazide
Calcium citrate may decrease the excretion rate Polythiazide and Polythiazide may increase the hypotensive activities of Hydrochlorothiazide
Calcium citrate may decrease the excretion rate Hydroflumethiazide and Hydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide
Calcium citrate may decrease the excretion rate Quinethazone and Quinethazone (Compound) resembles Hydrochlorothiazide (Compound)
Calcium citrate may decrease the therapeutic efficacy of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Hydrochlorothiazide
Calcium citrate may increase the arrhythmogenic activities of Deslanoside and Deslanoside may increase the severity of adverse effects when combined with Hydrochlorothiazide
Calcium citrate may decrease the therapeutic efficacy of Clevidipine and Clevidipine may increase the severity of adverse effects when combined with Hydrochlorothiazide
Calcium citrate may increase the severity of adverse effects when combined with Calcifediol and Calcifediol may increase the hypercalcemic activities of Hydrochlorothiazide
Calcium citrate may decrease the absorption and serum concentration of Sodium phosphate, monobasic and Sodium phosphate, monobasic may increase the nephrotoxic activities of Hydrochlorothiazide
|
DB00802
|
DB00203
| 419 | 615 |
Alfentanil
|
Sildenafil
|
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
|
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
|
The metabolism of Sildenafil can be decreased when combined with Alfentanil.
| 46 |
[
[
[
419,
69,
615
]
],
[
[
419,
6,
15658
],
[
15658,
160,
615
]
],
[
[
419,
21,
28396
],
[
28396,
175,
615
]
],
[
[
419,
251,
177
],
[
177,
26,
615
]
],
[
[
419,
180,
161
],
[
161,
26,
615
]
],
[
[
419,
76,
519
],
[
519,
186,
615
]
],
[
[
419,
71,
183
],
[
183,
186,
615
]
],
[
[
419,
225,
17
],
[
17,
186,
615
]
],
[
[
419,
255,
75
],
[
75,
186,
615
]
],
[
[
419,
69,
472
],
[
472,
186,
615
]
]
] |
[
[
[
"Alfentanil",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may increase the bradycardic activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trimethaphan"
],
[
"Trimethaphan",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may increase the central nervous system depressant and hypertensive activities of {v}",
"Pargyline"
],
[
"Pargyline",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Alfentanil",
"{u} may decrease the metabolism of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
]
] |
Alfentanil (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Sildenafil (Compound)
Alfentanil (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Sildenafil (Compound)
Alfentanil may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Sildenafil
Alfentanil can increase the metabolism of Primidone and Primidone can increase the metabolism of Sildenafil
Alfentanil may increase the bradycardic activities of Celiprolol and Celiprolol may increase the antihypertensive activities of Sildenafil
Alfentanil may increase the severity of adverse effects when combined with Indapamide and Indapamide may increase the antihypertensive activities of Sildenafil
Alfentanil may increase the severity of adverse effects when combined with Trimethaphan and Trimethaphan may increase the antihypertensive activities of Sildenafil
Alfentanil may increase the central nervous system depressant and hypertensive activities of Pargyline and Pargyline may increase the antihypertensive activities of Sildenafil
Alfentanil may decrease the metabolism of Isradipine and Isradipine may increase the antihypertensive activities of Sildenafil
|
DB06810
|
DB00749
| 899 | 460 |
Plicamycin
|
Etodolac
|
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
|
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
|
Plicamycin may decrease the excretion rate of Etodolac which could result in a higher serum level.
| 71 |
[
[
[
899,
94,
460
]
],
[
[
899,
94,
687
],
[
687,
28,
460
]
],
[
[
899,
225,
894
],
[
894,
205,
460
]
],
[
[
899,
94,
628
],
[
628,
225,
460
]
],
[
[
899,
200,
1339
],
[
1339,
225,
460
]
],
[
[
899,
94,
620
],
[
620,
71,
460
]
],
[
[
899,
95,
1421
],
[
1421,
225,
460
]
],
[
[
899,
94,
798
],
[
798,
79,
460
]
],
[
[
899,
233,
198
],
[
198,
79,
460
]
],
[
[
899,
80,
457
],
[
457,
95,
460
]
]
] |
[
[
[
"Plicamycin",
"{u} may decrease the excretion rate {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may decrease the excretion rate {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may decrease the excretion rate {v}",
"Suprofen"
],
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may increase the hypocalcemic activities of {v}",
"Tiludronic acid"
],
[
"Tiludronic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may decrease the excretion rate {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may increase the serum concentration of {v}",
"Tenofovir disoproxil"
],
[
"Tenofovir disoproxil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may decrease the excretion rate {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the nephrotoxic activities of {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may increase the nephrotoxic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Etodolac"
]
],
[
[
"Plicamycin",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may increase the serum concentration of {v}",
"Etodolac"
]
]
] |
Plicamycin may decrease the excretion rate Nafamostat and Nafamostat may increase the anticoagulant activities of Etodolac
Plicamycin may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Etodolac
Plicamycin may decrease the excretion rate Suprofen and Suprofen may increase the severity of adverse effects when combined with Etodolac
Plicamycin may increase the hypocalcemic activities of Tiludronic acid and Tiludronic acid may increase the severity of adverse effects when combined with Etodolac
Plicamycin may decrease the excretion rate Mycophenolate mofetil and Mycophenolate mofetil may increase the severity of adverse effects when combined with Etodolac
Plicamycin may increase the serum concentration of Tenofovir disoproxil and Tenofovir disoproxil may increase the severity of adverse effects when combined with Etodolac
Plicamycin may decrease the excretion rate Balsalazide and Balsalazide may increase the nephrotoxic activities of Etodolac
Plicamycin may increase the nephrotoxic activities of Cyclosporine and Cyclosporine may increase the nephrotoxic activities of Etodolac
Plicamycin may decrease the cardiotoxic activities of Digoxin and Digoxin may increase the serum concentration of Etodolac
|
DB01080
|
DB04953
| 1,268 | 1,097 |
Vigabatrin
|
Ezogabine
|
Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual deficits.[L13661,A202124]
|
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
|
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ezogabine.
| 48 |
[
[
[
1268,
71,
1097
]
],
[
[
1268,
21,
28926
],
[
28926,
175,
1097
]
],
[
[
1268,
38,
405
],
[
405,
192,
1097
]
],
[
[
1268,
192,
287
],
[
287,
38,
1097
]
],
[
[
1268,
225,
245
],
[
245,
42,
1097
]
],
[
[
1268,
71,
324
],
[
324,
42,
1097
]
],
[
[
1268,
54,
471
],
[
471,
208,
1097
]
],
[
[
1268,
225,
861
],
[
861,
71,
1097
]
],
[
[
1268,
71,
499
],
[
499,
71,
1097
]
],
[
[
1268,
71,
957
],
[
957,
225,
1097
]
]
] |
[
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} (Compound) causes {v} (Side Effect)",
"Amnesia"
],
[
"Amnesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the QTc prolonging activities of {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
]
],
[
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
]
]
] |
Vigabatrin (Compound) causes Amnesia (Side Effect) and Amnesia (Side Effect) is caused by Ezogabine (Compound)
Vigabatrin may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Ezogabine
Vigabatrin may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Ezogabine
Vigabatrin may increase the severity of adverse effects when combined with Haloperidol and Haloperidol may increase the QTc prolonging activities of Ezogabine
Vigabatrin may increase the severity of adverse effects when combined with Escitalopram and Escitalopram may increase the QTc prolonging activities of Ezogabine
Vigabatrin may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Ezogabine
Vigabatrin may increase the severity of adverse effects when combined with Fluvoxamine and Fluvoxamine may increase the severity of adverse effects when combined with Ezogabine
Vigabatrin may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Ezogabine
Vigabatrin may increase the severity of adverse effects when combined with Brexpiprazole and Brexpiprazole may increase the severity of adverse effects when combined with Ezogabine
|
DB06772
|
DB00548
| 152 | 1,186 |
Cabazitaxel
|
Azelaic acid
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is also produced by _Malassezia furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human skin. Azelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.
|
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azelaic acid.
| 48 |
[
[
[
152,
71,
1186
]
],
[
[
152,
21,
28522
],
[
28522,
175,
1186
]
],
[
[
152,
225,
292
],
[
292,
71,
1186
]
],
[
[
152,
80,
232
],
[
232,
234,
1186
]
],
[
[
152,
21,
28522
],
[
28522,
175,
2
],
[
2,
1,
1186
]
],
[
[
152,
225,
292
],
[
292,
71,
801
],
[
801,
1,
1186
]
],
[
[
152,
80,
232
],
[
232,
234,
801
],
[
801,
1,
1186
]
],
[
[
152,
21,
28522
],
[
28522,
175,
1431
],
[
1431,
155,
1186
]
],
[
[
152,
21,
28770
],
[
28770,
175,
292
],
[
292,
71,
1186
]
],
[
[
152,
225,
292
],
[
292,
21,
28522
],
[
28522,
175,
1186
]
]
] |
[
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound)",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vorinostat"
],
[
"Vorinostat",
"{u} (Compound) resembles {v} (Compound)",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Vorinostat"
],
[
"Vorinostat",
"{u} (Compound) resembles {v} (Compound)",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethanolamine oleate"
],
[
"Ethanolamine oleate",
"{u} (Compound) resembles {v} (Compound)",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Azelaic acid"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azelaic acid"
]
]
] |
Cabazitaxel (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Azelaic acid (Compound)
Cabazitaxel may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Azelaic acid
Cabazitaxel may decrease the cardiotoxic activities of Digitoxin and Digitoxin may decrease the cardiotoxic activities of Azelaic acid
Cabazitaxel (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Aminolevulinic acid (Compound) and Aminolevulinic acid (Compound) resembles Azelaic acid (Compound)
Cabazitaxel may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Vorinostat and Vorinostat (Compound) resembles Azelaic acid (Compound)
Cabazitaxel may decrease the cardiotoxic activities of Digitoxin and Digitoxin may decrease the cardiotoxic activities of Vorinostat and Vorinostat (Compound) resembles Azelaic acid (Compound)
Cabazitaxel (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ethanolamine oleate (Compound) and Ethanolamine oleate (Compound) resembles Azelaic acid (Compound)
Cabazitaxel (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may increase the severity of adverse effects when combined with Azelaic acid
Cabazitaxel may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Azelaic acid (Compound)
|
DB00006
|
DB06287
| 665 | 513 |
Bivalirudin
|
Temsirolimus
|
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
|
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
|
The risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.
| 48 |
[
[
[
665,
71,
513
]
],
[
[
665,
71,
243
],
[
243,
37,
513
]
],
[
[
665,
249,
648
],
[
648,
223,
513
]
],
[
[
665,
97,
508
],
[
508,
223,
513
]
],
[
[
665,
223,
461
],
[
461,
223,
513
]
],
[
[
665,
28,
613
],
[
613,
223,
513
]
],
[
[
665,
251,
1113
],
[
1113,
71,
513
]
],
[
[
665,
182,
677
],
[
677,
71,
513
]
],
[
[
665,
28,
654
],
[
654,
71,
513
]
],
[
[
665,
249,
376
],
[
376,
71,
513
]
]
] |
[
[
[
"Bivalirudin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may decrease the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may decrease the serum concentration of {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
]
],
[
[
"Bivalirudin",
"{u} may increase the serum concentration of {v}",
"Ergometrine"
],
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
]
]
] |
Bivalirudin may increase the severity of adverse effects when combined with Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Temsirolimus
Bivalirudin may increase the serum concentration of Nefazodone and Nefazodone may decrease the metabolism of Temsirolimus
Bivalirudin may decrease the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Temsirolimus
Bivalirudin may decrease the metabolism of Diltiazem and Diltiazem may decrease the metabolism of Temsirolimus
Bivalirudin may increase the anticoagulant activities of Ticlopidine and Ticlopidine may decrease the metabolism of Temsirolimus
Bivalirudin may decrease the serum concentration of Boceprevir and Boceprevir may increase the severity of adverse effects when combined with Temsirolimus
Bivalirudin may increase the anticoagulant activities of Dabigatran etexilate and Dabigatran etexilate may increase the severity of adverse effects when combined with Temsirolimus
Bivalirudin may increase the anticoagulant activities of Tipranavir and Tipranavir may increase the severity of adverse effects when combined with Temsirolimus
Bivalirudin may increase the serum concentration of Ergometrine and Ergometrine may increase the severity of adverse effects when combined with Temsirolimus
|
DB00899
|
DB00571
| 934 | 504 |
Remifentanil
|
Propranolol
|
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
|
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.
|
The risk or severity of adverse effects can be increased when Remifentanil is combined with Propranolol.
| 48 |
[
[
[
934,
71,
504
]
],
[
[
934,
71,
576
],
[
576,
95,
504
]
],
[
[
934,
71,
1026
],
[
1026,
155,
504
]
],
[
[
934,
71,
1037
],
[
1037,
71,
504
]
],
[
[
934,
76,
1031
],
[
1031,
155,
504
]
],
[
[
934,
21,
28440
],
[
28440,
175,
504
]
],
[
[
934,
71,
164
],
[
164,
26,
504
]
],
[
[
934,
225,
156
],
[
156,
26,
504
]
],
[
[
934,
225,
247
],
[
247,
47,
504
]
],
[
[
934,
91,
149
],
[
149,
47,
504
]
]
] |
[
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the bradycardic activities of {v}",
"Bevantolol"
],
[
"Bevantolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Propranolol"
]
],
[
[
"Remifentanil",
"{u} may increase the analgesic activities of {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Propranolol"
]
]
] |
Remifentanil may increase the severity of adverse effects when combined with Metoprolol and Metoprolol may increase the serum concentration of Propranolol
Remifentanil may increase the severity of adverse effects when combined with Acebutolol and Acebutolol (Compound) resembles Propranolol (Compound)
Remifentanil may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Propranolol
Remifentanil may increase the bradycardic activities of Bevantolol and Bevantolol (Compound) resembles Propranolol (Compound)
Remifentanil (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Propranolol (Compound)
Remifentanil may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Propranolol
Remifentanil may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Propranolol
Remifentanil may increase the severity of adverse effects when combined with Bromocriptine and Bromocriptine may increase the atrioventricular blocking activities of Propranolol
Remifentanil may increase the analgesic activities of Benzphetamine and Benzphetamine may increase the atrioventricular blocking activities of Propranolol
|
DB06145
|
DB12332
| 256 | 381 |
Spiramycin
|
Rucaparib
|
Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium. Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.
|
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
|
The metabolism of Rucaparib can be decreased when combined with Spiramycin.
| 46 |
[
[
[
256,
69,
381
]
],
[
[
256,
180,
177
],
[
177,
26,
381
]
],
[
[
256,
69,
143
],
[
143,
223,
381
]
],
[
[
256,
71,
307
],
[
307,
69,
381
]
],
[
[
256,
249,
457
],
[
457,
234,
381
]
],
[
[
256,
249,
531
],
[
531,
95,
381
]
],
[
[
256,
95,
1324
],
[
1324,
249,
381
]
],
[
[
256,
69,
1095
],
[
1095,
249,
381
]
],
[
[
256,
251,
495
],
[
495,
249,
381
]
],
[
[
256,
251,
225
],
[
225,
97,
381
]
]
] |
[
[
[
"Spiramycin",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may increase the serum concentration of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the serum concentration of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may increase the serum concentration of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Rucaparib"
]
],
[
[
"Spiramycin",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may decrease the serum concentration of {v}",
"Rucaparib"
]
]
] |
Spiramycin can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Rucaparib
Spiramycin may decrease the metabolism of Erythromycin and Erythromycin may decrease the metabolism of Rucaparib
Spiramycin may increase the severity of adverse effects when combined with Fluvastatin and Fluvastatin may decrease the metabolism of Rucaparib
Spiramycin may increase the serum concentration of Digoxin and Digoxin may decrease the cardiotoxic activities of Rucaparib
Spiramycin may increase the serum concentration of Conivaptan and Conivaptan may increase the serum concentration of Rucaparib
Spiramycin may increase the serum concentration of Ceritinib and Ceritinib may increase the serum concentration of Rucaparib
Spiramycin may decrease the metabolism of Cobicistat and Cobicistat may increase the serum concentration of Rucaparib
Spiramycin may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the serum concentration of Rucaparib
Spiramycin may decrease the serum concentration of Bosentan and Bosentan may decrease the serum concentration of Rucaparib
|
DB01282
|
DB01193
| 1,353 | 1,026 |
Carbetocin
|
Acebutolol
|
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
|
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
|
The risk or severity of adverse effects can be increased when Carbetocin is combined with Acebutolol.
| 48 |
[
[
[
1353,
71,
1026
]
],
[
[
1353,
71,
504
],
[
504,
1,
1026
]
],
[
[
1353,
71,
911
],
[
911,
236,
1026
]
],
[
[
1353,
71,
1028
],
[
1028,
225,
1026
]
],
[
[
1353,
71,
702
],
[
702,
32,
1026
]
],
[
[
1353,
71,
730
],
[
730,
47,
1026
]
],
[
[
1353,
52,
828
],
[
828,
206,
1026
]
],
[
[
1353,
71,
678
],
[
678,
206,
1026
]
],
[
[
1353,
225,
227
],
[
227,
71,
1026
]
],
[
[
1353,
71,
461
],
[
461,
71,
1026
]
]
] |
[
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the hypotensive activities of {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metipranolol"
],
[
"Metipranolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxazosin"
],
[
"Doxazosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
]
]
] |
Carbetocin may increase the severity of adverse effects when combined with Propranolol and Propranolol (Compound) resembles Acebutolol (Compound)
Carbetocin may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the hypotensive activities of Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Metipranolol and Metipranolol may increase the severity of adverse effects when combined with Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Tizanidine and Tizanidine may increase the atrioventricular blocking activities of Acebutolol
Carbetocin may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Doxazosin and Doxazosin may increase the orthostatic hypotensive activities of Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Bortezomib and Bortezomib may increase the severity of adverse effects when combined with Acebutolol
Carbetocin may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Acebutolol
|
DB09147
|
DB09275
| 1,555 | 78 |
Ferric pyrophosphate
|
Bismuth subcitrate potassium
|
Ferric pyrophosphate is an iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate. It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.
|
A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
|
Ferric pyrophosphate can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.
| 66 |
[
[
[
1555,
89,
78
]
],
[
[
1555,
97,
776
],
[
776,
89,
78
]
],
[
[
1555,
243,
1564
],
[
1564,
89,
78
]
],
[
[
1555,
89,
81
],
[
81,
92,
78
]
],
[
[
1555,
89,
843
],
[
843,
251,
78
]
],
[
[
1555,
97,
776
],
[
776,
225,
100
],
[
100,
179,
78
]
],
[
[
1555,
243,
1564
],
[
1564,
89,
1553
],
[
1553,
89,
78
]
],
[
[
1555,
89,
81
],
[
81,
25,
100
],
[
100,
179,
78
]
],
[
[
1555,
89,
843
],
[
843,
251,
1553
],
[
1553,
89,
78
]
],
[
[
1555,
79,
1554
],
[
1554,
233,
1557
],
[
1557,
89,
78
]
]
] |
[
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the serum concentration of {v}",
"Rosoxacin"
],
[
"Rosoxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Dipotassium phosphate"
],
[
"Dipotassium phosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Tromethamine"
],
[
"Tromethamine",
"{u} may decrease the therapeutic efficacy of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Chlortetracycline"
],
[
"Chlortetracycline",
"{u} may decrease the serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the serum concentration of {v}",
"Rosoxacin"
],
[
"Rosoxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difluocortolone"
],
[
"Difluocortolone",
"{u} can decrease the bioavailability of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Dipotassium phosphate"
],
[
"Dipotassium phosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Iron sucrose"
],
[
"Iron sucrose",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Tromethamine"
],
[
"Tromethamine",
"{u} can decrease the bioavailability of {v}",
"Difluocortolone"
],
[
"Difluocortolone",
"{u} can decrease the bioavailability of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may decrease the absorption and serum concentration of {v}",
"Chlortetracycline"
],
[
"Chlortetracycline",
"{u} may decrease the serum concentration of {v}",
"Iron sucrose"
],
[
"Iron sucrose",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Ferric pyrophosphate",
"{u} may increase the nephrotoxic activities of {v}",
"Dimercaprol"
],
[
"Dimercaprol",
"{u} may increase the nephrotoxic activities of {v}",
"Node-1557"
],
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
]
]
] |
Ferric pyrophosphate may decrease the serum concentration of Rosoxacin and Rosoxacin may decrease the absorption and serum concentration of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Dipotassium phosphate and Dipotassium phosphate may decrease the absorption and serum concentration of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Tromethamine and Tromethamine may decrease the therapeutic efficacy of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Chlortetracycline and Chlortetracycline may decrease the serum concentration of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the serum concentration of Rosoxacin and Rosoxacin may increase the severity of adverse effects when combined with Difluocortolone and Difluocortolone can decrease the bioavailability of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Dipotassium phosphate and Dipotassium phosphate may decrease the absorption and serum concentration of Iron sucrose and Iron sucrose may decrease the absorption and serum concentration of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Tromethamine and Tromethamine can decrease the bioavailability of Difluocortolone and Difluocortolone can decrease the bioavailability of Bismuth subcitrate potassium
Ferric pyrophosphate may decrease the absorption and serum concentration of Chlortetracycline and Chlortetracycline may decrease the serum concentration of Iron sucrose and Iron sucrose may decrease the absorption and serum concentration of Bismuth subcitrate potassium
Ferric pyrophosphate may increase the nephrotoxic activities of Dimercaprol and Dimercaprol may increase the nephrotoxic activities of Node-1557 and Node-1557 may decrease the absorption and serum concentration of Bismuth subcitrate potassium
|
DB00921
|
DB01623
| 491 | 970 |
Buprenorphine
|
Thiothixene
|
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,L46571] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet. Buprenorphine has a
|
A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
|
Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
| 15 |
[
[
[
491,
38,
970
]
],
[
[
491,
38,
478
],
[
478,
155,
970
]
],
[
[
491,
38,
653
],
[
653,
95,
970
]
],
[
[
491,
236,
1450
],
[
1450,
1,
970
]
],
[
[
491,
38,
1014
],
[
1014,
71,
970
]
],
[
[
491,
38,
681
],
[
681,
42,
970
]
],
[
[
491,
6,
12128
],
[
12128,
160,
970
]
],
[
[
491,
21,
28613
],
[
28613,
175,
970
]
],
[
[
491,
38,
674
],
[
674,
30,
970
]
],
[
[
491,
38,
1265
],
[
1265,
192,
970
]
]
] |
[
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} (Compound) resembles {v} (Compound)",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the hypotensive activities of {v}",
"Moricizine"
],
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the QTc prolonging activities of {v}",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Thiothixene"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Thiothixene"
]
]
] |
Buprenorphine may increase the central nervous system depressant activities of Olopatadine and Olopatadine (Compound) resembles Thiothixene (Compound)
Buprenorphine may increase the central nervous system depressant activities of Thioridazine and Thioridazine may increase the serum concentration of Thiothixene
Buprenorphine may increase the hypotensive activities of Moricizine and Moricizine (Compound) resembles Thiothixene (Compound)
Buprenorphine may increase the central nervous system depressant activities of Fluphenazine and Fluphenazine may increase the severity of adverse effects when combined with Thiothixene
Buprenorphine may increase the central nervous system depressant activities of Clozapine and Clozapine may increase the QTc prolonging activities of Thiothixene
Buprenorphine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thiothixene (Compound)
Buprenorphine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Thiothixene (Compound)
Buprenorphine may increase the central nervous system depressant activities of Pregabalin and Pregabalin can increase the therapeutic efficacy of Thiothixene
Buprenorphine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Thiothixene
|
DB00252
|
DB00706
| 142 | 509 |
Phenytoin
|
Tamsulosin
|
Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.
|
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension. Tamsulosin was first approved by the FDA on April 15, 1997.
|
The metabolism of Tamsulosin can be increased when combined with Phenytoin.
| 3 |
[
[
[
142,
26,
509
]
],
[
[
142,
6,
4590
],
[
4590,
160,
509
]
],
[
[
142,
21,
28631
],
[
28631,
175,
509
]
],
[
[
142,
180,
177
],
[
177,
26,
509
]
],
[
[
142,
192,
164
],
[
164,
26,
509
]
],
[
[
142,
137,
161
],
[
161,
26,
509
]
],
[
[
142,
251,
156
],
[
156,
26,
509
]
],
[
[
142,
26,
638
],
[
638,
181,
509
]
],
[
[
142,
251,
707
],
[
707,
181,
509
]
],
[
[
142,
26,
278
],
[
278,
32,
509
]
]
] |
[
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Cough increased"
],
[
"Cough increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may decrease the vasoconstricting activities of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may decrease the vasoconstricting activities of {v}",
"Tamsulosin"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may increase the antihypertensive activities of {v}",
"Tamsulosin"
]
]
] |
Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tamsulosin (Compound)
Phenytoin (Compound) causes Cough increased (Side Effect) and Cough increased (Side Effect) is caused by Tamsulosin (Compound)
Phenytoin can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Tamsulosin
Phenytoin may increase the central nervous system depressant activities of Phenobarbital and Phenobarbital can increase the metabolism of Tamsulosin
Phenytoin (Compound) resembles Primidone (Compound) and Phenytoin can increase the metabolism of Primidone and Primidone can increase the metabolism of Tamsulosin
Phenytoin may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Tamsulosin
Phenytoin can increase the metabolism of Olodaterol and Olodaterol may decrease the vasoconstricting activities of Tamsulosin
Phenytoin may decrease the serum concentration of Mephentermine and Mephentermine may decrease the vasoconstricting activities of Tamsulosin
Phenytoin can increase the metabolism of Alfuzosin and Alfuzosin may increase the antihypertensive activities of Tamsulosin
|
DB01035
|
DB00196
| 1,322 | 1,076 |
Procainamide
|
Fluconazole
|
A derivative of procaine with less CNS action.
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
Procainamide may increase the QTc-prolonging activities of Fluconazole.
| 19 |
[
[
[
1322,
42,
1076
]
],
[
[
1322,
42,
657
],
[
657,
155,
1076
]
],
[
[
1322,
21,
28408
],
[
28408,
175,
1076
]
],
[
[
1322,
42,
143
],
[
143,
42,
1076
]
],
[
[
1322,
55,
324
],
[
324,
42,
1076
]
],
[
[
1322,
69,
1091
],
[
1091,
42,
1076
]
],
[
[
1322,
209,
589
],
[
589,
42,
1076
]
],
[
[
1322,
95,
1098
],
[
1098,
42,
1076
]
],
[
[
1322,
196,
1019
],
[
1019,
196,
1076
]
],
[
[
1322,
209,
495
],
[
495,
55,
1076
]
]
] |
[
[
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound)",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may decrease the metabolism of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Procainamide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Fluconazole"
]
]
] |
Procainamide may increase the QTc prolonging activities of Voriconazole and Voriconazole (Compound) resembles Fluconazole (Compound)
Procainamide (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Fluconazole (Compound)
Procainamide may increase the QTc prolonging activities of Erythromycin and Erythromycin may increase the QTc prolonging activities of Fluconazole
Procainamide may increase the severity of QTc prolonging effects when combined with Escitalopram and Escitalopram may increase the QTc prolonging activities of Fluconazole
Procainamide may decrease the metabolism of Dronedarone and Dronedarone may increase the QTc prolonging activities of Fluconazole
Procainamide may increase the severity of QTc prolonging effects when combined with Disopyramide and Disopyramide may increase the QTc prolonging activities of Fluconazole
Procainamide may increase the serum concentration of Panobinostat and Panobinostat may increase the QTc prolonging activities of Fluconazole
Procainamide may increase the QTc prolonging activities of Mifepristone and Mifepristone may increase the QTc prolonging activities of Fluconazole
Procainamide may increase the severity of QTc prolonging effects when combined with Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Fluconazole
|
DB00530
|
DB00834
| 600 | 1,019 |
Erlotinib
|
Mifepristone
|
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
|
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
|
The serum concentration of Mifepristone can be increased when it is combined with Erlotinib.
| 72 |
[
[
[
600,
95,
1019
]
],
[
[
600,
6,
8339
],
[
8339,
160,
1019
]
],
[
[
600,
7,
3063
],
[
3063,
161,
1019
]
],
[
[
600,
18,
4623
],
[
4623,
172,
1019
]
],
[
[
600,
21,
28445
],
[
28445,
175,
1019
]
],
[
[
600,
69,
63
],
[
63,
185,
1019
]
],
[
[
600,
69,
244
],
[
244,
42,
1019
]
],
[
[
600,
95,
1324
],
[
1324,
249,
1019
]
],
[
[
600,
95,
764
],
[
764,
42,
1019
]
],
[
[
600,
251,
992
],
[
992,
42,
1019
]
]
] |
[
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} (Compound) upregulates {v} (Gene)",
"CBLB"
],
[
"CBLB",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} (Compound) downregulates {v} (Gene)",
"RNH1"
],
[
"RNH1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the hypoglycemic activities of {v}",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
],
[
"Ritonavir",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
],
[
[
"Erlotinib",
"{u} may decrease the serum concentration of {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
]
] |
Erlotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mifepristone (Compound)
Erlotinib (Compound) upregulates CBLB (Gene) and CBLB (Gene) is upregulated by Mifepristone (Compound)
Erlotinib (Compound) downregulates RNH1 (Gene) and RNH1 (Gene) is downregulated by Mifepristone (Compound)
Erlotinib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mifepristone (Compound)
Erlotinib may decrease the metabolism of Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Mifepristone
Erlotinib may decrease the metabolism of Ritonavir and Ritonavir may increase the QTc prolonging activities of Mifepristone
Erlotinib may increase the serum concentration of Ceritinib and Ceritinib may increase the serum concentration of Mifepristone
Erlotinib may increase the serum concentration of Dasatinib and Dasatinib may increase the QTc prolonging activities of Mifepristone
Erlotinib may decrease the serum concentration of Olanzapine and Olanzapine may increase the QTc prolonging activities of Mifepristone
|
DB00363
|
DB01002
| 681 | 214 |
Clozapine
|
Levobupivacaine
|
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
|
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In
|
The risk or severity of adverse effects can be increased when Clozapine is combined with Levobupivacaine.
| 48 |
[
[
[
681,
71,
214
]
],
[
[
681,
69,
611
],
[
611,
223,
214
]
],
[
[
681,
95,
379
],
[
379,
223,
214
]
],
[
[
681,
223,
541
],
[
541,
71,
214
]
],
[
[
681,
6,
4590
],
[
4590,
160,
214
]
],
[
[
681,
251,
161
],
[
161,
26,
214
]
],
[
[
681,
85,
156
],
[
156,
26,
214
]
],
[
[
681,
184,
674
],
[
674,
30,
214
]
],
[
[
681,
38,
1257
],
[
1257,
192,
214
]
],
[
[
681,
192,
287
],
[
287,
38,
214
]
]
] |
[
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may decrease the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may increase the myelosuppressive activities of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
],
[
[
"Clozapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
]
] |
Clozapine may decrease the metabolism of Lidocaine and Lidocaine may decrease the metabolism of Levobupivacaine
Clozapine may increase the serum concentration of Ranolazine and Ranolazine may decrease the metabolism of Levobupivacaine
Clozapine may decrease the metabolism of Ropivacaine and Ropivacaine may increase the severity of adverse effects when combined with Levobupivacaine
Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levobupivacaine (Compound)
Clozapine may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Levobupivacaine
Clozapine may increase the myelosuppressive activities of Carbamazepine and Carbamazepine can increase the metabolism of Levobupivacaine
Clozapine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Levobupivacaine
Clozapine may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Levobupivacaine
Clozapine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Levobupivacaine
|
DB00252
|
DB00207
| 142 | 645 |
Phenytoin
|
Azithromycin
|
Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.
|
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
|
The metabolism of Azithromycin can be increased when combined with Phenytoin.
| 3 |
[
[
[
142,
26,
645
]
],
[
[
142,
26,
143
],
[
143,
196,
645
]
],
[
[
142,
6,
8339
],
[
8339,
160,
645
]
],
[
[
142,
21,
28633
],
[
28633,
175,
645
]
],
[
[
142,
251,
156
],
[
156,
26,
645
]
],
[
[
142,
180,
150
],
[
150,
26,
645
]
],
[
[
142,
137,
161
],
[
161,
26,
645
]
],
[
[
142,
192,
164
],
[
164,
26,
645
]
],
[
[
142,
71,
878
],
[
878,
196,
645
]
],
[
[
142,
225,
992
],
[
992,
196,
645
]
]
] |
[
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
]
] |
Phenytoin can increase the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Azithromycin
Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Azithromycin (Compound)
Phenytoin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Azithromycin (Compound)
Phenytoin may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Azithromycin
Phenytoin can increase the metabolism of Fosphenytoin and Fos
Phenytoin (Compound) resembles Primidone (Compound) and Phenytoin can increase the metabolism of Primidone and Primidone can increase the metabolism of Azithromycin
Phenytoin may increase the central nervous system depressant activities of Phenobarbital and Phenobarbital can increase the metabolism of Azithromycin
Phenytoin may increase the severity of adverse effects when combined with Paroxetine and Paroxetine may increase the QTc prolonging activities of Azithromycin
Phenytoin may increase the severity of adverse effects when combined with Olanzapine and Olanzapine may increase the QTc prolonging activities of Azithromycin
|
DB06589
|
DB01234
| 437 | 119 |
Pazopanib
|
Dexamethasone
|
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
|
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
|
The serum concentration of Dexamethasone can be increased when it is combined with Pazopanib.
| 72 |
[
[
[
437,
95,
119
]
],
[
[
437,
95,
92
],
[
92,
1,
119
]
],
[
[
437,
6,
12846
],
[
12846,
160,
119
]
],
[
[
437,
7,
7405
],
[
7405,
161,
119
]
],
[
[
437,
18,
8902
],
[
8902,
161,
119
]
],
[
[
437,
5,
17044
],
[
17044,
164,
119
]
],
[
[
437,
18,
11704
],
[
11704,
172,
119
]
],
[
[
437,
6,
3684
],
[
3684,
172,
119
]
],
[
[
437,
7,
1792
],
[
1792,
172,
119
]
],
[
[
437,
21,
28895
],
[
28895,
175,
119
]
]
] |
[
[
[
"Pazopanib",
"{u} may increase the serum concentration of {v}",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} may increase the serum concentration of {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"SELL"
],
[
"SELL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) downregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) treats {v} (Disease)",
"kidney cancer"
],
[
"kidney cancer",
"{u} (Disease) is palliated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) downregulates {v} (Gene)",
"ADM"
],
[
"ADM",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"SH2B3"
],
[
"SH2B3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"RELB"
],
[
"RELB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Pazopanib",
"{u} (Compound) causes {v} (Side Effect)",
"Acute coronary syndrome"
],
[
"Acute coronary syndrome",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
]
] |
Pazopanib may increase the serum concentration of Hydrocortisone and Hydrocortisone (Compound) resembles Dexamethasone (Compound)
Pazopanib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dexamethasone (Compound)
Pazopanib (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Dexamethasone (Compound)
Pazopanib (Compound) downregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Dexamethasone (Compound)
Pazopanib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Dexamethasone (Compound)
Pazopanib (Compound) downregulates ADM (Gene) and ADM (Gene) is downregulated by Dexamethasone (Compound)
Pazopanib (Compound) binds SH2B3 (Gene) and SH2B3 (Gene) is downregulated by Dexamethasone (Compound)
Pazopanib (Compound) upregulates RELB (Gene) and RELB (Gene) is downregulated by Dexamethasone (Compound)
Pazopanib (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Dexamethasone (Compound)
|
DB01267
|
DB00924
| 1,007 | 195 |
Paliperidone
|
Cyclobenzaprine
|
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
|
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
|
Paliperidone may decrease the antihypertensive activities of Cyclobenzaprine.
| 36 |
[
[
[
1007,
59,
195
]
],
[
[
1007,
225,
288
],
[
288,
223,
195
]
],
[
[
1007,
71,
30
],
[
30,
225,
195
]
],
[
[
1007,
6,
5586
],
[
5586,
160,
195
]
],
[
[
1007,
21,
28747
],
[
28747,
175,
195
]
],
[
[
1007,
225,
164
],
[
164,
26,
195
]
],
[
[
1007,
71,
145
],
[
145,
26,
195
]
],
[
[
1007,
59,
543
],
[
543,
38,
195
]
],
[
[
1007,
192,
287
],
[
287,
38,
195
]
],
[
[
1007,
38,
1264
],
[
1264,
192,
195
]
]
] |
[
[
[
"Paliperidone",
"{u} may decrease the antihypertensive activities of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} (Compound) binds {v} (Gene)",
"HTR2A"
],
[
"HTR2A",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiamylal"
],
[
"Thiamylal",
"{u} can increase the metabolism of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclobenzaprine"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclobenzaprine"
]
]
] |
Paliperidone may increase the severity of adverse effects when combined with Promazine and Promazine may decrease the metabolism of Cyclobenzaprine
Paliperidone may increase the severity of adverse effects when combined with Cyproheptadine and Cyproheptadine may increase the severity of adverse effects when combined with Cyclobenzaprine
Paliperidone (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Cyclobenzaprine (Compound)
Paliperidone (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Cyclobenzaprine (Compound)
Paliperidone may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Cyclobenzaprine
Paliperidone may increase the severity of adverse effects when combined with Thiamylal and Thiamylal can increase the metabolism of Cyclobenzaprine
Paliperidone may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Cyclobenzaprine
Paliperidone may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Cyclobenzaprine
Paliperidone may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Cyclobenzaprine
|
DB08882
|
DB00230
| 693 | 674 |
Linagliptin
|
Pregabalin
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
|
The risk or severity of heart failure can be increased when Pregabalin is combined with Linagliptin.
| 49 |
[
[
[
693,
72,
674
]
],
[
[
693,
21,
28793
],
[
28793,
175,
674
]
],
[
[
693,
246,
932
],
[
932,
184,
674
]
],
[
[
693,
71,
465
],
[
465,
184,
674
]
],
[
[
693,
251,
925
],
[
925,
184,
674
]
],
[
[
693,
249,
586
],
[
586,
184,
674
]
],
[
[
693,
71,
656
],
[
656,
71,
674
]
],
[
[
693,
249,
581
],
[
581,
225,
674
]
],
[
[
693,
251,
198
],
[
198,
71,
674
]
],
[
[
693,
185,
769
],
[
769,
72,
674
]
]
] |
[
[
[
"Linagliptin",
"{u} may increase heart failure risks when combined with {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may decrease the therapeutic efficacy of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may decrease the serum concentration of {v}",
"Reserpine"
],
[
"Reserpine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may increase the serum concentration of {v}",
"Triazolam"
],
[
"Triazolam",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosinopril"
],
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may increase the serum concentration of {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may decrease the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pregabalin"
]
],
[
[
"Linagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Gliquidone"
],
[
"Gliquidone",
"{u} may increase heart failure risks when combined with {v}",
"Pregabalin"
]
]
] |
Linagliptin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Pregabalin (Compound)
Linagliptin may decrease the therapeutic efficacy of Aripiprazole and Aripiprazole can increase the therapeutic efficacy of Pregabalin
Linagliptin may increase the severity of adverse effects when combined with Meperidine and Meperidine can increase the therapeutic efficacy of Pregabalin
Linagliptin may decrease the serum concentration of Reserpine and Reserpine can increase the therapeutic efficacy of Pregabalin
Linagliptin may increase the serum concentration of Triazolam and Triazolam can increase the therapeutic efficacy of Pregabalin
Linagliptin may increase the severity of adverse effects when combined with Fosinopril and Fosinopril may increase the severity of adverse effects when combined with Pregabalin
Linagliptin may increase the serum concentration of Rosuvastatin and Rosuvastatin may increase the severity of adverse effects when combined with Pregabalin
Linagliptin may decrease the serum concentration of Cyclosporine and Cyclosporine may increase the severity of adverse effects when combined with Pregabalin
Linagliptin may increase the hypoglycemic activities of Gliquidone and Gliquidone may increase heart failure risks when combined with Pregabalin
|
DB01355
|
DB06292
| 298 | 426 |
Hexobarbital
|
Dapagliflozin
|
A barbiturate that is effective as a hypnotic and sedative.
|
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
|
Hexobarbital may increase the hypotensive activities of Dapagliflozin.
| 59 |
[
[
[
298,
82,
426
]
],
[
[
298,
6,
12128
],
[
12128,
160,
426
]
],
[
[
298,
180,
171
],
[
171,
26,
426
]
],
[
[
298,
82,
56
],
[
56,
185,
426
]
],
[
[
298,
225,
63
],
[
63,
185,
426
]
],
[
[
298,
71,
193
],
[
193,
185,
426
]
],
[
[
298,
69,
55
],
[
55,
185,
426
]
],
[
[
298,
69,
1079
],
[
1079,
223,
426
]
],
[
[
298,
225,
681
],
[
681,
223,
426
]
],
[
[
298,
71,
878
],
[
878,
223,
426
]
]
] |
[
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may increase the hypoglycemic activities of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the hypoglycemic activities of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the hypoglycemic activities of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} may increase the hypoglycemic activities of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may decrease the metabolism of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Dapagliflozin"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may decrease the metabolism of {v}",
"Dapagliflozin"
]
]
] |
Hexobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dapagliflozin (Compound)
Hexobarbital can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Dapagliflozin
Hexobarbital may increase the hypotensive activities of Rasagiline and Rasagiline may increase the hypoglycemic activities of Dapagliflozin
Hexobarbital may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Dapagliflozin
Hexobarbital may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may increase the hypoglycemic activities of Dapagliflozin
Hexobarbital may decrease the metabolism of Moclobemide and Moclobemide may increase the hypoglycemic activities of Dapagliflozin
Hexobarbital may decrease the metabolism of Crizotinib and Crizotinib may decrease the metabolism of Dapagliflozin
Hexobarbital may increase the severity of adverse effects when combined with Clozapine and Clozapine may decrease the metabolism of Dapagliflozin
Hexobarbital may increase the severity of adverse effects when combined with Paroxetine and Paroxetine may decrease the metabolism of Dapagliflozin
|
DB00875
|
DB01587
| 931 | 358 |
Flupentixol
|
Ketazolam
|
Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of both D1 and D2 dopamine receptors. Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. It is approved for use in Canada and other countries around the world, but not in the US. It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity. It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs
|
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
|
The risk or severity of adverse effects can be increased when Flupentixol is combined with Ketazolam.
| 48 |
[
[
[
931,
71,
358
]
],
[
[
931,
71,
552
],
[
552,
1,
358
]
],
[
[
931,
71,
259
],
[
259,
155,
358
]
],
[
[
931,
6,
8339
],
[
8339,
160,
358
]
],
[
[
931,
71,
150
],
[
150,
26,
358
]
],
[
[
931,
184,
674
],
[
674,
30,
358
]
],
[
[
931,
38,
1261
],
[
1261,
192,
358
]
],
[
[
931,
192,
287
],
[
287,
38,
358
]
],
[
[
931,
54,
1046
],
[
1046,
208,
358
]
],
[
[
931,
42,
479
],
[
479,
223,
358
]
]
] |
[
[
[
"Flupentixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} (Compound) resembles {v} (Compound)",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunitrazepam"
],
[
"Flunitrazepam",
"{u} (Compound) resembles {v} (Compound)",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Ketazolam"
]
],
[
[
"Flupentixol",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may decrease the metabolism of {v}",
"Ketazolam"
]
]
] |
Flupentixol may increase the severity of adverse effects when combined with Methsuximide and Methsuximide (Compound) resembles Ketazolam (Compound)
Flupentixol may increase the severity of adverse effects when combined with Flunitrazepam and Flunitrazepam (Compound) resembles Ketazolam (Compound)
Flupentixol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ketazolam (Compound)
Flupentixol may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Ketazolam
Flupentixol can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Ketazolam
Flupentixol may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Ketazolam
Flupentixol may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Ketazolam
Flupentixol may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Ketazolam
Flupentixol may increase the QTc prolonging activities of Posaconazole and Posaconazole may decrease the metabolism of Ketazolam
|
DB01248
|
DB06813
| 357 | 1,197 |
Docetaxel
|
Pralatrexate
|
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel].[A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin. The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention
|
Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma. Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes. As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. Pralatrexate was approved by the FDA on September 24, 2009. It is also being studied for other types of lymphoma and solid malignancy such as non-small-cell lung cancer, breast cancer, and bladder cancer.
|
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.
| 48 |
[
[
[
357,
71,
1197
]
],
[
[
357,
71,
1233
],
[
1233,
155,
1197
]
],
[
[
357,
71,
1200
],
[
1200,
1,
1197
]
],
[
[
357,
18,
11160
],
[
11160,
160,
1197
]
],
[
[
357,
21,
28646
],
[
28646,
175,
1197
]
],
[
[
357,
56,
1389
],
[
1389,
210,
1197
]
],
[
[
357,
71,
152
],
[
152,
71,
1197
]
],
[
[
357,
225,
292
],
[
292,
71,
1197
]
],
[
[
357,
80,
232
],
[
232,
234,
1197
]
],
[
[
357,
69,
827
],
[
827,
249,
1197
]
]
] |
[
[
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Raltitrexed"
],
[
"Raltitrexed",
"{u} (Compound) resembles {v} (Compound)",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} (Compound) resembles {v} (Compound)",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} (Compound) downregulates {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is bound by {v} (Compound)",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may increase the immunosuppressive activities of {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may increase the immunosuppressive activities of {v}",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Pralatrexate"
]
],
[
[
"Docetaxel",
"{u} may decrease the metabolism of {v}",
"Naftifine"
],
[
"Naftifine",
"{u} may increase the serum concentration of {v}",
"Pralatrexate"
]
]
] |
Docetaxel may increase the severity of adverse effects when combined with Raltitrexed and Raltitrexed (Compound) resembles Pralatrexate (Compound)
Docetaxel may increase the severity of adverse effects when combined with Methotrexate and Methotrexate (Compound) resembles Pralatrexate (Compound)
Docetaxel (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Pralatrexate (Compound)
Docetaxel (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pralatrexate (Compound)
Docetaxel may increase the immunosuppressive activities of Tofacitinib and Tofacitinib may increase the immunosuppressive activities of Pralatrexate
Docetaxel may increase the severity of adverse effects when combined with Cabazitaxel and Cabazitaxel may increase the severity of adverse effects when combined with Pralatrexate
Docetaxel may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Pralatrexate
Docetaxel may decrease the cardiotoxic activities of Digitoxin and Digitoxin may decrease the cardiotoxic activities of Pralatrexate
Docetaxel may decrease the metabolism of Naftifine and Naftifine may increase the serum concentration of Pralatrexate
|
DB00363
|
DB13323
| 681 | 927 |
Clozapine
|
Trichloroethylene
|
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
|
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits.
|
The risk or severity of adverse effects can be increased when Clozapine is combined with Trichloroethylene.
| 48 |
[
[
[
681,
71,
927
]
],
[
[
681,
184,
674
],
[
674,
30,
927
]
],
[
[
681,
38,
1257
],
[
1257,
192,
927
]
],
[
[
681,
192,
491
],
[
491,
38,
927
]
],
[
[
681,
54,
471
],
[
471,
208,
927
]
],
[
[
681,
71,
552
],
[
552,
225,
927
]
],
[
[
681,
71,
639
],
[
639,
71,
927
]
],
[
[
681,
85,
156
],
[
156,
71,
927
]
],
[
[
681,
223,
434
],
[
434,
225,
927
]
],
[
[
681,
223,
270
],
[
270,
71,
927
]
]
] |
[
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may increase the myelosuppressive activities of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
]
] |
Clozapine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Trichloroethylene
Clozapine may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Trichloroethylene
Clozapine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Trichloroethylene
Clozapine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Trichloroethylene
Clozapine may increase the severity of adverse effects when combined with Methsuximide and Methsuximide may increase the severity of adverse effects when combined with Trichloroethylene
Clozapine may increase the severity of adverse effects when combined with Valproic acid and Valproic acid may increase the severity of adverse effects when combined with Trichloroethylene
Clozapine may increase the myelosuppressive activities of Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Trichloroethylene
Clozapine may decrease the metabolism of Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Trichloroethylene
Clozapine may decrease the metabolism of Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Trichloroethylene
|
DB00623
|
DB04871
| 1,014 | 578 |
Fluphenazine
|
Lorcaserin
|
A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.
|
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients
|
The metabolism of Lorcaserin can be decreased when combined with Fluphenazine.
| 46 |
[
[
[
1014,
69,
578
]
],
[
[
1014,
225,
171
],
[
171,
26,
578
]
],
[
[
1014,
71,
142
],
[
142,
26,
578
]
],
[
[
1014,
71,
522
],
[
522,
69,
578
]
],
[
[
1014,
69,
414
],
[
414,
223,
578
]
],
[
[
1014,
225,
540
],
[
540,
69,
578
]
],
[
[
1014,
246,
968
],
[
968,
69,
578
]
],
[
[
1014,
82,
647
],
[
647,
69,
578
]
],
[
[
1014,
249,
437
],
[
437,
69,
578
]
],
[
[
1014,
71,
611
],
[
611,
223,
578
]
]
] |
[
[
[
"Fluphenazine",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
],
[
"Halothane",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may decrease the metabolism of {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the hypotensive activities of {v}",
"Timolol"
],
[
"Timolol",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Lorcaserin"
]
]
] |
Fluphenazine may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Lorcaserin
Fluphenazine may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Lorcaserin
Fluphenazine may increase the severity of adverse effects when combined with Halothane and Halothane may decrease the metabolism of Lorcaserin
Fluphenazine may decrease the metabolism of Cholecalciferol and Cholecalciferol may decrease the metabolism of Lorcaserin
Fluphenazine may increase the severity of adverse effects when combined with Morphine and Morphine may decrease the metabolism of Lorcaserin
Fluphenazine may decrease the therapeutic efficacy of Levodopa and Levodopa may decrease the metabolism of Lorcaserin
Fluphenazine may increase the hypotensive activities of Timolol and Timolol may decrease the metabolism of Lorcaserin
Fluphenazine may increase the serum concentration of Pazopanib and Pazopanib may decrease the metabolism of Lorcaserin
Fluphenazine may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Lorcaserin
|
DB00843
|
DB01203
| 209 | 1,038 |
Donepezil
|
Nadolol
|
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
|
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979.
|
Donepezil may increase the bradycardic activities of Nadolol.
| 53 |
[
[
[
209,
76,
1038
]
],
[
[
209,
76,
1033
],
[
1033,
236,
1038
]
],
[
[
209,
18,
2683
],
[
2683,
172,
1038
]
],
[
[
209,
21,
28398
],
[
28398,
175,
1038
]
],
[
[
209,
69,
297
],
[
297,
31,
1038
]
],
[
[
209,
69,
615
],
[
615,
32,
1038
]
],
[
[
209,
69,
530
],
[
530,
47,
1038
]
],
[
[
209,
230,
730
],
[
730,
47,
1038
]
],
[
[
209,
76,
643
],
[
643,
47,
1038
]
],
[
[
209,
1,
678
],
[
678,
206,
1038
]
]
] |
[
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} may increase the hypotensive activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Guanfacine"
],
[
"Guanfacine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Nadolol"
]
],
[
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nadolol"
]
]
] |
Donepezil may increase the bradycardic activities of Bupranolol and Bupranolol may increase the hypotensive activities of Nadolol
Donepezil (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Nadolol (Compound)
Donepezil (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Nadolol (Compound)
Donepezil may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Nadolol
Donepezil may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Nadolol
Donepezil may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may increase the atrioventricular blocking activities of Nadolol
Donepezil may increase the bradycardic activities of Tizanidine and Tizanidine may increase the atrioventricular blocking activities of Nadolol
Donepezil may increase the bradycardic activities of Guanfacine and Guanfacine may increase the atrioventricular blocking activities of Nadolol
Donepezil (Compound) resembles Doxazosin (Compound) and Doxazosin may increase the orthostatic hypotensive activities of Nadolol
|
DB00645
|
DB06144
| 982 | 257 |
Dyclonine
|
Sertindole
|
Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.
|
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
|
The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.
| 48 |
[
[
[
982,
71,
257
]
],
[
[
982,
225,
413
],
[
413,
1,
257
]
],
[
[
982,
155,
245
],
[
245,
1,
257
]
],
[
[
982,
225,
156
],
[
156,
26,
257
]
],
[
[
982,
71,
161
],
[
161,
26,
257
]
],
[
[
982,
192,
679
],
[
679,
38,
257
]
],
[
[
982,
38,
405
],
[
405,
192,
257
]
],
[
[
982,
54,
1365
],
[
1365,
208,
257
]
],
[
[
982,
225,
18
],
[
18,
58,
257
]
],
[
[
982,
71,
200
],
[
200,
223,
257
]
]
] |
[
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} (Compound) resembles {v} (Compound)",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
],
[
"Haloperidol",
"{u} (Compound) resembles {v} (Compound)",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Sertindole"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may decrease the metabolism of {v}",
"Sertindole"
]
]
] |
Dyclonine may increase the severity of adverse effects when combined with Pimozide and Pimozide (Compound) resembles Sertindole (Compound)
Dyclonine (Compound) resembles Haloperidol (Compound) and Haloperidol (Compound) resembles Sertindole (Compound)
Dyclonine may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Sertindole
Dyclonine may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Sertindole
Dyclonine may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Sertindole
Dyclonine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Sertindole
Dyclonine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Sertindole
Dyclonine may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Sertindole
Dyclonine may increase the severity of adverse effects when combined with Cocaine and Cocaine may decrease the metabolism of Sertindole
|
DB08899
|
DB06786
| 1,110 | 122 |
Enzalutamide
|
Halcinonide
|
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
|
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.
|
The serum concentration of Halcinonide can be decreased when it is combined with Enzalutamide.
| 74 |
[
[
[
1110,
97,
122
]
],
[
[
1110,
97,
620
],
[
620,
71,
122
]
],
[
[
1110,
97,
209
],
[
209,
225,
122
]
],
[
[
1110,
95,
1019
],
[
1019,
92,
122
]
],
[
[
1110,
97,
1113
],
[
1113,
249,
122
]
],
[
[
1110,
95,
1095
],
[
1095,
249,
122
]
],
[
[
1110,
251,
150
],
[
150,
97,
122
]
],
[
[
1110,
97,
142
],
[
142,
97,
122
]
],
[
[
1110,
97,
1092
],
[
1092,
251,
122
]
],
[
[
1110,
95,
1324
],
[
1324,
100,
122
]
]
] |
[
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may decrease the therapeutic efficacy of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the hyperglycemic activities of {v}",
"Halcinonide"
]
]
] |
Enzalutamide may decrease the serum concentration of Mycophenolate mofetil and Mycophenolate mofetil may increase the severity of adverse effects when combined with Halcinonide
Enzalutamide may decrease the serum concentration of Donepezil and Donepezil may increase the severity of adverse effects when combined with Halcinonide
Enzalutamide may increase the serum concentration of Mifepristone and Mifepristone may decrease the therapeutic efficacy of Halcinonide
Enzalutamide may decrease the serum concentration of Boceprevir and Boceprevir may increase the serum concentration of Halcinonide
Enzalutamide may increase the serum concentration of Cobicistat and Cobicistat may increase the serum concentration of Halcinonide
Enzalutamide may decrease the serum concentration of Fosphenytoin and Fosphenytoin may decrease the serum concentration of Halcinonide
Enzalutamide may decrease the serum concentration of Phenytoin and Phenytoin may decrease the serum concentration of Halcinonide
Enzalutamide may decrease the serum concentration of Telaprevir and Telaprevir may decrease the serum concentration of Halcinonide
Enzalutamide may increase the serum concentration of Ceritinib and Ceritinib may increase the hyperglycemic activities of Halcinonide
|
DB00470
|
DB01685
| 1,261 | 1,417 |
Dronabinol
|
Topiroxostat
|
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in
|
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as and, and non-purine agents which includes topiroxostat. While is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. Renal complications are major comorbidities that limit the therapy as dose reductions are recommended. Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases. Approved for therapeutic use in Japan since 2013, topiroxostat is
|
The serum concentration of Topiroxostat can be increased when it is combined with Dronabinol.
| 72 |
[
[
[
1261,
95,
1417
]
],
[
[
1261,
95,
451
],
[
451,
69,
1417
]
],
[
[
1261,
192,
202
],
[
202,
69,
1417
]
],
[
[
1261,
261,
44
],
[
44,
69,
1417
]
],
[
[
1261,
251,
1110
],
[
1110,
69,
1417
]
],
[
[
1261,
107,
415
],
[
415,
69,
1417
]
],
[
[
1261,
69,
319
],
[
319,
69,
1417
]
],
[
[
1261,
95,
530
],
[
530,
71,
1417
]
],
[
[
1261,
251,
225
],
[
225,
95,
1417
]
],
[
[
1261,
95,
267
],
[
267,
95,
1417
]
]
] |
[
[
[
"Dronabinol",
"{u} may increase the serum concentration of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the serum concentration of {v}",
"Omeprazole"
],
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the tachycardic activities of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the tachycardic activities of {v}",
"Dopamine"
],
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may decrease the metabolism of {v}",
"Nicotine"
],
[
"Nicotine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the serum concentration of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Topiroxostat"
]
],
[
[
"Dronabinol",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may increase the serum concentration of {v}",
"Topiroxostat"
]
]
] |
Dronabinol may increase the serum concentration of Omeprazole and Omeprazole may decrease the metabolism of Topiroxostat
Dronabinol may increase the central nervous system depressant activities of Ketamine and Ketamine may decrease the metabolism of Topiroxostat
Dronabinol may increase the tachycardic activities of Tolterodine and Tolterodine may decrease the metabolism of Topiroxostat
Dronabinol may decrease the serum concentration of Enzalutamide and Enzalutamide may decrease the metabolism of Topiroxostat
Dronabinol may increase the tachycardic activities of Dopamine and Dopamine may decrease the metabolism of Topiroxostat
Dronabinol may decrease the metabolism of Nicotine and Nicotine may decrease the metabolism of Topiroxostat
Dronabinol may increase the serum concentration of Dihydroergotamine and Dihydroergotamine may increase the severity of adverse effects when combined with Topiroxostat
Dronabinol may decrease the serum concentration of Bosentan and Bosentan may increase the serum concentration of Topiroxostat
Dronabinol may increase the serum concentration of Lovastatin and Lovastatin may increase the serum concentration of Topiroxostat
|
DB06772
|
DB00675
| 152 | 568 |
Cabazitaxel
|
Tamoxifen
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tamoxifen.
| 48 |
[
[
[
152,
71,
568
]
],
[
[
152,
71,
574
],
[
574,
1,
568
]
],
[
[
152,
6,
8607
],
[
8607,
160,
568
]
],
[
[
152,
6,
4070
],
[
4070,
172,
568
]
],
[
[
152,
21,
28937
],
[
28937,
175,
568
]
],
[
[
152,
180,
142
],
[
142,
26,
568
]
],
[
[
152,
249,
218
],
[
218,
26,
568
]
],
[
[
152,
69,
613
],
[
613,
33,
568
]
],
[
[
152,
249,
379
],
[
379,
33,
568
]
],
[
[
152,
95,
266
],
[
266,
33,
568
]
]
] |
[
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
],
[
"Diethylstilbestrol",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) binds {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} may increase the serum concentration of {v}",
"Rifaximin"
],
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
],
[
[
"Cabazitaxel",
"{u} may increase the serum concentration of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
]
] |
Cabazitaxel may increase the severity of adverse effects when combined with Diethylstilbestrol and Diethylstilbestrol (Compound) resembles Tamoxifen (Compound)
Cabazitaxel (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Tamoxifen (Compound)
Cabazitaxel (Compound) binds TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Tamoxifen (Compound)
Cabazitaxel (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Tamoxifen (Compound)
Cabazitaxel can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Tamoxifen
Cabazitaxel may increase the serum concentration of Rifaximin and Rifaximin can increase the metabolism of Tamoxifen
Cabazitaxel may decrease the metabolism of Ticlopidine and Ticlopidine may reduce the serum concentration of the active metabolites of Tamoxifen
Cabazitaxel may increase the serum concentration of Ranolazine and Ranolazine may reduce the serum concentration of the active metabolites of Tamoxifen
Cabazitaxel may increase the serum concentration of Indinavir and Indinavir may reduce the serum concentration of the active metabolites of Tamoxifen
|
DB01210
|
DB13783
| 1,029 | 1,351 |
Levobunolol
|
Acemetacin
|
A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
|
Acemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin. In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin. It was developed by E. Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and it kept the same side effects.
|
Levobunolol may decrease the antihypertensive activities of Acemetacin.
| 36 |
[
[
[
1029,
59,
1351
]
],
[
[
1029,
59,
166
],
[
166,
71,
1351
]
],
[
[
1029,
225,
1352
],
[
1352,
71,
1351
]
],
[
[
1029,
225,
894
],
[
894,
241,
1351
]
],
[
[
1029,
59,
805
],
[
805,
92,
1351
]
],
[
[
1029,
1,
1035
],
[
1035,
246,
1351
]
],
[
[
1029,
71,
731
],
[
731,
246,
1351
]
],
[
[
1029,
225,
385
],
[
385,
246,
1351
]
],
[
[
1029,
71,
1455
],
[
1455,
92,
1351
]
],
[
[
1029,
270,
647
],
[
647,
246,
1351
]
]
] |
[
[
[
"Levobunolol",
"{u} may decrease the antihypertensive activities of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may decrease the antihypertensive activities of {v}",
"Zaltoprofen"
],
[
"Zaltoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
],
[
"Sacubitril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the excretion rate {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may decrease the antihypertensive activities of {v}",
"Choline magnesium trisalicylate"
],
[
"Choline magnesium trisalicylate",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Carteolol"
],
[
"Carteolol",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamoylcholine"
],
[
"Carbamoylcholine",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Timolol"
],
[
"Timolol",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
]
]
] |
Levobunolol may decrease the antihypertensive activities of Zaltoprofen and Zaltoprofen may increase the severity of adverse effects when combined with Acemetacin
Levobunolol may increase the severity of adverse effects when combined with Sacubitril and Sacubitril may increase the severity of adverse effects when combined with Acemetacin
Levobunolol may increase the severity of adverse effects when combined with Furosemide and Furosemide may increase the excretion rate Acemetacin
Levobunolol may decrease the antihypertensive activities of Choline magnesium trisalicylate and Choline magnesium trisalicylate may decrease the therapeutic efficacy of Acemetacin
Levobunolol (Compound) resembles Carteolol (Compound) and Carteolol may decrease the therapeutic efficacy of Acemetacin
Levobunolol may increase the severity of adverse effects when combined with Nebivolol and Nebivolol may decrease the therapeutic efficacy of Acemetacin
Levobunolol may increase the severity of adverse effects when combined with Amlodipine and Amlodipine may decrease the therapeutic efficacy of Acemetacin
Levobunolol may increase the severity of adverse effects when combined with Carbamoylcholine and Carbamoylcholine may decrease the therapeutic efficacy of Acemetacin
Levobunolol (Compound) resembles Timolol (Compound) and Levobunolol may increase the severity of adverse effects when combined with Timolol and Timolol may decrease the therapeutic efficacy of Acemetacin
|
DB06702
|
DB01433
| 35 | 984 |
Fesoterodine
|
Methadyl acetate
|
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
|
A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
|
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadyl acetate.
| 48 |
[
[
[
35,
71,
984
]
],
[
[
35,
253,
568
],
[
568,
1,
984
]
],
[
[
35,
225,
72
],
[
72,
38,
984
]
],
[
[
35,
71,
942
],
[
942,
155,
984
]
],
[
[
35,
71,
289
],
[
289,
71,
984
]
],
[
[
35,
155,
589
],
[
589,
1,
984
]
],
[
[
35,
71,
1083
],
[
1083,
38,
984
]
],
[
[
35,
253,
491
],
[
491,
38,
984
]
],
[
[
35,
107,
1265
],
[
1265,
192,
984
]
],
[
[
35,
253,
1262
],
[
1262,
192,
984
]
]
] |
[
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the tachycardic activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Fesoterodine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
]
] |
Fesoterodine may increase the serum concentration of the active metabolites of Tamoxifen and Tamoxifen (Compound) resembles Methadyl acetate (Compound)
Fesoterodine may increase the severity of adverse effects when combined with Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Methadyl acetate
Fesoterodine may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate (Compound) resembles Methadyl acetate (Compound)
Fesoterodine may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Methadyl acetate
Fesoterodine (Compound) resembles Disopyramide (Compound) and Disopyramide (Compound) resembles Methadyl acetate (Compound)
Fesoterodine may increase the severity of adverse effects when combined with Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Methadyl acetate
Fesoterodine may increase the serum concentration of the active metabolites of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Methadyl acetate
Fesoterodine may increase the tachycardic activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Methadyl acetate
Fesoterodine may increase the serum concentration of the active metabolites of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Methadyl acetate
|
DB00590
|
DB01158
| 678 | 1,044 |
Doxazosin
|
Bretylium
|
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
|
Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
|
The risk or severity of adverse effects can be increased when Doxazosin is combined with Bretylium.
| 48 |
[
[
[
678,
71,
1044
]
],
[
[
678,
21,
28741
],
[
28741,
175,
1044
]
],
[
[
678,
236,
506
],
[
506,
32,
1044
]
],
[
[
678,
59,
230
],
[
230,
213,
1044
]
],
[
[
678,
71,
662
],
[
662,
225,
1044
]
],
[
[
678,
225,
214
],
[
214,
71,
1044
]
],
[
[
678,
71,
304
],
[
304,
71,
1044
]
],
[
[
678,
69,
227
],
[
227,
71,
1044
]
],
[
[
678,
82,
146
],
[
146,
71,
1044
]
],
[
[
678,
206,
1025
],
[
1025,
71,
1044
]
]
] |
[
[
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Mood swings"
],
[
"Mood swings",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the hypotensive activities of {v}",
"Avanafil"
],
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clevidipine"
],
[
"Clevidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the hypotensive activities of {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Doxazosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
]
] |
Doxazosin (Compound) causes Mood swings (Side Effect) and Mood swings (Side Effect) is caused by Bretylium (Compound)
Doxazosin may increase the hypotensive activities of Avanafil and Avanafil may increase the antihypertensive activities of Bretylium
Doxazosin may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Bretylium
Doxazosin may increase the severity of adverse effects when combined with Clevidipine and Clevidipine may increase the severity of adverse effects when combined with Bretylium
Doxazosin may increase the severity of adverse effects when combined with Levobupivacaine and Levobupivacaine may increase the severity of adverse effects when combined with Bretylium
Doxazosin may increase the severity of adverse effects when combined with Candesartan cilexetil and Candesartan cilexetil may increase the severity of adverse effects when combined with Bretylium
Doxazosin may decrease the metabolism of Bortezomib and Bortezomib may increase the severity of adverse effects when combined with Bretylium
Doxazosin may increase the hypotensive activities of Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Bretylium
Doxazosin may increase the orthostatic hypotensive activities of Arotinolol and Arotinolol may increase the severity of adverse effects when combined with Bretylium
|
DB01028
|
DB06603
| 477 | 1,098 |
Methoxyflurane
|
Panobinostat
|
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
The serum concentration of Panobinostat can be increased when it is combined with Methoxyflurane.
| 72 |
[
[
[
477,
95,
1098
]
],
[
[
477,
38,
1262
],
[
1262,
196,
1098
]
],
[
[
477,
225,
1007
],
[
1007,
42,
1098
]
],
[
[
477,
69,
645
],
[
645,
196,
1098
]
],
[
[
477,
71,
1097
],
[
1097,
196,
1098
]
],
[
[
477,
69,
1079
],
[
1079,
42,
1098
]
],
[
[
477,
225,
354
],
[
354,
196,
1098
]
],
[
[
477,
69,
267
],
[
267,
223,
1098
]
],
[
[
477,
69,
582
],
[
582,
225,
1098
]
],
[
[
477,
95,
1529
],
[
1529,
249,
1098
]
]
] |
[
[
[
"Methoxyflurane",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Panobinostat"
]
],
[
[
"Methoxyflurane",
"{u} may increase the serum concentration of {v}",
"Fusidic acid"
],
[
"Fusidic acid",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
]
]
] |
Methoxyflurane may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may decrease the metabolism of Azithromycin and Azithromycin may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may increase the severity of adverse effects when combined with Ezogabine and Ezogabine may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may decrease the metabolism of Crizotinib and Crizotinib may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may increase the severity of adverse effects when combined with Sevoflurane and Sevoflurane may increase the QTc prolonging activities of Panobinostat
Methoxyflurane may decrease the metabolism of Lovastatin and Lovastatin may decrease the metabolism of Panobinostat
Methoxyflurane may decrease the metabolism of Leflunomide and Leflunomide may increase the severity of adverse effects when combined with Panobinostat
Methoxyflurane may increase the serum concentration of Fusidic acid and Fusidic acid may increase the serum concentration of Panobinostat
|
DB00937
|
DB00850
| 1,334 | 525 |
Diethylpropion
|
Perphenazine
|
A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
Diethylpropion may decrease the stimulatory activities of Perphenazine.
| 60 |
[
[
[
1334,
83,
525
]
],
[
[
1334,
83,
971
],
[
971,
225,
525
]
],
[
[
1334,
83,
1378
],
[
1378,
155,
525
]
],
[
[
1334,
98,
69
],
[
69,
1,
525
]
],
[
[
1334,
83,
270
],
[
270,
71,
525
]
],
[
[
1334,
83,
970
],
[
970,
1,
525
]
],
[
[
1334,
98,
1448
],
[
1448,
155,
525
]
],
[
[
1334,
21,
28387
],
[
28387,
175,
525
]
],
[
[
1334,
97,
164
],
[
164,
26,
525
]
],
[
[
1334,
225,
587
],
[
587,
38,
525
]
]
] |
[
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the sedative activities of {v}",
"Profenamine"
],
[
"Profenamine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the sedative activities of {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Perphenazine"
]
],
[
[
"Diethylpropion",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Perphenazine"
]
]
] |
Diethylpropion may decrease the stimulatory activities of Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Perphenazine
Diethylpropion may decrease the stimulatory activities of Acetophenazine and Acetophenazine (Compound) resembles Perphenazine (Compound)
Diethylpropion may decrease the sedative activities of Profenamine and Profenamine (Compound) resembles Perphenazine (Compound)
Diethylpropion may decrease the stimulatory activities of Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Perphenazine
Diethylpropion may decrease the stimulatory activities of Thiothixene and Thiothixene (Compound) resembles Perphenazine (Compound)
Diethylpropion may decrease the sedative activities of Alimemazine and Alimemazine (Compound) resembles Perphenazine (Compound)
Diethylpropion (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Perphenazine (Compound)
Diethylpropion may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Perphenazine
Diethylpropion may increase the severity of adverse effects when combined with Ethanol and Ethanol may increase the central nervous system depressant activities of Perphenazine
|
DB01200
|
DB09054
| 247 | 1,099 |
Bromocriptine
|
Idelalisib
|
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above.
|
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
|
The metabolism of Idelalisib can be decreased when combined with Bromocriptine.
| 46 |
[
[
[
247,
69,
1099
]
],
[
[
247,
71,
243
],
[
243,
37,
1099
]
],
[
[
247,
71,
448
],
[
448,
69,
1099
]
],
[
[
247,
69,
482
],
[
482,
69,
1099
]
],
[
[
247,
47,
519
],
[
519,
69,
1099
]
],
[
[
247,
92,
288
],
[
288,
69,
1099
]
],
[
[
247,
249,
198
],
[
198,
69,
1099
]
],
[
[
247,
86,
296
],
[
296,
69,
1099
]
],
[
[
247,
225,
587
],
[
587,
69,
1099
]
],
[
[
247,
95,
561
],
[
561,
69,
1099
]
]
] |
[
[
[
"Bromocriptine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clofazimine"
],
[
"Clofazimine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may decrease the therapeutic efficacy of {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the serotonergic activities of {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Bromocriptine",
"{u} may increase the serum concentration of {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
]
] |
Bromocriptine may increase the severity of adverse effects when combined with Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Idelalisib
Bromocriptine may increase the severity of adverse effects when combined with Clofazimine and Clofazimine may decrease the metabolism of Idelalisib
Bromocriptine may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Idelalisib
Bromocriptine may increase the atrioventricular blocking activities of Celiprolol and Celiprolol may decrease the metabolism of Idelalisib
Bromocriptine may decrease the therapeutic efficacy of Promazine and Promazine may decrease the metabolism of Idelalisib
Bromocriptine may increase the serum concentration of Cyclosporine and Cyclosporine may decrease the metabolism of Idelalisib
Bromocriptine may increase the serotonergic activities of Dolasetron and Dolasetron may decrease the metabolism of Idelalisib
Bromocriptine may increase the severity of adverse effects when combined with Ethanol and Ethanol may decrease the metabolism of Idelalisib
Bromocriptine may increase the serum concentration of Ixazomib and Ixazomib may decrease the metabolism of Idelalisib
|
DB00252
|
DB13874
| 142 | 323 |
Phenytoin
|
Enasidenib
|
Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.
|
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.
|
The metabolism of Enasidenib can be increased when combined with Phenytoin.
| 3 |
[
[
[
142,
26,
323
]
],
[
[
142,
137,
161
],
[
161,
26,
323
]
],
[
[
142,
180,
173
],
[
173,
26,
323
]
],
[
[
142,
192,
164
],
[
164,
26,
323
]
],
[
[
142,
251,
156
],
[
156,
26,
323
]
],
[
[
142,
97,
59
],
[
59,
223,
323
]
],
[
[
142,
26,
266
],
[
266,
223,
323
]
],
[
[
142,
95,
396
],
[
396,
223,
323
]
],
[
[
142,
69,
658
],
[
658,
223,
323
]
],
[
[
142,
251,
639
],
[
639,
223,
323
]
]
] |
[
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may decrease the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may decrease the metabolism of {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may decrease the metabolism of {v}",
"Enasidenib"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may decrease the metabolism of {v}",
"Enasidenib"
]
]
] |
Phenytoin (Compound) resembles Primidone (Compound) and Phenytoin can increase the metabolism of Primidone and Primidone can increase the metabolism of Enasidenib
Phenytoin can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Enasidenib
Phenytoin may increase the central nervous system depressant activities of Phenobarbital and Phenobarbital can increase the metabolism of Enasidenib
Phenytoin may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Enasidenib
Phenytoin may decrease the serum concentration of Quinidine and Quinidine may decrease the metabolism of Enasidenib
Phenytoin can increase the metabolism of Indinavir and Indinavir may decrease the metabolism of Enasidenib
Phenytoin may increase the serum concentration of Terbinafine and Terbinafine may decrease the metabolism of Enasidenib
Phenytoin may decrease the metabolism of Chloramphenicol and Chloramphenicol may decrease the metabolism of Enasidenib
Phenytoin may decrease the serum concentration of Valproic acid and Valproic acid may decrease the metabolism of Enasidenib
|
DB00420
|
DB01210
| 288 | 1,029 |
Promazine
|
Levobunolol
|
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
|
A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
|
Promazine may increase the hypotensive activities of Levobunolol.
| 59 |
[
[
[
288,
82,
1029
]
],
[
[
288,
223,
1035
],
[
1035,
155,
1029
]
],
[
[
288,
42,
705
],
[
705,
155,
1029
]
],
[
[
288,
82,
1033
],
[
1033,
155,
1029
]
],
[
[
288,
82,
1038
],
[
1038,
71,
1029
]
],
[
[
288,
223,
1022
],
[
1022,
1,
1029
]
],
[
[
288,
18,
5274
],
[
5274,
172,
1029
]
],
[
[
288,
69,
297
],
[
297,
31,
1029
]
],
[
[
288,
69,
530
],
[
530,
41,
1029
]
],
[
[
288,
246,
247
],
[
247,
41,
1029
]
]
] |
[
[
[
"Promazine",
"{u} may increase the hypotensive activities of {v}",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Carteolol"
],
[
"Carteolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may increase the QTc prolonging activities of {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may increase the hypotensive activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may increase the hypotensive activities of {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} (Compound) downregulates {v} (Gene)",
"PRPF4"
],
[
"PRPF4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the vasoconstricting activities of {v}",
"Levobunolol"
]
],
[
[
"Promazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the vasoconstricting activities of {v}",
"Levobunolol"
]
]
] |
Promazine may decrease the metabolism of Carteolol and Carteolol (Compound) resembles Levobunolol (Compound)
Promazine may increase the QTc prolonging activities of Salbutamol and Salbutamol (Compound) resembles Levobunolol (Compound)
Promazine may increase the hypotensive activities of Bupranolol and Bupranolol (Compound) resembles Levobunolol (Compound)
Promazine may increase the hypotensive activities of Nadolol and Nadolol may increase the severity of adverse effects when combined with Levobunolol
Promazine may decrease the metabolism of Pindolol and Pindolol (Compound) resembles Levobunolol (Compound)
Promazine (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is downregulated by Levobunolol (Compound)
Promazine may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Levobunolol
Promazine may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may increase the vasoconstricting activities of Levobunolol
Promazine may decrease the therapeutic efficacy of Bromocriptine and Bromocriptine may increase the vasoconstricting activities of Levobunolol
|
DB00508
|
DB05271
| 964 | 471 |
Triflupromazine
|
Rotigotine
|
A phenothiazine used as an antipsychotic agent and as an antiemetic.
|
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
|
Triflupromazine may increase the sedative activities of Rotigotine.
| 31 |
[
[
[
964,
54,
471
]
],
[
[
964,
6,
6643
],
[
6643,
160,
471
]
],
[
[
964,
225,
828
],
[
828,
206,
471
]
],
[
[
964,
225,
914
],
[
914,
54,
471
]
],
[
[
964,
71,
486
],
[
486,
54,
471
]
],
[
[
964,
38,
1265
],
[
1265,
54,
471
]
],
[
[
964,
184,
674
],
[
674,
54,
471
]
],
[
[
964,
192,
72
],
[
72,
54,
471
]
],
[
[
964,
155,
653
],
[
653,
54,
471
]
],
[
[
964,
212,
980
],
[
980,
54,
471
]
]
] |
[
[
[
"Triflupromazine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} (Compound) binds {v} (Gene)",
"DRD1"
],
[
"DRD1",
"{u} (Gene) is bound by {v} (Compound)",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
],
[
[
"Triflupromazine",
"{u} may increase the antipsychotic activities of {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
]
]
] |
Triflupromazine (Compound) binds DRD1 (Gene) and DRD1 (Gene) is bound by Rotigotine (Compound)
Triflupromazine may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Rotigotine
Triflupromazine may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the sedative activities of Rotigotine
Triflupromazine may increase the severity of adverse effects when combined with Doxepin and Doxepin may increase the sedative activities of Rotigotine
Triflupromazine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the sedative activities of Rotigotine
Triflupromazine can increase the therapeutic efficacy of Pregabalin and Pregabalin may increase the sedative activities of Rotigotine
Triflupromazine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the sedative activities of Rotigotine
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may increase the sedative activities of Rotigotine
Triflupromazine may increase the antipsychotic activities of Amisulpride and Amisulpride may increase the sedative activities of Rotigotine
|
DB00813
|
DB00227
| 961 | 267 |
Fentanyl
|
Lovastatin
|
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
|
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
|
The serum concentration of Lovastatin can be increased when it is combined with Fentanyl.
| 72 |
[
[
[
961,
95,
267
]
],
[
[
961,
249,
439
],
[
439,
69,
267
]
],
[
[
961,
6,
4590
],
[
4590,
160,
267
]
],
[
[
961,
21,
28622
],
[
28622,
175,
267
]
],
[
[
961,
251,
147
],
[
147,
26,
267
]
],
[
[
961,
95,
173
],
[
173,
26,
267
]
],
[
[
961,
225,
46
],
[
46,
69,
267
]
],
[
[
961,
38,
1257
],
[
1257,
69,
267
]
],
[
[
961,
95,
615
],
[
615,
69,
267
]
],
[
[
961,
116,
469
],
[
469,
69,
267
]
]
] |
[
[
[
"Fentanyl",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may increase the serum concentration of {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
]
] |
Fentanyl may increase the serum concentration of Simvastatin and Simvastatin may decrease the metabolism of Lovastatin
Fentanyl (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lovastatin (Compound)
Fentanyl (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Lovastatin (Compound)
Fentanyl may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Lovastatin
Fentanyl may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Lovastatin
Fentanyl may increase the severity of adverse effects when combined with Solifenacin and Solifenacin may decrease the metabolism of Lovastatin
Fentanyl may increase the central nervous system depressant activities of Perampanel and Perampanel may decrease the metabolism of Lovastatin
Fentanyl may increase the serum concentration of Sildenafil and Sildenafil may decrease the metabolism of Lovastatin
Fentanyl (Compound) resembles Dextropropoxyphene (Compound) and Fentanyl may increase the severity of adverse effects when combined with Dextropropoxyphene and Dextropropoxyphene may decrease the metabolism of Lovastatin
|
DB00960
|
DB09084
| 1,022 | 789 |
Pindolol
|
Benzydamine
|
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982.
|
Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system. Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.
|
Pindolol may decrease the antihypertensive activities of Benzydamine.
| 36 |
[
[
[
1022,
59,
789
]
],
[
[
1022,
59,
687
],
[
687,
28,
789
]
],
[
[
1022,
225,
894
],
[
894,
205,
789
]
],
[
[
1022,
155,
1016
],
[
1016,
59,
789
]
],
[
[
1022,
270,
504
],
[
504,
59,
789
]
],
[
[
1022,
52,
248
],
[
248,
59,
789
]
],
[
[
1022,
225,
1035
],
[
1035,
59,
789
]
],
[
[
1022,
116,
1038
],
[
1038,
59,
789
]
],
[
[
1022,
123,
911
],
[
911,
59,
789
]
],
[
[
1022,
1,
1028
],
[
1028,
59,
789
]
]
] |
[
[
[
"Pindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Practolol"
],
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carteolol"
],
[
"Carteolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the hypotensive activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metipranolol"
],
[
"Metipranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
]
]
] |
Pindolol may decrease the antihypertensive activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Benzydamine
Pindolol may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Benzydamine
Pindolol (Compound) resembles Practolol (Compound) and Practolol may decrease the antihypertensive activities of Benzydamine
Pindolol (Compound) resembles Propranolol (Compound) and Pindolol may increase the severity of adverse effects when combined with Propranolol and Propranolol may decrease the antihypertensive activities of Benzydamine
Pindolol may increase the orthostatic hypotensive activities of Carvedilol and Carvedilol may decrease the antihypertensive activities of Benzydamine
Pindolol may increase the severity of adverse effects when combined with Carteolol and Carteolol may decrease the antihypertensive activities of Benzydamine
Pindolol (Compound) resembles Nadolol (Compound) and Pindolol may increase the severity of adverse effects when combined with Nadolol and Nadolol may decrease the antihypertensive activities of Benzydamine
Pindolol (Compound) resembles Oxprenolol (Compound) and Pindolol may increase the hypotensive activities of Oxprenolol and Oxprenolol may decrease the antihypertensive activities of Benzydamine
Pindolol (Compound) resembles Metipranolol (Compound) and Metipranolol may decrease the antihypertensive activities of Benzydamine
|
DB00219
|
DB00295
| 37 | 540 |
Oxyphenonium
|
Morphine
|
A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]
|
Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.
|
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Morphine.
| 48 |
[
[
[
37,
71,
540
]
],
[
[
37,
71,
1083
],
[
1083,
38,
540
]
],
[
[
37,
71,
921
],
[
921,
225,
540
]
],
[
[
37,
246,
31
],
[
31,
30,
540
]
],
[
[
37,
107,
1265
],
[
1265,
192,
540
]
],
[
[
37,
61,
1400
],
[
1400,
215,
540
]
],
[
[
37,
71,
59
],
[
59,
223,
540
]
],
[
[
37,
71,
60
],
[
60,
71,
540
]
],
[
[
37,
225,
57
],
[
57,
71,
540
]
],
[
[
37,
178,
12
],
[
12,
71,
540
]
]
] |
[
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} can increase the therapeutic efficacy of {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the tachycardic activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the constipating activities of {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may increase the constipating activities of {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gallamine triethiodide"
],
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trospium"
],
[
"Trospium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
],
[
[
"Oxyphenonium",
"{u} may increase the anticholinergic activities of {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
]
]
] |
Oxyphenonium may increase the severity of adverse effects when combined with Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Morphine
Oxyphenonium may increase the severity of adverse effects when combined with Nalbuphine and Nalbuphine may increase the severity of adverse effects when combined with Morphine
Oxyphenonium may decrease the therapeutic efficacy of Minaprine and Minaprine can increase the therapeutic efficacy of Morphine
Oxyphenonium may increase the tachycardic activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Morphine
Oxyphenonium may increase the constipating activities of Eluxadoline and Eluxadoline may increase the constipating activities of Morphine
Oxyphenonium may increase the severity of adverse effects when combined with Quinidine and Quinidine may decrease the metabolism of Morphine
Oxyphenonium may increase the severity of adverse effects when combined with Gallamine triethiodide and Gallamine triethiodide may increase the severity of adverse effects when combined with Morphine
Oxyphenonium may increase the severity of adverse effects when combined with Trospium and Trospium may increase the severity of adverse effects when combined with Morphine
Oxyphenonium may increase the anticholinergic activities of Aclidinium and Aclidinium may increase the severity of adverse effects when combined with Morphine
|
DB01131
|
DB00705
| 251 | 508 |
Proguanil
|
Delavirdine
|
Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
|
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
|
The metabolism of Delavirdine can be decreased when combined with Proguanil.
| 46 |
[
[
[
251,
69,
508
]
],
[
[
251,
6,
10999
],
[
10999,
160,
508
]
],
[
[
251,
21,
28825
],
[
28825,
175,
508
]
],
[
[
251,
180,
173
],
[
173,
26,
508
]
],
[
[
251,
69,
307
],
[
307,
69,
508
]
],
[
[
251,
249,
288
],
[
288,
69,
508
]
],
[
[
251,
69,
1084
],
[
1084,
223,
508
]
],
[
[
251,
71,
314
],
[
314,
69,
508
]
],
[
[
251,
182,
219
],
[
219,
69,
508
]
],
[
[
251,
69,
886
],
[
886,
243,
508
]
]
] |
[
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may increase the serum concentration of {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may decrease the absorption and serum concentration of {v}",
"Delavirdine"
]
]
] |
Proguanil (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Delavirdine (Compound)
Proguanil (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Delavirdine (Compound)
Proguanil can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Delavirdine
Proguanil may decrease the metabolism of Fluvastatin and Fluvastatin may decrease the metabolism of Delavirdine
Proguanil may increase the serum concentration of Promazine and Promazine may decrease the metabolism of Delavirdine
Proguanil may decrease the metabolism of Itraconazole and Itraconazole may decrease the metabolism of Delavirdine
Proguanil may increase the severity of adverse effects when combined with Dapsone and Dapsone may decrease the metabolism of Delavirdine
Proguanil may increase the anticoagulant activities of Warfarin and Warfarin may decrease the metabolism of Delavirdine
Proguanil may decrease the metabolism of Cimetidine and Cimetidine may decrease the absorption and serum concentration of Delavirdine
|
DB06702
|
DB00673
| 35 | 191 |
Fesoterodine
|
Aprepitant
|
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
|
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
|
The serum concentration of Aprepitant can be increased when it is combined with Fesoterodine.
| 72 |
[
[
[
35,
95,
191
]
],
[
[
35,
6,
4590
],
[
4590,
160,
191
]
],
[
[
35,
21,
28419
],
[
28419,
175,
191
]
],
[
[
35,
253,
535
],
[
535,
180,
191
]
],
[
[
35,
180,
164
],
[
164,
26,
191
]
],
[
[
35,
69,
575
],
[
575,
180,
191
]
],
[
[
35,
69,
755
],
[
755,
223,
191
]
],
[
[
35,
253,
886
],
[
886,
223,
191
]
],
[
[
35,
71,
1108
],
[
1108,
223,
191
]
],
[
[
35,
71,
163
],
[
163,
225,
191
]
]
] |
[
[
[
"Fesoterodine",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Irbesartan"
],
[
"Irbesartan",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may decrease the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topiramate"
],
[
"Topiramate",
"{u} may decrease the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Fesoterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aprepitant"
]
]
] |
Fesoterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Fesoterodine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Aprepitant (Compound)
Fesoterodine may increase the serum concentration of the active metabolites of Irbesartan and Irbesartan can increase the metabolism of Aprepitant
Fesoterodine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Aprepitant
Fesoterodine may decrease the metabolism of Sulfisoxazole and Sulfisoxazole can increase the metabolism of Aprepitant
Fesoterodine may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Aprepitant
Fesoterodine may increase the serum concentration of the active metabolites of Cimetidine and Cimetidine may decrease the metabolism of Aprepitant
Fesoterodine may increase the severity of adverse effects when combined with Topiramate and Topiramate may decrease the metabolism of Aprepitant
Fesoterodine may increase the severity of adverse effects when combined with Oxycodone and Oxycodone may increase the severity of adverse effects when combined with Aprepitant
|
DB00889
|
DB00254
| 383 | 755 |
Granisetron
|
Doxycycline
|
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
|
Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
|
The metabolism of Doxycycline can be decreased when combined with Granisetron.
| 46 |
[
[
[
383,
69,
755
]
],
[
[
383,
6,
4590
],
[
4590,
160,
755
]
],
[
[
383,
251,
495
],
[
495,
55,
755
]
],
[
[
383,
69,
539
],
[
539,
209,
755
]
],
[
[
383,
69,
613
],
[
613,
69,
755
]
],
[
[
383,
196,
633
],
[
633,
69,
755
]
],
[
[
383,
42,
280
],
[
280,
69,
755
]
],
[
[
383,
240,
324
],
[
324,
69,
755
]
],
[
[
383,
99,
35
],
[
35,
69,
755
]
],
[
[
383,
95,
1394
],
[
1394,
69,
755
]
]
] |
[
[
[
"Granisetron",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may decrease the metabolism of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may increase the QTc prolonging activities of {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may increase the QTc prolonging activities of {v}",
"Propofol"
],
[
"Propofol",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may increase the serotonergic activities of {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Granisetron",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
]
] |
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxycycline (Compound)
Granisetron may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Doxycycline
Granisetron may decrease the metabolism of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Doxycycline
Granisetron may decrease the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Doxycycline
Granisetron may increase the QTc prolonging activities of Cisapride and Cisapride may decrease the metabolism of Doxycycline
Granisetron may increase the QTc prolonging activities of Propofol and Propofol may decrease the metabolism of Doxycycline
Granisetron may increase the serotonergic activities of Escitalopram and Escitalopram may decrease the metabolism of Doxycycline
Granisetron may increase the serum concentration of the active metabolites of Fesoterodine and Fesoterodine may decrease the metabolism of Doxycycline
Granisetron may increase the serum concentration of Palbociclib and Palbociclib may decrease the metabolism of Doxycycline
|
DB00296
|
DB00413
| 541 | 1,365 |
Ropivacaine
|
Pramipexole
|
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
|
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
|
Ropivacaine may increase the sedative activities of Pramipexole.
| 31 |
[
[
[
541,
54,
1365
]
],
[
[
541,
21,
28404
],
[
28404,
175,
1365
]
],
[
[
541,
71,
962
],
[
962,
54,
1365
]
],
[
[
541,
225,
586
],
[
586,
54,
1365
]
],
[
[
541,
180,
150
],
[
150,
54,
1365
]
],
[
[
541,
192,
587
],
[
587,
54,
1365
]
],
[
[
541,
38,
1262
],
[
1262,
54,
1365
]
],
[
[
541,
69,
681
],
[
681,
54,
1365
]
],
[
[
541,
95,
280
],
[
280,
54,
1365
]
],
[
[
541,
236,
932
],
[
932,
54,
1365
]
]
] |
[
[
[
"Ropivacaine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} (Compound) causes {v} (Side Effect)",
"Vascular purpura"
],
[
"Vascular purpura",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mepivacaine"
],
[
"Mepivacaine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triazolam"
],
[
"Triazolam",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may decrease the metabolism of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the serum concentration of {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Ropivacaine",
"{u} may increase the hypotensive activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
]
] |
Ropivacaine (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Pramipexole (Compound)
Ropivacaine may increase the severity of adverse effects when combined with Mepivacaine and Mepivacaine may increase the sedative activities of Pramipexole
Ropivacaine may increase the severity of adverse effects when combined with Triazolam and Triazolam may increase the sedative activities of Pramipexole
Ropivacaine can increase the metabolism of Fosphenytoin and Fosphenytoin may increase the sedative activities of Pramipexole
Ropivacaine may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the sedative activities of Pramipexole
Ropivacaine may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the sedative activities of Pramipexole
Ropivacaine may decrease the metabolism of Clozapine and Clozapine may increase the sedative activities of Pramipexole
Ropivacaine may increase the serum concentration of Propofol and Propofol may increase the sedative activities of Pramipexole
Ropivacaine may increase the hypotensive activities of Aripiprazole and Aripiprazole may increase the sedative activities of Pramipexole
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.